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I 
FOREWORD BY LORD PATEL

was asked to take on the role of Chair, and to establish the Prison Drug 
Treatment Strategy Review Group, to carry out a review of drug treatment and 
interventions in prisons and for people on release from prisons in England. 
I have worked for many years, as a practitioner, manager and policy maker in 
tackling drug use and was aware of the additional complexities involved in 
tackling drug use in prisons. However, it was important for me to understand the 
real practical issues and barriers to effective drug treatment and interventions in 
prisons. I therefore undertook a series of visits to prisons and talked to staff at all 
levels, commissioners, providers and most importantly to prisoners themselves, in 
order to gain a personal understanding of the key issues for this review. 
This review was different to many Government reviews in that it was not based 
on my work or observations alone, but on the work of a diverse group of people 
with knowledge, expertise and experience on drug treatment and interventions in 
prisons. 
I want to acknowledge the importance of this diverse group of people who have 
worked together over many months to achieve consensus and produce 
constructive recommendations in a complex area. 
This review was also different in that Government officials were invited to all the 
meetings as observers and the Review Group work programme was carried out 
with the full support of the Ministry of Justice, Department of Health, Home 
Office and National Treatment Agency for Substance Misuse. The review 
represents the commitment of external organisations and Government to work 
together and make a positive impact on the lives of drug users in prison and on 
release. 
I especially want to thank the large number of service users and carers who 
engaged in our consultation process or communicated their views via our 
website. I am in no doubt from the responses that we received that drug users, 
ex-drug users and their families do have an appetite to be more actively involved 
and we need to create many more opportunities for them to do so. 
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I recognise that since work began on the review that we all face a tightening 
financial climate. I believe, however, we still have an opportunity to achieve the 
cultural and system change needed to engage drug users and the communities 
within which they reside, in effective drug treatment while in prison; to maximise 
their prospects for recovery and reintegration on release into the community; 
and, get value for money by increasing innovation, raising standards and quality, 
achieving efficiencies and improving cost effectiveness. 
Making recommendations are only the first stage - implementation is key. 
We have an opportunity for effective implementation through the work 
programme being developed within the Coalition's programme for Government 
across the fields of criminal justice, health and drugs. 
I would propose to Government that implementation is not done in isolation 
across Government, but once again with the active involvement of external 
organisations and particularly with service users and carers. 
This, I believe is the way to raise the levels of ambition about what can be 
achieved and to harness the full potential of drug users to actively engage with 
and assume responsibility for their own recovery. 
Professor Lord Patel of Bradford OBE
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EXECUTIVE SUMMARY AND RECOMMENDATIONS 
INTRODUCTION 
1.	 The Prison Drug Treatment Strategy Review Group (henceforth known as the Review 
Group), chaired by Professor Lord Patel of Bradford OBE, is an independent expert 
group commissioned to take a fresh look at drug treatment in prisons. 
2.	 The review commenced in April 2009 and the Review Group’s remit was to focus on 
drug treatment and interventions for people in prison, people moving between 
prisons and the continuity of care for people on release from prison. 
3.	 There is a wider range of issues, including mental health problems, alcohol issues and 
treatment, drug treatment in the community, the criminal justice system, and 
rehabilitation issues (housing, employment, skills and education), which have an 
impact on this scope. While these issues are not the primary focus of this review, 
they have been considered by the Review Group, as appropriate. It is important to 
note that the cross-Government Health and Criminal Justice Programme are taking 
forward the specific issues pertaining to mental health problems and alcohol issues 
in prison. The Review Group established links with this programme via Government 
officials. 
4.	 The review focuses on adults (18 years old plus); therefore, young people under the 
age of 18 years are not covered within this review. 
5.	 This report outlines the evidence gathered and work carried out by the Review 
Group and summarises their conclusions and recommendations. 
6.	 The recommendations are focused on prisons and the drug treatment sector in 
England. The Review Group established links with the Welsh Assembly Government 
to ensure that the continuity of care for drug users on release from prisons, moving 
between England and Wales, was taken into consideration. 
7.	 These recommendations have been sent to Ministers in the Ministry of Justice, 
Department of Health and the Home Office, and have been submitted as a response 
to the new drug strategy consultation. 
THE NEED FOR REFORM 
“Looking back 10 years ago there was very little help available. There is more help now 
but still not nearly enough” (Prison questionnaire respondent - Review Group Service User 
and Carer Consultation) 
8.	 Existing drug treatment funding, commissioning and delivery systems in prisons have 
been subject to increasing criticism. While the current systems have helped to 
deliver an increase in drug treatment in prisons, they are complex and characterised 
by a multitude of funding streams, commissioning and process targets. This has 
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resulted in a fragmented system with the risk of a ‘one-size-fits-all’ approach, with 
limited choices in the type of treatment and broader social support available. 
9.	 The Price Waterhouse Coopers (PWC) report specifically identified: 
•	 The lack of a clear, unified inter-departmental strategy across Government; 
•	 Fragmented organisational arrangements for funding, commissioning,

performance management and delivery of services in prisons;

•	 The lack of a clear evidence-base for some services currently offered in prisons; 
and, 
•	 Inefficiencies and gaps in services. 
10. The criminal justice system presents an opportunity and a challenge when addressing 
a wide range of clinical and social care needs of drug users. We know that getting 
drug users in prison to engage in treatment can have a positive impact. 
11. We recognise that the continuity of care of drug treatment for people entering 
prisons, moving between prisons and on release is a complicated issue due to the 
nature of the prison environment – a rising prison population resulting in a strain on 
limited staffing resources, disrupted regimes and some prisoners being placed 
further from home. 
12. However, there is now a strong call amongst drug users and carers for greater 
continuity of drug treatment both within and between prisons. And there is a very 
clearly articulated need for much greater support and help on release especially with 
respect to appropriate housing, having enough money, having something meaningful 
to do and greater integration and co-ordination with community services. 
13. We have been concerned that the progress required to make the kind of system 
changes necessary to address the criticisms raised has been slow. 
14. However, since the inception of this review, there has been a substantial change in 
the political landscape. The Coalition’s programme has indicated a keenness to re-
look at issues with regard to drug use, crime and rehabilitation and the NHS White 
Paper, Equity and excellence: Liberating the NHS, has already announced 
fundamental changes to the commissioning system. 
15. With further changes likely to be announced within the new drug strategy, the 
Ministry of Justice Green Paper, 'Engaging Communities in Criminal Justice', etc. we 
now have an opportunity to achieve the cultural and system change needed to 
engage drug users and the communities within which they reside in effective drug 
treatment while in prison, and to maximise their prospects for recovery and 
reintegration on release into the community. 
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16. Our recommendations are intended to be in step with this changing political 
landscape - e.g. streamlined commissioning systems and a move towards outcomes. 
We seek to raise the levels of ambition about what can be achieved and to challenge 
the reluctance to recognise and harness the full potential of drug users to actively 
engage with and assume responsibility for their own recovery, including a renewed 
focus on abstinence as a clear goal. 
ECONOMIC CONSTRAINTS 
17. There can be no doubt that developing effective drug treatment and interventions in 
prisons and continuity of care on release in the context of tightening resources will 
be demanding - drug users’ priorities may become low ranking in a difficult economic 
climate. 
18. Within a tight fiscal context, local partnerships, commissioners and prison governors 
will have to make tough choices about where to target investment for the future and 
have a determination to get value for money from every pound spent by increasing 
innovation, raising standards and quality, achieving efficiencies and improving cost 
effectiveness. 
19. Equally, economic constraints can have the potential to be catalysts for change. 
Improvements can come from making changes in current practice and refocusing 
efforts and resources, including better working practices in terms of commissioning 
and delivery to allow the frontline more capacity to innovate. 
20. Therefore, we have worked on the basis that our recommendations should not need 
additional money to implement them, but would need to address: 
•	 Improving the quality of drug treatment for people in prison and on release from 
prison, through the development of clear standards and outcomes. 
•	 Increasing innovation – in terms of service delivery, commissioning and 
partnership working - to contribute to a reduction in re-offending and reduced 
mortality from accidental drugs overdose or chronic health problems such as 
blood borne viruses. 
•	 Achieving efficiencies and improving cost effectiveness within the drug treatment 
system in prison and for people on release from prison. 
21. Achieving the above will require genuine collaboration cross-Government and co-
ordinated commissioning between local prisons and their community partners if 
effective drug treatment and interventions in prisons and continuity of care on 
release is to be established as a fundamental part of the work of the whole prison 
establishment and an integral part of local commissioning partnerships. 
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REVIEW GROUP APPROACH AND KEY PRINCIPLES 
22. Our review and recommendations have been strengthened by a thorough review of 
the evidence base for drug treatment in prisons incorporating over 160 high quality 
peer reviewed papers, and a service user and carer consultation based on 553 
responses. 
23. Our aim is not to ‘reinvent the wheel’ but to build on the successes of preceding 
strategies, research and reviews. Accordingly, we have taken into consideration a 
wide range of key work programmes and reviews, including the Bradley Report, the 
Drug Interventions Programme review and the National Offender Management 
Service (NOMS) review of accredited substance misuse interventions. Research on 
efficiency savings and value for money on drug treatment in the community and in 
prisons was also considered. 
24. We believe that the goal of all treatment is for drug users to achieve abstinence from 
their drug – or drugs – of dependency. For some this can be achieved immediately, 
but others will need a period of drug-assisted treatment with prescribed medication 
first so their overall health can be improved, which will enable them to work, 
participate in training or support their families. They can then be supported in trying 
to achieve abstinence. 
“The worst experience was being detoxed without any warning or consultation” 
(Service user forum - Review Group Service User and Carer Consultation) 
25. We believe that an integrated care pathway, from the community into prisons and 
visa versa, and a balanced treatment system are vital to ensure that individuals get 
access to the types of treatment that is appropriate to their changing needs and 
circumstances. Local commissioners need to be able to choose from a broad 
spectrum of treatment options in both prisons and the community including 
prescribing and residential rehabilitation. 
26. Treatment alone can only go so far and we need to be more ambitious in helping 
drug users to make lasting changes, to maintain their recovery and ensure that there 
is help and support from outside the treatment system – family and friends, peer 
support/mutual aid networks, access to housing, and education and employment 
opportunities. 
27. Hence, our work during this review has been underpinned by the following key 
principles: 
•	 Continuity of care as people pass through, in and out of the prison system is the 
critical issue. 
•	 Drug users in prison should have access to drug treatment and health and social 
care provision equivalent to those provided in the community and appropriate to 
a prison environment. 
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•	 Drug users released from prison should be offered on-going rehabilitation and 
support on their return to the community and be encouraged to maintain their 
contact with community substance misuse services, as appropriate. 
•	 Existing finite resources should be used more effectively. 
•	 The range of services provided should be appropriate, supported by best 
available evidence and ensure an equivalence of national standards of care 
across the country. 
•	 The needs of particular groups, e.g. transitional issues of the 18-21 year old 
prison population, women, Black and minority ethnic groups, people with dual 
diagnosis (mental health and substance use problems) must be considered. 
•	 It is vital that the service users ‘voice’ is heard and their experiences are taken 
into account. 
KEY ISSUES FOR CHANGE 
28. We believe an effective and balanced drug treatment and interventions system 
would contribute to a range of criminal justice and health outcomes, including: 
•	 Reducing drug related offending and re-offending 
•	 Reducing drug use in prison 
•	 Community safety 
•	 Individual drug user’s health and social functioning 
•	 Lower public health risks from blood borne viruses and overdose 
29. In developing our recommendations, there was a wide range of issues that this 
review could potentially focus on. However, to attempt to tackle all issues could 
result in a diluted approach that fails to have any impact at all. 
30. Therefore, we have chosen to focus on challenging and making improvements in the 
key areas outlined below. We believe making changes in these areas would have the 
most significant impact and deliver improvements in the outcomes and experiences 
of drug users in prison and on release: 
•	 More decentralisation around commissioning enabling a more autonomous and 
accountable system: Decision-making should be focused at a local level, and 
more responsibility given to local partnerships, commissioners, prison governors 
and users and carers. Maximising local ownership will sustain and improve 
outcomes in terms of both re-offending and reduction of harm to the individual, 
their families and their communities. Local areas require greater autonomy and 
flexibility to deliver better services by focusing on increasing the access and 
quality of drug interventions, matched to individual needs, and on reducing 
bureaucracy. 
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•	 Clear outcomes to improve efficiency and effectiveness of commissioning: The 
development of an outcomes framework for assessing and managing 
performance at a local level, which is focused on recovery, is crucial. This will 
ensure that the services that are commissioned are needs based; delivered to 
high standards and achieve best value for money; and, realise any efficiency 
savings by removing duplication and reinvesting in improvements to services. 
•	 Needs based treatment and interventions: It is vital that drug treatment and 
interventions are matched to individual need and appropriate to individuals at 
the time that they are within the criminal justice system i.e. making sure that the 
right people, get the right intervention, at the right time. All available evidence 
must be used to make sure we are creating an integrated care pathway between 
prisons and community services that supports the treatment and interventions 
that are most effective, targeted at the right users with abstinence-based 
treatment for some, drug-replacement over time for others. 
•	 Improving access to reintegration pathways and provision: Integrated care 
pathways can help to ensure that there is a focus on reintegration and 
appropriate support services at an early a stage as possible, to begin to address 
the broad range of issues around recovery and reintegration presented by people 
with drug problems in prison and on release. 
•	 Integrated partnership working: To create an integrated care pathway and 
integrated services by improving partnership working between criminal justice, 
health and social care organisations, enabling effective health, social care and 
criminal justice outcomes. 
•	 Improving capacity and capability: To have an informed and effective workforce 
to deliver services for drug users in prison with health and social care needs, 
making sure that they are able to work confidently across organisational 
boundaries, by equipping them with the right skills and knowledge to share 
information and take co-ordinated action that supports the continuity of care. 
•	 Diversity and equity of access to services: Encourage the development of skills, 
awareness and knowledge in relation to issues of diversity with respect to drug 
use. This would include those relating to diversity of the workforce in prison and 
probation so that they can deliver quality drug services to the full diverse range 
of the population being served and firmly embed this into the working culture of 
the criminal justice system. This is vital to ensure that all offenders – irrespective 
of race, gender, disability, age, sexual orientation, religion or belief – will secure 
the same access to health and social care services, appropriate to their needs and 
in line with standards set for the rest of the population. 
•	 Breaking barriers - Government Departments need to work closely with external 
organisations and partners to ensure joined up national thinking across 
institutional boundaries; to help break down any barriers to local partnership 
working; establish shared objectives; and, facilitate integrated care pathways 
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between local agencies. This cross-boundary work should also continuously 
consider improvements in value for money. 
31. It is important to note that all our recommendations are interlinked and so need to 
be viewed in an integrated way. For example, the commissioning and outcomes 
recommendations are complementary and both are necessary – without clear 
outcomes, effective commissioning standards cannot be established and the 
commissioning of effective care pathways covering drug treatment and 
interventions, continuity of care provision and mainstream reintegration/recovery 
services (housing, employment) are essential in helping drug users to make lasting 
changes. 
32. A summary of our recommendations are outlined below. 
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SUMMARY OF THE REVIEW GROUP’S RECOMMENDATIONS

We recommend that any new Government drug strategy covers not 
only community-based drug treatment but, for the first time in England, 
RECOMMENDATION 1: 
CROSS-GOVERNMENT 
includes a streamlined, unified cross-Government drug treatment and STRATEGY 
interventions strategy for people in prisons, moving between prisons 
and on release. Achieve efficiencies and 
improve cost effectiveness 
This cross-Government strategy should be based on: by developing (for the first 
time in England) a unified 
•	 The twin aims of reducing drug-related crime caused by re-cross-Government drug 
offending and improving the health and rehabilitation of offenders. treatment and interventions 
strategy for people in 
•	 An integrated approach between Government Departments with a prisons, moving between 
renewed focus on abstinence as a clear goal. prisons and on release 
•	 A revised streamlined commissioning system and a new outcomes 
model that focuses on the outcomes that matter i.e. a stable place 
to live, a job, positive mental health and well-being. 
•	 A robust evidence-base, including evidence of cost-effectiveness. 
•	 Making more effective use of existing residential rehabilitation 
services - offenders who have become drug-free and need secure 
and safe accommodation on release should have access to these 
services to support their ongoing recovery and abstinence. 
•	 Reintegration/resettlement options – in both employment and 
housing terms, as an integral part of the building blocks to 
maximise recovery. 
•	 Active involvement of drug users, their families and local 
communities. 
A unified prisons drug treatment and interventions strategy should also 
incorporate the elements outlined in the recommendations below. 
We recommend that the Government adopt the first cross-
Government outcomes model for drug treatment and interventions in 
RECOMMENDATION 2: 
ESTABLISHING OUTCOMES 
prisons with the twin aims of reducing re-offending and improving 
health and rehabilitation. This outcome model focuses on 4 main Shift focus and resources 
towards reducing re- themes: 
offending outcomes and 
better health outcomes, •	 Reduced drug use 
•	 Reduced re-offending through a national health 
• Improved health & social functioning and criminal justice 
•	 Increased employment and enhanced workforce skills outcomes model 
This outcomes model can provide a benchmark for the quality of 
services provided that would support commissioners and providers to 
evidence, assess and improve the quality of service provision. 
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This model can use existing sources of data and, with a performance 
assurance framework, could replace all current NOMS drug treatment 
key performance targets and the Prison Health and Performance and 
Quality Indictor for drug treatment, thereby reducing the burdens and 
duplication within the existing system. 
We recommend moving away from the current complex commissioning 
systems, characterised by a multitude of funding streams and process 
RECOMMENDATION 3: 
STREAMLINED 
targets, which have resulted in a fragmented system with the risk of a COMMISSIONING 
‘one-size-fits-all’ approach, with limited choices in the type of SYSTEMS 
treatment and broader social support available. 
Shift focus and resources to 
We recommend moving to a streamlined effective and efficient develop a streamlined, 
commissioning system that is reflective of consensus on evidence and autonomous and 
good practice and clearly aligned with outcomes. It is proposed that for accountable commissioning 
the first time in England, the majority of drug funds be jointly system that is coherent, 
commissioned at a local level - this includes NOMS CARATs funding. cost-effective and enables 
This would mean that local health commissioners, potentially within more effective decision-
new consortia of GP practices, and local drug partnerships including making by local 
local authorities, local Directors of Public Health, prison governors, etc. commissioners and 
would share the responsibility for commissioning drug treatment both partnerships 
in prisons and on release and would have a collective responsibility to 
ensure effective joint commissioning and to align/pool budgets to 
obtain the best outcomes, efficiencies and value for money. Some 
commissioning at a national level may still be needed, for example, to 
ensure the needs of the women estate and under 21-year-old offenders 
are addressed and, under this proposed system, services can be 
commissioned based on needs, at whichever level (national, regional or 
local) is appropriate for the intervention. 
We are aware that even as our work programme and recommendations 
were being completed major changes to commissioning systems within 
the NHS were being announced. Our proposed model, however, is 
aligned with the Coalition’s programme approach for a more 
autonomous and accountable system and with the NHS White Paper, 
Equity and excellence: Liberating the NHS, around GP commissioning 
consortia, which focuses on the patient’s needs – i.e. ensuring that 
patients get the right treatment, at the right place, at the right time. 
There is no detail yet about what will happen to local drugs 
partnerships and where the commissioning of drug treatment will fit. 
However, these changes to local commissioning systems reinforce the 
need for collaboration and joint commission to ensure that the needs of 
drug user in prison and on release are met against a clear strategy that 
is reflective of consensus on evidence and good practice, and clearly 
aligned with outcomes. 
Therefore, we recommend that the Government consider putting in 
place this revised commissioning system by 2011/12. 
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Helping people get off drugs for good must be a crucial ambition for the 
new drug strategy and for the drug treatment and interventions system 
RECOMMENDATION 4: 
SERVICE DELIVERY 
both in the community and in prisons.

Delivering optimal systems of care that are evidence-based and
Refocus and increase 
supported by a range of choices and different pathways that promote ambition, quality and 
reintegration and recovery is a vital challenge in developing a truly innovation in service delivery 
effective and balanced treatment system. through an updated national 
drug treatment and 
Therefore, we recommend the Government agree to an updated interventions framework 
national framework that for the first time in England: that covers both community 
and prisons to: 
•	 Outlines the ambition to maximize drug users prospects for 
recovery (i.e. becoming free of dependency) •	 increase the numbers of 
drug users who are able 
to achieve recovery from •	 Spans drug treatment both in the community and in prison 
dependency and sustain 
this for the longer-term; •	 Outlines an appropriate ‘menu of services’ including medical 
treatment, psychosocial interventions, harm minimisation and and, 
broader social care that promotes resettlement and recovery •	 contribute to a reduction 
in re-offending and 
reduced mortality from •	 Ensures that the service user and their recovery are at the heart of 
all commissioning and service delivery suicide, accidental drug 
overdose, blood borne

viruses and other chronic
 An effective outcomes framework and commissioning system will 
require access to a range of treatment and intervention services that 
are able to meet the varied, and at times, complex needs of drug users. 
Therefore, it is vital that any ‘menu of services’ must cover both drug 
treatment in the community and in prisons to avoid creating further 
silos and to enable genuine joint commissioning. 
health problems 
The appropriate place to develop a clear ‘menu’ of evidence-based, 
effective and cost-effective services would be within a new national 
framework that spans drug treatment in the community and in prison 
to ensure consistency and continuity of care as people are released 
from prison. This should be an early aim of the new drug strategy. 
A drug treatment system that promotes achieving abstinence needs a 
robust, realistic narrative of recovery that is meaningful to the drug-
RECOMMENDATION 5: 
SERVICE USER AND 
users and their families, and endorses ‘Recovery Champions’, peer CARER ENGAGEMENT 
support and mentoring groups. 
Increase social capital by 
Therefore, we recommend that commissioners and local partners focus identifying ‘Recovery 
on increasing the social capital through the identification of Recovery Champions’ in the 
Champions and appropriate community groups - local councillors, community and prisons to 
business people; families and friends of users; ex-drug users. We need reduce poor social cohesion 
to make more effective use of people who understand the problems of in local communities and 
dependency; those who want to understand more; and those who may support the creation and 
have resources to help make recovery a more realistic option. expansion of volunteering, 
co-operatives, charities and 
All offenders, irrespective of race, gender, disability, age, ethnicity, social enterprise 
religion and sexual orientation should be able to secure the same 
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access to drug treatment services as the rest of the population. At a 
local level, active engagement with users and their families can help 
tackle the unmet treatment needs and barriers to treatment, including 
the needs of young people, women drug users, Black or ethnic or other 
minority communities, sex workers or parents with dependent children. 
Recovery Champions would need to reflect this diversity. 
In order to move away from centralisation and ‘big’ government to 
creating a ‘Big Society’, Recovery Champions, community groups and 
the families of drug users can play an important role in articulating 
ambition, championing routes to recovery and challenging partnerships 
and services to retain a recovery focus – both prior to release and on 
release. People who have personal experience of problematic drug use 
and who have achieved successful recovery, and feel ready to volunteer 
and support others, should be encouraged to become involved in peer 
support, mentoring groups and other community groups, and talking 
about what made their recovery a reality e.g. access to housing and 
jobs. 
Increasing social capital is important not only to those who are 
recovering from substance misuse, but is significant from a community 
perspective. The role of social capital is important in keeping drug 
dealers from infiltrating into neighbourhoods - illegal markets tend to 
flourish in areas where there is poor social cohesion, resulting in 
difficulties regulating nuisance and problematic behaviours; increasing 
social capital can support the well-being of drug users and their families 
and minimize nuisance factors. 
Government Departments need to work closely with external RECOMMENDATION 6: 
organisations and partners to ensure joined up national thinking across 
institutional boundaries; to help break down any barriers to local 
ESTABLISHING LINKS TO 
WIDER CRIMINAL JUSTICE 
partnership working; establish shared objectives; and, facilitate AND HEALTH AND SOCIAL 
integrated care pathways between local agencies. This cross-boundary 
CARE SYSTEM 
work should also continuously consider improvements in value for 
money. 
Increase efficiencies and 
improve cost effectiveness 
Therefore, it is vital that any drug treatment and intervention strategies 
by ensuring drug treatment 
in the community and in prisons are not developed in isolation but 
and interventions strategy in 
linked to other relevant initiatives and strategies as they emerge. 
prisons is not developed in 
isolation but linked to other 
However, past reports by the National Audit Office, the Committee of 
relevant initiatives and 
Public Accounts and others have identified failures in the delivery of 
strategies as they develop 
public services that could have been avoided. 
A 2009 National Audit Office (NAO) report found many instances where 
major programmes and projects have been either frustrated, or 
severely hampered, by failure to take on board lessons from their own 
past experiences or those of others. The main barriers experienced by 
departments are silo structures, ineffective mechanisms to support 
learning, a high turnover within the workforce and a lack of time for 
learning. 
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j• 
• 
• 
• 
• 
• 
To achieve value for money in public services, Government 
Departments need to learn from success and failure, and to improve 
their capacity to learn from each other. The NAO report found that 
Departments often found cross-Departmental networks and 
communities of practice most valuable to supporting learning. 
Therefore, to avoid fragmentation of approach and to increase 
efficiencies and improve cost effectiveness, we recommend that efforts 
must be made to effectively link drug treatment issues with a range of 
criminal ustice, health and social care issues, which are currently under 
development, including: 
Green Paper on rehabilitation 
NHS White Paper, Equity and excellence: Liberating the NHS 
Review of sentencing policy - ensuring that sentencing for drug 
use helps offenders come off drugs. 
Exploring drug rehabilitation prisons 
Implementation of the Prisoners’ Earnings Act 1996 
New Mental Health strategy 
17

1.	 SETTING THE SCENE - THE CHALLENGE 
INTRODUCTION 
1.1	 In order to develop our recommendations, we needed to have a good overall 
understanding of the current position around drug treatment and interventions 
in prisons, so we reviewed and examined a number of critical areas, specifically: 
•	 The scale of the challenge 
•	 Drug treatment need 
•	 The current approaches and the views of service users and carers 
•	 The evidence base 
1.2	 The results of these various pieces of work are outlined below. 
THE SCALE OF THE CHALLENGE 
1.3	 It is clear that while the criminal justice system presents an opportunity to 
address a wide range of clinical and social care needs of drug users, the scale of 
the challenge cannot be underestimated. 
1.4	 Many drug users will need repeated treatments before they finally overcome 
their dependence, whilst others are ‘lost’ when transferred between local 
treatment services and prisons, and vice versa. Some of the current fragmented 
organisational arrangements, as outlined in the Price Waterhouse Coopers 
report, can result in organisations and community services finding it difficult to 
match treatment to individual need at the right time. 
1.5	 Moreover, given the environment in which prison treatment is provided, there 
are specific challenges to be considered in developing good quality drug 
treatment and interventions services in prisons: 
•	 Prison population – According to the Prison Service, there are 136 adult 
prisons in England and Wales with more than 84,000 people in prison. 
Around 26 per cent of male prisoners and 29 per cent of female prisoners are 
from Black and minority ethnic groups, with a majority serving longer 
sentences than their white counterparts. In 2008, the prison system received 
134,000 new admissions or receptions (60 per cent increase on prison 
numbers since 1995), a great many of whom have complex problems 
including: 
�	 10 per cent of the overall prison population have a serious mental health 
problem; 
�	 69 per cent of those who enter prison have taken drugs within the 
previous 12 months; 
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� Of these, 40 per cent report injecting drug use within the 28 days

preceding imprisonment; and,

�	 Someone received into a prison who is drug dependent is twice as likely 
to commit suicide in the first week of imprisonment as a non-dependent 
prisoner. 
•	 High volume and frequency of movement of prisoners - A busy remand 
prison can see upwards of ten new drug dependent prisoners per night i.e. 
over 3,000 new drug dependent prisoners a year. Many of these prisoners 
will move to other prisons within weeks or even days of arrival, and many will 
be transferred to a third or even fourth prison during a single prison 
sentence. 
“When arriving from a transfer sometimes you only get to see a nurse and 
have to wait to see a doctor in the morning and as meds do not travel with 
you this causes immense discomfort” (Service user forum - Review Group 
Service User and Carer Consultation) 
•	 Polydrug use is common among offenders entering custody - People arrive 
in prison co-dependent on any combination of alcohol, opiates, stimulants 
and benzodiazepines. 
“There is more visible support for heroin but is this at the expense of alcohol 
and others?” (Prison questionnaire respondent - Review Group Service User 
and Carer Consultation) 
•	 Dual diagnosis or the co-existence of mental health and substance use 
problems - Dual diagnosis has become far more common in both the 
community and within prisons. A 2008 study looking at prison mental health 
in-reach services suggested that dual diagnosis should be regarded as the 
norm, rather than the exception. A 2003 study showed that: 
�	 74.5 per cent of users of drug services and 85.5 per cent of users of 
alcohol services experienced mental health problems; and 
�	 44 per cent of mental health service users reported drug use and/or were 
assessed to have used alcohol at hazardous or harmful levels in the past 
year. 
Despite the recognised high prevalence of dual diagnosis among offenders 
with mental health problems, the Bradley Report found that services are not 
well organised to meet this need. In fact, services are currently organised in 
such a way as to positively disadvantage those needing to access services for 
both mental health and substance use/alcohol problems. 
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“I don’t feel my mental health needs have been addressed, I’ve now self 
harmed for 18 months cutting my arms/wrists, hanging myself and taking 
overdose. I still self harm and I feel nobody cares. I’ve had no counselling at 
all and I got bullied and the suicide liaison officer rewarded one of the bullies.” 
(Prison questionnaire respondent - Review Group Service User and Carer 
Consultation) 
•	 Social exclusion issues, including people from Black and minority ethnic 
backgrounds being over-represented in the prison population - Many 
prisoners have a history of social exclusion, including high levels of family, 
educational and health disadvantage, and poor prospects in the labour 
market. People from Black and minority ethnic backgrounds are over-
represented in almost all these dimensions of social exclusion. A 2002 report 
from the Social Exclusion Unit demonstrated that it is no coincidence that 
people from some Black and minority ethnic backgrounds are over-
represented in the prison population. 
•	 Specific needs of women - The Corston Report described the effect of prison 
sentences on women’s lives. Women are often in prison for very short 
sentences, and often on remand. However, prison regimes were not properly 
geared up for women prisoners and Prison Service practice was focused on 
incarcerating men. Treating men and women equally in prison did not 
produce equal outcomes. A woman-centred approach to regimes was 
necessary and could turn women’s lives around and help them to develop 
much needed self-esteem and life skills. Since the Corston Report, there has 
been progress towards gender specific standards and staff training, including 
the abolition of routine strip-searching in prisons from April 2009. 
“The women felt strongly about being re-housed away from their original 
home address in decent accommodation which would help to give a feeling of 
‘a fresh start’ and make a move away from old habits. This can often be 
hampered by the requirement of some housing associations to have a family 
connection in order to live in a particular area.” (Service user forum - Review 
Group Service User and Carer Consultation) 
•	 Many drug users lead chaotic lives and experience a range of issues with 
housing, employment education and health that need to be addressed - A 
2008 UK Drug Policy Commission report stated that up to 80 per cent of drug 
users are unemployed and most employers would refuse to employ even an 
abstinent recovered drug user, let alone one who is still in treatment. The 
report highlighted the importance of being realistic about the time required 
before many drug users will be in a position to participate in the job market. 
The physical and mental health problems experienced by drug users may also 
impact on their ability to achieve and sustain employment and these need to 
be recognised and adequately addressed. This will have implications for 
benefit regime procedures and other support mechanisms. The report also 
stated that there is a need for improved provision of a range of suitable 
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accommodation to facilitate recovery and rehabilitation. Housing agencies in 
particular need to be more closely involved in local drug partnerships and 
there is a need for identification and sharing of good practice in provision. 
“You can do all of the work in prison only to be left with nowhere to live, 
leaving you to go to a hostel which is full of drugs. We need more help in 
resettlement.” (Service user forum - Review Group Service User and Carer 
Consultation) 
•	 Release from prison is a critical time – A 2005 study from Farrell and 
Marsden found that, in the week following release, prisoners are 37 times 
more likely to die of a drug overdose than other members of the public due 
to diminished opioid tolerance. Women are 69 times more likely to do so. 
“I mean for me I found it quite daunting because I didn’t know when I was 
going. I was woken up at five in the morning and told to get my stuff because 
I was leaving and that was it and I was put on the street with a bag.” (Service 
user forum - Review Group Service User and Carer Consultation) 
Moreover, a 2010 study from Stover and Michels highlighted that "coercive 
abstinence in prison may be followed by relapse immediately after release, 
often resulting in overdose, drug emergencies and death". This study on 
prison deaths confirms the increased risk of drug-related death in the first 
two weeks on release from prison. Importantly, it also shows that the risk 
persists through to weeks three and four though, as expected, it tapers off as 
time passes. The high death rates demonstrated in this study is a reminder of 
the real risk that prisoners, particularly newly detoxed ones, face on release. 
•	 Support for prisoners on release - In a Home Office review of the Drug 
Interventions Programme help with housing was rated as the most important 
issue to drug-using offenders. More emphasis was also needed on 
developing life skills to help prevent relapse into drug use and offending, and 
a lot of importance was placed on crisis support, peer support and daytime 
activities to help make the transition to a normal life. This review stated that 
current thinking about service delivery has not recognised the importance of 
these factors. The Corston Report highlighted the specific needs of women 
prisoners on release, particularly those on short sentences. A woman in 
prison for a month could lose her home and see her children taken into care. 
Following release, the fact that her children were in care could lead to 
problems obtaining housing and this, in turn, could lead to problems getting 
her children back. 
•	 Multi-agency working needs strengthening: Partnership working is still too 
reliant on persuasion and goodwill despite the strengthening of governance 
structures. Multi-agency working is an area for further development 
particularly in respect of working with prison, police and probation and wider 
agencies such as housing. 
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Security Issues 
1.6	 For drug treatment and interventions staff working in prisons, the challenges are 
compounded by the routine movement of prisoners and the security imperative, 
which limits access to prisons, and the sudden lowering of mood consistent with 
the occurrence of imprisonment and drug withdrawal. 
“...the Screws are so understaffed, when the CARAT team come on the wing and 
the Screws are like, ‘No we’re not unlocking anybody because we haven’t got the 
staff to supervise you’. You can see the CARAT team arguing with them saying, 
‘We have to see these people to give them some support and help them for when 
they get out’. But the Screws are saying, ‘We haven’t got the staff to unlock them 
and supervise you doing this work’. I only saw them once and that was on my 
second day there, then I didn’t see them after that in the whole six months I was 
there.” (Service user forum - Review Group Service User and Carer Consultation) 
1.7	 The Blakey Review specifically considered security issues and measures to disrupt 
the supply of drugs into prison. The review made 10 recommendations on how 
to improve the effectiveness of the Prison Service’s measures for disrupting the 
supply of illegal drugs into prison, which were accepted by Government. 
1.8	 This complex backdrop makes prisons a uniquely complicated drug treatment 
setting and highlights the difficulties in establishing integrated care pathways and 
a comprehensive drug treatment and interventions system within prisons and for 
people on release. 
Continuity of care for drug users moving between England and Wales 
1.9	 In Wales, all health and community safety issues and funding have been devolved 
and are now the responsibility of the Welsh Assembly Government, including the 
provision of drug treatment in the community and in prisons. 
1.10	 This means that there are some differences in the types of drug treatment 
provision available, waiting times for treatment, etc. in prisons and in the 
community in England and Wales. This can create difficulties around ensuring 
effective continuity of care for drug users moving between drug treatment 
services in England and Wales. 
DRUG TREATMENT NEED 
1.11	 We found that there is an incomplete picture of drug treatment need. 
Historically, need has been determined on a local basis, so we were reliant on 
epidemiological surveys to provide central estimates of treatment need. 
1.12	 Epidemiological data indicates that on average 55 per cent of prisoners report a 
serious drug problem on arrival, with 80 per cent reporting some misuse and 
around 7 per cent of prisoners reporting severe alcohol dependency. These 
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figures are derived from an Office for National Statistics report. This report 
followed a large psychiatric survey of morbidity among prisoners in 1997, which 
indicated that levels of drug dependency for males was between 43 per cent and 
51 per cent and for females between 41 per cent and 54 per cent. 
1.13	 Other surveys have corroborated this estimate. A survey carried out by the 
Home Office in 2003 indicated that up to 60 per cent of female prisoners had a 
drug problem. 
1.14	 Despite the considerable investment in prison drug treatment in recent years, it 
is estimated that there remains a significant unmet treatment need. 
CURRENT APPROACHES AND THE VIEWS OF SERVICE USERS AND CARERS 
1.15	 A variety of initiatives and programmes have established drug treatment and 
intervention services both in prisons and in the community to address the wide 
range of issues presented by drug users. Overall, this appears to have had a 
positive impact, for example: 
•	 Funding for prison drug treatment has increased year on year and is now over 
15 times that of 1997 – with record numbers engaging in treatment. 
•	 In this time drug use in prisons, as measured by random mandatory drug 
tests, has decreased by 68 per cent. 
•	 There has been a significant decline in adult re-offending since 2000, and 
figures show a fall of 13 per cent between 2005 and 2006. 
•	 Since the development of the Drug Interventions Programme (DIP) in 2002, to 
provide a route out of crime and into treatment, recorded acquisitive crime – 
of which drug-related crime makes a significant contribution – has fallen by 
almost a third. 
•	 Record numbers continue to be engaged in drug treatment in the community, 
including drug-using offenders - 207,580 were in treatment in 2008/09; and 
24,656 successfully completed their treatment free of dependence , which is 
a 35 per cent increase on the previous year’s figures and almost double the 
rate of a few years ago. 
1.16	 In order to gain a full picture of the impact of the current approaches, we not 
only reviewed the range of drug treatment and interventions available but also 
carried out a service user and carer consultation process and asked their views on 
the best and the worst aspects of the current system and the changes they would 
like to see. 
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1.17	 This review was carried out in a very short space of time and the results exceeded 
expectations - responses were received from 553 drug users, ex-drug users and 
carers and included responses from service user forums held in prisons and 
service user groups in the community. 
1.18	 The full report on the service user and carer consultation can be found in 
Appendix A. 
1.19	 One of the overall themes to emerge is that people need to feel they have 
choices. This is as important when deciding about treatment and interventions 
options and in choosing their own route to recovery i.e. working toward 
abstinence. The reality of supported self-change is vital in a recovery focused 
treatment system in order to raise aspirations and create opportunities for 
further self-change and personal development. 
“The drug treatment in prison has improved due to the fact that no-one likes to be 
forced to stop like they did a year ago and before. So now when we get released, 
we can still be on scripts if we choose that we are not ready to stop. Us prisoners 
basically have more choices now.” (Prison questionnaire respondent - Review 
Group Service User and Carer Consultation) 
1.20	 Carers identified themselves as the major support for someone leaving prison 
and yet they often felt left out of the treatment process. Carers recognised that 
improvements had taken place but wanted to receive more information early on 
in treatment and to be more involved prior to release. Early involvement was felt 
to be especially important with respect to younger offenders. 
“In general, better information sharing and dialogue with families would facilitate 
a smoother release process and make the family feel more engaged in an issue 
they invariably have a large stake in.” (Carer forum - Review Group Service User 
and Carer Consultation) 
1.21	 The current range of drug treatment and interventions available in prisons and 
for people on release are briefly outlined below, along with views from users and 
carers. 
Clinical Drug Treatment Services 
1.22	 An range of clinical services, funded by the Department of Health, are available in 
prisons to: 
•	 Provide clinical management of drug use problems through detoxification 
and/or maintenance prescribing programmes. 
•	 Address the associated wider health issues, which arise from drug use, such 
as blood borne viruses, deep vein thromboses, abscesses and dental disease. 
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•	 Provide clinical management to drug users with serious mental health 
problems (dual diagnosis). 
1.23	 The Department of Health were committed to ensuring that prison clinical drug 
treatment was brought to a minimum standard across all English prisons by 2011. 
In 2009/10, £39.7 million was allocated for primary care trusts (PCTs) to 
commission clinical drug treatment services on behalf of prison/PCT partnerships 
and from April 2010, clinical drug treatment funding was available for all adult 
(over 18 years of age) in English prisons. 
1.24	 Increased funding for clinical drug treatment has resulted in an increase from 
40,000 people on detoxification and prescribing programmes in prisons in 
2001/02 to 59,000 people in 2007/08. By 2009/10, a total of 60,067 prisoners 
had received a clinical drug intervention. Of these, 36,323 received detoxification 
and 23,744 received a maintenance prescription for opioid dependency of either 
methadone or buprenorphine. 
Service Users and Carers’ Views: 
•	 Drug users recognise that drug treatment has improved and many saw this as 
being significant. 
•	 The factors that drug users report as being good include speed of access, being 
able to exercise choice and having continuity of treatment both on entering 
prison and during transfer within the prison estate. 
“They give you what you need and the doctor listens to you and he will give you 
what you’re more comfortable with subutex or methadone.” (Prison 
questionnaire respondent - Review Group Service User and Carer Consultation) 
•	 Drug users also rate good clinical treatment as having an impact on reducing the 
need to use illicit drugs in prison and reducing bullying and debt. 
“Means we don’t buy illegal drugs in jail, so we all have money for canteen, etc. 
also puts people off bringing in drugs as they struggle to sell them.” (Prison 
questionnaire respondent - Review Group Service User and Carer Consultation) 
•	 Different categories of prison, however, varied in access to detoxification or 
maintenance and the availability of certain programmes. Fewer drug users had 
experience of Category A prisons but amongst those who had, they more 
generally reported the experience of drug treatment as being negative. 
“Only been in Cat A and it’s not good they treat everybody as if they’re still on the 
street and lying and cheating to get what they can to get high when they really 
just want to feel calm and sleep at night!” (Prison questionnaire respondent -
Review Group Service User and Carer Consultation) 
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•	 Transfers were felt to result in unmet needs when the new prison has a different 
regime that restricts choice about what medication or programme is being 
followed. This was also said to affect care on release adversely. 
“I was on a detoxification and I got shipped to another prison and then that 
particular prison didn’t allow people there who were on medication for the high 
amount I was on. So I had to stay there for two days without anything and they 
sent me back.” (Service users forum - Review Group Service User and Carer 
Consultation) 
Dual Diagnosis 
1.25	 Responsibility for dual diagnosis, by its nature, overlaps a number of the health 
and social care services provided in prisons, including primary mental health 
services, secondary mental health services, drug treatment services, chaplaincy 
and peer support groups. Prisons vary in the way in which the functions of 
mental health and substance use interventions are divided between these 
respective departments. 
1.26	 Improved services for prisoners who have a dual diagnosis of mental health and 
substance use problems is a recommendation under the Bradley Review and 
work is underway to improve the management of dual diagnosis among 
offenders, through the cross-Government Health and Criminal Justice 
Programme, specifically: 
•	 In response to the need identified by Her Majesty's Inspectorate of Prisons 
for more coordinated care for people in prisons with dual diagnosis, the 
Department of Health and Ministry of Justice issued joint guidance in 2009 for 
prison commissioners, service providers and practitioners on the 
management of dual diagnosis within prisons. This work incorporates the 
instruction from the mental health Care Programme Approach policy that 
individuals with dual diagnosis should have their care coordinated within the 
Care Programme Approach process. This is the first published national 
guidance for any prison system in the world. 
•	 A partnership dual diagnosis training project was initiated in March 2009 that 
involves the Department of Health, Skills for Health and the Pan-London 
Lifelong Learning Network. The project is producing a national higher 
education accredited set of dual diagnosis training modules for staff working 
in prisons. These modules will be available for inclusion in higher education 
courses across England and Wales for any practitioner working in any part of 
the criminal justice sector. The module will also be approved under the 
Bologna agreement for the whole of Europe, the first dual diagnosis course to 
be so accredited for any patient group or setting. 
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Service Users and Carers’ Views: 
•	 One of the biggest problems cited by people as not being met was mental health 
problems. 
•	 Drug users cited lack of awareness and knowledge about dual diagnosis, poor 
medical responses, including long waiting times to see a mental health 
professional and differences across all categories of prison. 
“I am on anti-depressants and I have still not been seen by a member of the 
mental health team to assess my health. They seem to want to throw tablets at 
us to shut us up.” (Prison questionnaire respondent - Review Group Service User 
and Carer Consultation) 
“I suffer with bad depression but wasn’t given anything for it just placed on the 
hospital wing. No one seemed to address my mental health needs, if you’re on 
methadone they won’t give you anything else, that’s what the doctor told me.” 
(Community questionnaire respondent - Review Group Service User and Carer 
Consultation) 
Drug Related Deaths 
1.27	 Farrell and Marsden found that in the week following release, prisoners are 37 
times more likely to die of drug overdose than other members of the public, due 
to diminished opioid tolerance. Women are 69 times more likely to do so. 
1.28	 A 2010 study by Stover and Michels highlighted that "coercive abstinence in 
prison may be followed by relapse immediately after release, often resulting in 
overdose, drug emergencies and death". The high death rates demonstrated in 
this study is a reminder of the real risk that prisoners, particularly newly detoxed 
ones, face on release. 
1.29	 There is no doubt that these death rates are likely to be significantly reduced by 
the provision and continuation of substitution treatment, so FP10 MDA 
prescriptions to prisoners were piloted in eight prisons and now being fully rolled 
out. 
Service Users and Carers’ Views: 
•	 Continuity of prescriptions on release i.e. access to a prescription on the day of 
release was highlighted as important. 
•	 However, the need for ID or a formal letter was cited as a block to gaining a 
prescription from a GP in the community. 
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“Sometimes when you get out of jail you have to wait a few days before you can start 
your script up again ‘cos sometimes it takes a while to get in touch with the jail or 
whatever excuse they’ve got. But if you get out and you’ve got your script waiting for 
you, then it might be aright, ‘cos if you haven’t, you’ve got to go out and do 
whatever you have to do to make the money and then buy the heroin to substitute.” 
(Service user forum - Review Group Service User and Carer Consultation) 
Harm Minimisation Approaches 
1.30	 In 2001, a universal prison hepatitis B vaccination programme was established. 
English prisons are now the health setting that immunises the greatest number of 
injecting drug users per annum. 
1.31	 A number of health promotion initiatives for the prevention of blood borne 
viruses have been developed including a DVD “Hepatitis C: inside and out”. 
1.32	 In 2007/2008 a series of policy and programme initiatives in prisons in England & 
Wales were established to prevent and control blood borne viruses including the 
distribution of disinfecting tablets in prison. 
Service Users and Carers’ Views: 
•	 In spite of the above, harm minimisation was generally thought to be lacking, in 
particular with respect to sharing of needles and razors. 
“There are a lot of problems with needles in prison, people making them from 
anything they find (pens for example) or stealing them from clinical waste bins. 
There are people who already have an abscess who are continuing to inject in 
prison.” (Service user forum - Review Group Service User and Carer Consultation) 
Psychosocial Interventions 
1.33	 The Ministry of Justice funds psychosocial drug services in prison, comprising of 
CARAT services, including IDTS (£33.9m in 2009/10) and Accredited Drug 
Treatment programmes (£22.2m in 2009/10). Details on these programmes are 
briefly summarised below. 
CARAT (Counselling, Assessment, Referral, Advice, Throughcare) Services 
1.34	 CARAT services have been available in all adult and young offender prisons in 
England and Wales since 1999. CARATs provide psychosocial support and advice 
to drug users by assessing the nature and extent of their problematic drug use 
before providing, or referring to, a range of psychosocial interventions. The 
service is designed to address the needs of low, moderate and severe drug users 
and to act as a gateway or link to other services within prisons and the 
community through the following key provisions: 
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•	 Access, referral & throughcare 
•	 Assessment 
•	 Key working 
•	 Care planning and reviewing 
•	 Structured psychosocial intervention 
Accredited Drug Treatment Programmes 
1.35	 Prisons run a variety of rehabilitation programmes for drug users. The 
programmes are designed to reduce the risk of re-offending through alleviating 
prisoners’ substance use problems. There are three types of programme, based 
on different therapeutic approaches: 
•	 Cognitive behavioural therapy (CBT) - Examples of prison CBT programmes 
include P-ASRO (Prison-Addressing Substance Related Offending), which is a 
low/medium intensity programme that runs in 39 male prisons (a gender 
specific P-ASRO for Women is available at Low Newton) and Short Duration 
Programmes available in 43 prisons across the estate. 
•	 12-step programme - The 12-step approach works on the assumption that 
addiction is a life-long illness that can be controlled but not necessarily 
completely cured. The 12-step programme is available in twelve prisons. The 
programmes are high intensity for highly dependent individuals and last for 
15-18 weeks. 
•	 Structured therapeutic community (TC) - TCs are based on hierarchical 
treatment and aims to teach new behaviours, attitudes and values, reinforced 
through peer and TC support. It is available for adult prisoners with a 
medium or high risk of reconviction and level of dependence on drugs. There 
are currently four TCs across the prison estate. 
1.36	 Referral to these programmes is through CARATs, based on risk and need. The 
different approaches allow the individual to be directed towards the treatment 
that is most suited to the severity of their problem and fits with their personal 
characteristics and circumstances. Some of the CBT programmes are suitable for 
people who are stabilised on methadone prescribing as part of the process of 
working towards abstinence, while the 12-step and TC models require 
participants to be entirely drug-free before commencing the programme. 
Service Users and Carers’ Views: 
•	 In terms of psychosocial interventions, the factors which are rated as being good 
include the quality of relationships, ease of access and experiencing a 
transformation in which drug users describe their life as having being ‘turned 
around’. 
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“It helps me to focus on turning my life around. It stops me from wanting to use 
drugs in the prison and I can learn to control my addiction problems and move 
forward in life. I think it is the best way forward in tackling drugs and it motivates 
yourself to change your life style.” (Prison questionnaire respondent - Review 
Group Service User and Carer Consultation) 
•	 CARATs are very well regarded but drug users reported having difficulties in 
access in some prisons and waiting long periods. 
“CARATs really explained things to you, help you, advise you and they do really 
listen to you and do care what your life is about.” (Prison questionnaire 
respondent - Review Group Service User and Carer Consultation) 
“In most prisons it just takes too long to get to see a CARAT worker that would be 
my main concern (Prison questionnaire respondent - Review Group Service User 
and Carer Consultation) 
•	 Intensive courses and programmes including 12-step were very highly valued but 
drug users reported difficulties in access resulting from waiting times, lack of 
capacity and differences across the prison estate. 
“It’s given me the chance to get my life back on track and to live clean and sober. 
I can now see a future for myself and all I have to do is keep going to my meetings 
and work my recovery daily.” (Service user forum - Review Group Service User and 
Carer Consultation) 
Voluntary/Compact-Based Drug Testing 
1.37	 Compact-based drug testing is intended to provide an incentive for people in 
prisons to stay drug free – either because they are recovering from drug 
dependence or because they wish to continue receiving particular privileges, 
such as a release on temporary licence or a more desirable job within the prison. 
They provide a level of assurance to staff that people are sticking to the terms of 
their compact, but this would also be considered in light of other factors such as 
their general behaviour, drug finds or mandatory drug tests. 
Integrated Drug Treatment System for Prisons (IDTS) 
1.38	 IDTS was introduced in 2006 with the aim of enhancing clinical interventions for 
drug users in prison, reducing duplication in assessments, improving integration 
between healthcare and CARAT services, and reinforcing continuity of care 
between prisons and the community. The development of IDTS has resulted in 
considerable investment in clinical drug treatment, case management and 
psychosocial provision, including the development of pathways of care and 
improved contract management. 
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Service Users and Carers’ Views: 
•	 In terms of continuity of care, drug users’ experience is very varied and this 
reflects the fact that there are clearly different levels and quality of service. For 
example, one aspect of the lack of continuity of care concerned the differences 
between different categories of prison, which ranged from having no treatment 
to being treated very well. 
•	 Lack of choice features prominently, especially with respect to issues beyond the 
person or the prison’s control such as early release from court. 
“It could even happen while you go to court; your space may have been taken 
over by the jail that you have come from and you’re in the middle of a detox 
programme, you get shifted out to another jail and you have to start all over 
again, back to square one. You have to contact a doctor again and all that kind of 
stuff.” (Service user forum - Review Group Service User and Carer Consultation) 
•	 Concerns were raised about poor relationships with prison officers and between 
officers and drug treatment workers. These poor relationships are often 
characterised by security and staffing issues. 
“It’s just that battle between CARAT workers and the Screws…you hear them ‘Oh 
them bloody CARAT workers are here again’…They see them as interference.” 
(Service user forum -- Review Group Service User and Carer Consultation) 
•	 People with substance problems other than heroin stated that their needs were 
often unmet e.g. alcohol and crack use. 
“The help for heroin addicts is good but I myself need help for depression, crack 
addiction, alcohol and cannabis and as they are not physically as bad so I don’t 
get any help…”(Prison questionnaire respondent - Review Group Service User and 
Carer Consultation) 
•	 Experience on reception and assessments were stated as being problematic, 
especially when the person entered prison on a Friday night and could not be 
assessed adequately until Monday morning. 
“Say you’ve landed on a Friday and it has gone passed the times for the chemist 
to check, you’ve got all weekend then until Monday until they arrive before it is 
found out. So if you say well actually I’m on this medication or that medication 
they don’t give it you.” (Service user forum - Review Group Service User and Carer 
Consultation) 
•	 Drug users reported having to undertake repeat assessments and finding it 
difficult to keep stating their needs. 
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Drug Interventions Programme (DIP) 
1.39	 Drug users released from prison requiring assistance for drug problems can 
access DIP services, which are made up of multi-disciplinary teams, known as 
Criminal Justice Intervention Teams (CJITs). The CJIT allocates a worker following 
an assessment process. This can occur at any point in the criminal justice system 
or on leaving treatment. Where a CJIT client is remanded into custody, CARATs 
take responsibility for managing drug treatment whilst the person is in prison and 
liaise with the CJIT in preparing release plans at the end of the sentence. 
1.40	 Research shows that offending levels can fall following contact with DIP, which 
has made drug users face tough choices about their drug use and need for 
treatment. 
Service Users and Carers’ Views: 
•	 Drug users identified lack of, or poor, care planning on release as a factor that 
could influence their progress. 
•	 More integrated care planning and greater joined up services between prisons 
and the community, including end-to-end management, were cited as 
improvements that drug users would like to see. 
“It would be nice to get picked up by your drug worker so you don't end up getting 
drugs on the way home”. (Service user forum - Review Group Service User and 
Carer Consultation) 
“Someone to meet you from either the local DIP teams or a trusted person to 
make sure you are not going to slip straight back to your old habits”. (Service user 
forum - Review Group Service User and Carer Consultation) 
Drug Rehabilitation Requirements 
1.41	 From April 2005, the Drug Rehabilitation Requirement (DRR) has gradually 
replaced the Drug Treatment and Testing Order (DTTO) as the main delivery 
route for drug interventions for adults within community sentencing. The DRR is 
targeted at drug users who commit acquisitive crime to fund their drug habit and 
show a willingness to co-operate with treatment. The DRR requires the individual 
to undergo treatment for a specified period, to be regularly tested for drug use 
and to attend review hearings where the court will assess progress under the 
order. 
1.42	 The DRR offers courts an intensive vehicle for tackling the drug use and offending 
of many of the most serious and persistent drug using offenders and as such, 
represents a viable alternative to custody. The number of DRRs/DTTOs has 
increased from 4,854 DTTOs in 2001-02 to 17,642 DRRs and DTTOs in 2008/9. 
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The proportion of offenders successfully completing DRRs/DTTOs has increased 
from 28 per cent in 2003 to 47 per cent in 2008/9. 
Service Users and Carers’ Views: 
•	 Having something meaningful to do, including employment, education and 
structured programmes, was cited as a key determinant in remaining drug free. 
•	 Appropriate accommodation - hostels were cited as places where drug use was 
common and a risk to those who had been released drug free. Women in 
particular identified the importance of being re-housed way from their old areas 
as significant to their progress and remaining drug free. 
“I need to go to secondary rehab so that I can keep the work that I’m doing in 
here. It’s my last chance to stay drug free and I can’t afford to waste it.” (Prison 
questionnaire respondent - Review Group Service User and Carer Consultation) 
•	 Many drug users cited inadequate access to funds as being a factor that would 
lead them back to old habits, especially offending. 
“They say to you that there is a thing called a crisis loan and they don’t even give 
you that. You’re sitting there saying I’ve got no food in my house. When I’m in 
prison I get three meals a day. I’m now out of prison and I’m not eating.” (Service 
user forum - Review Group Service User and Carer Consultation) 
1.43	 There is no doubt that progress has been made, and service users and carers 
acknowledged the improvements and increased access to drug treatment and 
interventions in prisons and on release. However, more action needs to be taken 
to build on current gains and to address the issues and concerned raised by 
service users and carers. 
THE EVIDENCE BASE 
1.44	 At the start of the review, we agreed that as far as possible our 
recommendations should be evidence-based. Therefore, we carried out a 
thorough review of the evidence base for drug treatment and interventions in 
prisons incorporating over 160 high quality peer reviewed papers, to consider: 
•	 The current drug treatment and interventions services provided in prisons 
•	 An overview of evidence for effectiveness by treatment modality 
•	 The issues that influence effectiveness and interpretation of evidence 
1.45	 This review concluded that good quality drug treatment and interventions are 
effective and can contribute to a reduction in re-offending and reduced mortality 
from accidental drugs overdose or chronic health problems such as blood borne 
viruses. 
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1.46	 To address the gaps around the evidence base, which are mostly around 
psychosocial interventions, we agreed an expert consensus on ‘good-practice’ 
and the importance of having integrated medical and psychosocial services 
within a menu of drug treatment services if recovery and rehabilitation of drug 
users are to be realised. 
1.47	 Research on efficiency savings and value for money on drug treatment and, 
specifically, on drug treatment and interventions in prisons was also reviewed. 
Prison-based treatment services can provide good value for money providing 
they are linked to rehabilitation and resettlement, and offer good potential for 
improving the life expectancy, reducing costs associated with deaths in custody, 
and reducing re-offending and future criminal justice system costs. 
1.48	 The evidence review was used to inform our debates and is one of a number of 
information-based papers produced to inform discussions. It should be read, 
therefore, in conjunction with other papers within the Appendices, specifically 
the papers on outcomes as evidence and outcomes are interrelated. 
1.49	 Full details of this evidence base review can be found in Appendix B and the 
impact of this and the service user and carer consultation can be found in Part 2, 
which outlines the recommendations of the Review Group. 
CHANGES IN THE POLITICAL LANDSCAPE 
1.50	 Since the inception of this review, there has been a substantial change in the 
political landscape. The Coalition’s programme has indicated that this 
Government will re-look at issues with regard to drug use, crime and 
rehabilitation and the NHS White Paper, Equity and excellence: Liberating the 
NHS, has already announced fundamental changes to the NHS commissioning 
system. 
1.51	 There is no doubt that further changes are likely to be announced within the new 
drug strategy, the Green Paper on rehabilitation and so forth. This provides an 
opportunity to achieve the cultural and system change needed to engage drug 
users and the communities within which they reside in effective drug treatment 
while in prison and to maximise their prospects for recovery and reintegration on 
release into the community. 
1.52	 We believe that our recommendations are in step with this changing political 
landscape - e.g. streamlined commission systems and a move towards outcomes. 
1.53	 And, with these recommendations, we seek to raise the levels of ambition about 
what can be achieved and to challenge the reluctance to recognise and harness 
the full potential of drug users to actively engage with and assume responsibility 
for their own recovery, including a renewed focus on abstinence as a clear goal. 
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2.	 THE RECOMMENDATIONS 
DEVELOPMENT OF THE REVIEW GROUP’S RECOMMENDATIONS 
2.1	 The aim of this review has been to learn where there is good practice and 
innovative approaches and to improve and re-focus existing drug treatment and 
interventions systems and services in prison. 
2.2	 Therefore, the focus of our recommendations is on highlighting the potential for 
more effective use of resources and the gains that can be made by improving the 
quality of drug treatment and intervention services in prison. The 
recommendations are based on doing more within existing resources, reinvesting 
short- and long-term savings across the system, unlocked by implementing good 
practice more widely and supported by clear streamlined systems and evidence 
about what needs to be delivered. 
2.3	 We recognise that within the current economic climate it is important that any 
recommendations achieve greater efficiency and cost effectiveness. Any future 
strategy around drug treatment and interventions in prisons must be able to face 
tough choices about where to target resources and a determination to get value 
for money from every pound spent and, where possible, demonstrate a 
quantifiable return on investment by increasing innovation, raising standards and 
quality, and achieving efficiencies. 
2.4	 Therefore, we have worked on the basis that our recommendations should not 
need additional money to implement them, but would need to address: 
•	 Improving the quality of drug treatment for people in prison and on release 
from prison, through the development of clear standards and outcomes. 
•	 Increasing innovation – in terms of service delivery, commissioning and 
partnership working - to contribute to a reduction in re-offending and 
reduced mortality from accidental drugs overdose or chronic health problems 
such as blood borne viruses. 
•	 Achieving efficiencies and improving cost effectiveness within the drug 
treatment system in prison and for people on release from prison. 
2.5	 There was a wide range of issues that this review could potentially focus on, 
however, to attempt to tackle all issues could result in a diluted approach that 
actually fails to have any impact. Therefore, we chose to focus on six key areas 
that we believe would have the most significant impact and deliver 
improvements in the outcomes and experiences of drug users in prison and on 
release. 
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2.6	 All these recommendations are interlinked and need to be viewed in an 
integrated way. For example, the commissioning and outcomes 
recommendations are complementary and both are necessary – without clear 
outcomes, effective commissioning standards cannot be established and the 
commissioning of effective care pathways covering drug treatment and 
interventions, continuity of care provision and mainstream 
reintegration/recovery services (housing, employment) are essential in helping 
drug users to make lasting changes. 
2.7	 Our work programme, the key elements to be addressed and our 
recommendations are outlined below. 
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RECOMMENDATION 1: CROSS-GOVERNMENT STRATEGY

Criticisms of current system: Lack of a clear inter-departmental strategy; no 
agreement on priority of outcomes – health vs. re-offending, therefore, unclear 
what commissioning is for; variability of views between Government 
Departments. 
Review Group Recommendation: Achieve efficiencies and improve cost 
effectiveness by developing (for the first time in England) a unified cross-
Government drug treatment and interventions strategy that covers people in the 
community and in prisons, moving between prisons and on release. 
2.8	 We recommend that the proposed new drug strategy covers not only community 
based drug treatment but also includes a streamlined, unified cross-Government 
drug treatment and interventions strategy for people in prisons, moving between 
prisons and on release. 
2.9	 The lack of a unified cross-Government strategic approach to drug treatment and 
interventions within prisons and the community has created a fragmented 
treatment system with individual services and providers separated from one 
another, at times due to differing ideology and targets. 
2.10	 A unified approach to drug treatment and interventions needs to focus on 
recovery i.e. achieving abstinence; to situate the individual at the heart of 
provision; and, to encourage more inter-service partnerships, which allows 
greater flexibility and movement between system elements based on responsive, 
needs-based placement to the most appropriate service from locally available 
choices. 
2.11	 We recognise that effectively addressing the needs of drug users can be a 
challenging aspect of the management of prisoners, not only for health services 
but also for the prison regime. Tensions can develop, for example, between 
some harm reduction measures and other issues around the running of a prison 
(security, criminal justice and occupational health). Issues can also arise around 
the need to maintain confidentiality and the assurance of health and safety 
arrangements for prison staff. 
2.12	 Therefore, addressing drug use and achieving continuity of care will require an 
acceptance of practices amongst prison staff, prisoners themselves, 
professionals, and legal authorities, and will require a comprehensive, multi-
disciplinary approach including clinical and psychosocial interventions. 
2.13	 A unified approach to drug treatment and interventions at the centre is vital to 
begin the process of developing these integrated local systems where all the 
various elements are co-coordinated, speak the same language, communicate 
with each other and have an agreed set of values, principles and outcomes 
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around achieving the goal of working towards abstinence. Therefore, a cross-
Government strategy on drug treatment and interventions in prison should be 
based on: 
•	 The twin aims of reducing drug-related crime caused by re-offending and 
improving the rehabilitation of offenders. 
•	 An integrated approach (including integrated/streamlined care pathways) 
between Government Departments with a renewed focus on abstinence as a 
clear goal. 
•	 A revised streamlined commissioning system and a new outcomes model that 
focuses on the outcomes that matter i.e. a stable place to live, a job, positive 
mental health and well-being. 
•	 A robust evidence-base, including evidence of cost-effectiveness. 
•	 Making more effective use of existing residential rehabilitation services -
offenders who have become drug-free and need secure and safe 
accommodation on release should have access to these services to support 
their ongoing recovery and abstinence. 
•	 Reintegration/resettlement options – in both employment and housing 
terms, as an integral part of the building blocks to maximise recovery. 
•	 Active involvement of drug users, their families and local communities. 
2.14	 A unified prison drug treatment and interventions strategy should also 
incorporate the elements outlined in the recommendations below. 
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RECOMMENDATION 2: ESTABLISHING AN OUTCOMES FRAMEWORK

j
Criticisms of current system: Lack of minimum standards for the prison setting; 
measures of activity currently gathered not outcomes, data on outcomes 
incomplete; lack of accountability, no one in overall charge in terms of 
performance management. 
Review Group Recommendation: Shift focus and resources towards reducing re-
offending outcomes and better health outcomes, through a national health and 
criminal ustice outcomes model. 
2.15	 We carried out a thorough review of existing standards and outcomes to help us 
gain an understanding of the national context and the key factors shaping the 
drug treatment and interventions sector, which have an impact in determining 
outcomes for people in prison who require drug treatment. We considered a 
variety of issues in relation to outcomes, including: 
• The wide range of literature on outcomes 
• Factors that affect outcomes in prisons 
• Government targets in the community and in prisons 
• Relevant data/information, research and surveys 
2.16	 We concluded that there are no existing outcome models appropriate for drug 
treatment in a prison setting. 
2.17	 We, therefore, developed the first national health and criminal justice outcomes 
model for drug treatment in prisons with the twin aims of reducing re-offending 
and improving rehabilitation. This outcome model focuses on four main themes: 
•	 Reduced drug use 
•	 Reduced re-offending 
•	 Improved health and social functioning 
•	 Increased employment and enhanced workforce skills 
2.18	 This model can use existing sources of data and with a performance assurance 
framework could replace all current NOMS drug treatment key performance 
targets and the Prison Health and Performance and Quality Indictor for drug 
treatment, thereby reducing the burdens and duplication within the existing 
system. 
2.19	 We recommend that the Government adopt this model to provide a benchmark 
for the quality of service provided and to support commissioners and providers 
to evidence, assess and improve the quality of service provision. This will ensure 
consistency around service delivery across England. 
2.20	 A full report on the outcomes review and model can be found in Appendices C 
and D. 
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RECOMMENDATION 3: STREAMLINED COMMISSIONING SYSTEM

Criticisms of current system: Commissioning arrangements are complex and 
fragmented; multiple agencies involved at a national, regional and local level 
resulting in fragmented funding streams, commissioning routes, and a lack of 
consistency of approach in prisons. 
Review Group Recommendation: Shift focus and resources to develop a 
streamlined, autonomous and accountable system that is coherent, cost effective 
and enables more effective decision-making by local commissioners and 
partnerships. 
2.21	 The current complex commissioning systems are characterized by a multitude of 
funding streams and process targets, which has resulted in a fragmented system 
with the risk of a ‘one-size-fits-all’ approach with limited choices in the types of 
treatment and broader social support available. 
2.22	 In light of this, Lord Patel established an expert Commissioning Sub-Group to 
consider a range of options to streamline drug treatment and interventions 
commissioning systems for people in prison, moving between prisons and on 
release from prison. 
2.23	 Following the work and conclusions of this expert sub-group, we recommend 
that for the first time in England, the majority of drug funds be jointly 
commissioned at a local level - this includes NOMS CARATs funding. This would 
mean that local health commissioners, potentially within the new consortia of GP 
practices, and local drug partnerships including local authorities, local Directors of 
Public Health, prison governors, etc. will share the responsibility for 
commissioning drug treatment both in prisons and on release and will have a 
collective responsibility to ensure effective joint commissioning and to align/pool 
budgets to obtain the best outcomes, efficiencies and value for money. 
2.24	 Some commissioning at a national level may still be needed, for example, to 
ensure the needs of the women estate and under 21-year-old offenders are 
addressed and under this system, services can be commissioned based on needs, 
at whichever level (national, regional or local) is appropriate for the intervention. 
2.25	 We are aware that even as our work programme and recommendations were 
being completed major changes to commissioning systems within the NHS were 
being announced. Our proposed model, however, is aligned with the Coalition’s 
programme approach for a more autonomous and accountable system and with 
the NHS White Paper, Equity and excellence: Liberating the NHS. 
2.26	 PCTs will be abolished by April 2013; the main commissioning functions will pass 
to GP consortia and the public health function will pass to local authority 
commissioners. Healthcare commissioning will be the responsibility of GP 
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consortiums working with local communities to commission the majority of local 
health services from the NHS, voluntary sector and private providers. 
2.27	 There is no detail yet about what will happen to local drugs partnerships and 
where the commissioning of drug treatment will fit - it may be that it would be 
the remit of GP consortia or be part of the public health remit of the local 
authority, or it may even be split between the two. 
2.28	 These changes reinforce the need to collaborate and jointly commission locally to 
ensure that the needs of drug users in prison and on release are met, against a 
clear strategy that is reflective of consensus on evidence and good practice and 
clearly aligned with outcomes. The challenge will be persuading GP consortia to 
engage and support commissioning of community services for drug-using 
offenders when their focus will primarily be upon their registered patients and 
other higher volume/cost services. 
2.29	 Therefore, we recommend that the Government consider putting in place this 
revised commissioning system by 2011/12. 
2.30	 A full report on the work of the Commissioning Sub-Group can be found in 
Appendix E. 
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RECOMMENDATION 4: FRAMEWORK FOR SERVICE DELIVERY

j
• 
• 
Criticisms of current system: There are a number of drug treatment programmes 
in prison where both the effectiveness and whether it is ustifiable to invest 
resources on the provision of these services is uncertain; financial allocation of 
funds not linked to impact; lack of consistency of approach e.g. around what 
prisons provide; unmet demand for psychosocial programmes; poor links with 
mental health and wraparound programmes e.g. housing and employment; 
geographical inequity of provision. 
Review Group Recommendation: Refocus and increase ambition, quality and 
innovation in service delivery through an updated national drug treatment and 
interventions framework that covers both community and prisons to: 
Increase the number of drug users who are able to achieve recovery from 
dependency and sustain this for the longer-term; and, 
Contribute to a reduction in re-offending and reduced mortality from suicide, 
accidental drug overdose, blood borne viruses and other chronic health 
problems. 
2.31	 We carried out a thorough review of the evidence base for drug treatment in 
prisons incorporating over 160 high quality peer reviewed papers. 
2.32	 This review concluded that good quality drug treatment and interventions are 
effective and can contribute to a reduction in re-offending and reduced mortality 
from accidental drugs overdose or chronic health problems such as blood borne 
viruses. 
2.33	 To address the gaps around the evidence base, which are mostly around 
psychosocial interventions, we agreed an expert consensus on ‘good-practice’ 
and the importance of having integrated medical and psychosocial services 
within a menu of drug treatment services if recovery and rehabilitation of drug 
users are to be realised. 
2.34	 We also reviewed key research on efficiency savings and value for money on drug 
treatment and specifically on drug treatment and interventions in prisons. 
Prison-based treatment services can provide good value for money providing 
they are linked to rehabilitation and resettlement and offer good potential for 
improving the life expectancy, reducing costs associated with deaths in custody, 
and reducing re-offending and future criminal justice system costs. 
2.35	 Helping people get off drugs for good must be a crucial ambition for the drug 
treatment system. Delivering optimal systems of care that are evidence-based 
and supported by a range of choices and different pathways that promote 
reintegration and recovery is a vital challenge in developing a truly effective and 
balanced treatment system. 
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2.36	 Our remit covers drug treatment and interventions for people in prison, people 
moving between prisons and on release from prison, but not drug treatment in 
the community. A menu of services must cover both drug treatment in the 
community and in prisons to avoid creating further ‘silos’ and to enable genuine 
joint commissioning. Therefore, the appropriate place to develop a clear menu 
of services must be within a new national drug treatment and interventions 
framework that spans drug treatment in the community and in prison to ensure 
consistency and continuity of care. 
2.37	 Therefore, we recommend the Government agree to an updated national 
framework that for the first time in England: 
•	 Outlines the ambition to maximize drug users prospects for recovery (i.e. 
becoming free of dependency) 
•	 Spans drug treatment both in the community and in prison 
•	 Outlines an appropriate menu of services, including medical treatment, 
psychosocial interventions, harm minimisation and broader social care that 
promotes resettlement and recovery 
•	 Ensures that the service users (and carers) and their recovery are at the heart 
of all commissioning and service delivery 
2.38	 An effective outcomes framework and commissioning system will require access 
to a range of treatment and intervention services that are able to meet the 
varied, and at times, complex needs of drug users. The mix of services within any 
local area should also be based on local needs assessments to inform local joint 
commissioning practises. 
2.39	 The development of this national framework should be an early goal of the new 
drugs strategy. 
2.40	 A full report on the Evidence Base can be found in Appendix B. 
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RECOMMENDATION 5: SERVICE USER AND CARER ENGAGEMENT

Criticisms of current system: Lack of active involvement of service users in key 
aspects of decision-making in relation to their care and to the planning, delivery 
and evaluation of service provision; particular difficulties of drug user 
engagement across prison estate has lead to lack of ambition and will to involve 
drug-using offenders. 
Review Group Recommendation: Increase social capital by identifying ‘Recovery 
Champions’ in the community and prisons to reduce poor social cohesion in local 
communities and support the creation and expansion of volunteering, co-
operatives, charities and social enterprises. 
2.41	 A drug treatment system that promotes abstinence needs a robust, realistic 
narrative of recovery that is meaningful to the drug-users and their families, and 
endorses ‘Recovery Champions’, peer support and mentoring groups. 
2.42	 We are aware of the particular difficulties of drug user involvement across the 
prison estate, but believe that there is a lack of ambition and will to involve drug-
using offenders. So, within a short space of time, we established a service user 
and carer consultation process around drug treatment in prisons, developed with 
the help of ex-drug users. 
2.43	 The results exceeded expectations - responses were received from 553 drug 
users, ex-drug users, and carers, and included responses from service user 
forums held in prisons and service user groups in the community. 
2.44	 We are, therefore, in no doubt that drug users, ex-drug users and their 
families/carers have an appetite to be more actively involved and opportunities 
to increase their potential social capital should be addressed. 
2.45	 We recommend that commissioners and local partners focus on increasing the 
social capital through the identification of ‘Recovery Champions’ and appropriate 
community groups - local councillors, business people; families and friends of 
users; ex-drug users. We need to make more effective use of people who understand 
the problems of dependency; those who want to understand more; and those who may 
have resources to help make recovery a more realistic option. 
2.46	 All offenders, irrespective of race, gender, disability, age, ethnicity, religion and 
sexual orientation should be able to secure the same access to drug treatment 
services as the rest of the population. It is vital to take into account the differing 
patterns of drug use and treatment access amongst key groups. 
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2.47	 Women prisoners often present with the most complex needs amongst the 
population particularly in terms of their substance misuse. The disclosed use of 
prescribed drugs, illicit drug use and alcohol use together with a mental health 
problem can be common amongst women entering custody. 
2.48	 At a local level, active engagement with users and their families/carers can help 
tackle the unmet treatment needs and barriers to treatment, including the needs 
of young people, women drug users, Black or ethnic or other minority 
communities, sex workers or parents with dependent children - Recovery 
Champions would need to reflect this diversity. 
2.49	 In order to move away from centralisation and ‘big’ government to creating a 
‘Big Society’, Recovery Champions, community groups and the families/carers of 
drug users can play an important role in articulating ambition, championing 
routes to recovery and challenging partnerships and services to retain a recovery 
focus – both prior to release and on release. People who have personal 
experience of problematic drug use and who have achieved successful recovery, 
and feel ready to volunteer and support others, should be encouraged to become 
involved in peer support, mentoring groups and other community groups, and 
talking about what made their recovery a reality e.g. access to housing and jobs. 
2.50	 Increasing social capital is important not only to those who are recovering from 
substance misuse, but is significant from a community perspective. The role of 
social capital is important in keeping drug dealers from infiltrating into 
neighbourhoods - illegal markets tend to flourish in areas where there is poor 
social cohesion, resulting in difficulties regulating nuisance and problematic 
behaviours - and increasing social capital can support the well being of drug users 
and their families and minimize nuisance factors. 
2.51	 A full report and the result of the user and carer consultation are available in 
Appendix A. 
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RECOMMENDATION 6: ESTABLISHING LINKS TO WIDER CRIMINAL JUSTICE AND 
HEALTH AND SOCIAL CARE SYSTEM 
Criticisms of current system: Lack of consistency of approach; remand prisoners 
can get lost when release is unplanned; fragmented care pathways and lack of 
continuity of care. 
Review Group Recommendation: Increase efficiencies and improve cost 
effectiveness by ensuring drug treatment and interventions strategy in prisons is 
not developed in isolation but linked to other relevant initiatives and strategies as 
they develop. 
2.52	 Government Departments need to work closely with external organisations and 
partners to ensure joined up national thinking across institutional boundaries; to 
help break down any barriers to local partnership working; establish shared 
objectives; and, facilitate integrated care pathways between local agencies. This 
cross-boundary work should also continuously consider improvements in value 
for money. 
2.53	 Therefore, it is vital that any drug treatment and intervention strategies in the 
community and in prisons are not developed in isolation but linked to other 
relevant initiatives and strategies as they emerge. 
2.54	 Previous reports by the National Audit Office, the Committee of Public Accounts 
and others have identified failures in the delivery of public services that could 
have been avoided. A 2009 National Audit Office (NAO) report found many 
instances where major programmes and projects have been either frustrated, or 
severely hampered, by failure to take on board lesson from their own past 
experiences or those of others. The main barriers experienced by departments 
are silo structures, ineffective mechanisms to support learning, a high turnover 
within the workforce and a lack of time for learning. 
2.55	 To achieve value for money in public services, Government Departments need to 
learn from success and failure and to improve their capacity to learn from each 
other. The NAO report found that Departments often found cross-Departmental 
networks and communities of practice most valuable to supporting learning. 
2.56	 The Coalition’s programme indicated a keenness to re-look at issues with regard 
to drug use, crime and rehabilitation, so presents an opportunity to avoid 
fragmentation of approach across Government and to increase efficiencies and 
improve cost effectiveness. 
2.57	 Therefore, we recommend that all efforts are made to effectively link drug 
treatment issues with a range of other criminal justice, health and social care 
issues as they are under development, including: 
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•	 Green Paper on rehabilitation 
•	 NHS White Paper, Equity and excellence: Liberating the NHS 
•	 Review of sentencing policy - ensuring that sentencing for drug use helps 
offenders come off drugs. 
•	 Exploring drug rehabilitation prisons 
•	 Implementation of the Prisoners’ Earnings Act 1996 
•	 New Mental Health Strategy 
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EXECUTIVE SUMMARY 
INTRODUCTION 
1.	 This report provides the findings of the consultation that was undertaken 
between July and October 2009 and involved the return of 553 individual 
questionnaires and over 200 participants in 26 service user and carer forums. 
2.	 The response rate to the consultation was very good and there is a clear interest 
amongst many people to remain involved and be consulted further as the work 
of the Review Group progressed. Involvement of service users and carers was a 
priority for the Review Group and there was a commitment to ensure that there 
was open access to the Review Group’s work via the website (www.pdtsrg.co.uk). 
FINDINGS 
What is good about drug treatment in prisons and how has this improved? 
3.	 Respondents recognise that drug treatment has improved and many state this is 
significant. The factors that are rated as being good about drug treatment can be 
grouped according to two broad categories of treatment: psychosocial 
interventions and medical or clinical interventions. 
Psychosocial interventions 
4.	 The term psychosocial intervention is used very loosely to refer to all 
interventions based on human interaction and environment including CARATs, 
intensive programmes, 12-step and drug free wings, Therapeutic Communities 
and group work. The factors that are rated as being good about these 
interventions include: 
•	 The quality of relationships; 
•	 Ease of access; and, 
•	 Experiencing a transformation in which respondents describe their life having 
being ‘turned around’. 
Medical interventions 
5.	 The factors that are rated as being good about these interventions include: 
•	 Speed of access; 
•	 Being able to exercise choice and having continuity of treatment both on 
entering prison and during transfer within the prison estate; and, 
•	 Reducing the need to use illicit drugs in prison and reducing bullying and 
debt. 
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What is not so good about drug treatment in prisons and which needs were not 
addressed? 
6.	 Experience is very varied and this reflects the fact that there are different levels 
and quality of service experienced by service users. Some key differences are 
identified below: 
• Variances in different categories of prison in access to detoxification or 
maintenance and availability of certain psychosocial programmes. 
•	 Lack of choice features prominently especially in terms of issues beyond the 
person’s or the prison’s control such as early release from court. 
•	 Transfers are felt to result in unmet needs when the new prison has a 
different regime that restricts choice about what medication or programme 
was being followed. This was also said to affect aftercare adversely. 
•	 Concerns were raised about poor relationships with prison officers, and 
between officers and drug treatment workers. These poor relationships are 
often characterised by security and staffing issues. 
•	 Respondents with substance use problems other than heroin, e.g. alcohol and 
crack use, stated that their needs were often unmet. 
•	 One of the biggest problems cited by respondents as not being met was 
mental health problems. In particular, respondents cited a lack of awareness 
and knowledge about dual diagnosis, poor medical responses including long 
waiting times to see a mental health professional, and differences across 
categories of prison. 
•	 Experience of reception and assessments were cited as being problematic 
especially when the person entered prison on a Friday night and could not be 
assessed adequately until Monday morning. 
•	 Respondents also reported having to undertake repeat assessments and 
feeling that it was difficult to keep stating their needs. 
•	 Harm minimisation was generally thought to be lacking, in particular with 
respect to sharing of needles and razors. 
•	 CARATs are very well regarded, but respondents reported having difficulties 
in access in some prisons and waiting long periods. 
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•	 Intensive courses and programmes including 12-step were very highly valued 
but respondents reported difficulties in access resulting from waiting times, 
lack of capacity, and differences across the prison estate. 
What are the key factors on release that would prevent returning to old habits? 
7.	 Amongst the factors that respondents stated would prevent them from returning 
to old habits were: 
•	 Continuity of prescription on release by which they meant having one on the 
same day. The need for identification or a formal letter was cited as a block 
to gaining a prescription from a GP in the community. 
•	 Appropriate accommodation - hostels were frequently cited as being places 
where drug use was common and as such a risk to those who had been 
released drug free. 
•	 Women in particular identified the need to be able to be re-housed away 
from their old areas as significant to their ongoing progress and remaining 
drug free. 
•	 Many respondents cited inadequate access to funds as being a factor that 
would lead them back to old habits, especially offending. 
•	 Having something meaningful to do including employment, education and 
structured programmes was cited as a key determinant in remaining drug 
free. 
•	 Respondents identified lack of, or poor, care planning on release as a factor 
that could influence their progress. 
•	 More integrated care planning and greater joined-up services between prison 
and community, including end-to-end management, were cited as 
improvements that respondents would like to see. 
•	 In most cases, carers identified themselves as the major support for someone 
leaving prison, and yet they often felt left out of the treatment process. 
•	 Carers did recognise that improvements had taken place but they wanted to 
see carers receive more information early on in treatment and to be more 
involved prior to release. Early involvement was felt to be especially 
important with respect to younger offenders. 
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CONCLUSIONS 
8.	 One of the key themes to emerge is that people need to feel they have choices. 
This is as important when deciding about treatment options as it is in choosing 
their own route to recovery. 
9.	 Carers feel very strongly that they should be more involved in decision-making 
about treatment options and better informed about what happens to people 
while they are in prison and prior release. 
10.	 There is a very strong call amongst service users and carers for greater continuity 
of treatment both within and between prisons and from community to prison. 
11.	 There is also a very clearly articulated need for much greater support and help on 
release especially with respect to appropriate housing, having enough money, 
having something meaningful to do, and greater integration and co-ordination 
with community services. 
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1.	 INTRODUCTION 
1.1	 Prison Drug Treatment Strategy Review Group (henceforth known as the Review 
Group), chaired by Professor Lord Patel of Bradford OBE has been tasked by 
Ministers with overseeing a programme of work to address ways in which drug 
treatment in prisons can be improved. 
1.2	 In order to inform this work the Review Group has undertaken a consultation 
with service users and carers about their experiences of drug treatment. This 
report provides the findings of the consultation, which was undertaken between 
July and October 2009 and involved the return of 553 individual questionnaires 
and over 200 participants in 26 service user and carer forums. 
1.3	 Manjit Singh Johal, the service user representative for the Review Group, and 
Rachael Hunter (Project Team) with additional help in the analysis and 
presentation of the report from Dr Jon Bashford and Sherife Hasan (Project 
Team), conducted the consultation. 
1.4	 The consultation sought both positive and negative views about the experience 
of drug treatment and interventions in prisons and asked respondents to identify 
which needs they felt were unmet and how this could be improved. 
1.5	 The response rate to the questionnaires was almost a third and the attendance at 
service user and carer forums varied from two to forty with an average of six 
people at each event. 
1.6	 This is largely a qualitative piece of work where respondents were asked to 
provide their views and opinions to a number of open questions. The analysis 
consisted in the identification of core themes grouped according to the core 
scripts used in the questionnaires and service user and carer forums. The report 
is structured around these core questions, which are: 
•	 What is good about drug treatment in prisons and how has this improved? 
•	 What is not so good about drug treatment in prisons and which needs were 
not addressed? 
•	 What are the key factors on release that would prevent returning to old 
habits? 
1.7	 There is a final section on the process of the consultation and ways in which 
respondents have asked to be kept informed about the work of the Review 
Group and the outcomes from the consultation. 
1.8	 The clear message from the service users and carers is that drug treatment is 
very personal to the individual and the road to recovery is something people are 
very passionate about, as shown by the large number of responses received. For 
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those who have gone through it all and come out the other side they wanted to 
share their journey with others with the hope it might help someone else, but for 
each person the process was different. Many of the responses indicated a desire 
to give something back to others. 
1.9	 For those still struggling with their drug use they had an idea where they are up 
to and what currently works for them - this varied from person to person. At all 
stages - entry to prison, moving between prisons, or on release - each person 
describes their journey towards recovery as being very individual. The wide 
range of responses demonstrates the variety of experience and knowledge and 
how different respondents can be anywhere along this spectrum. 
1.10	 Some know a lot about drug treatment having done many courses and 
experienced many clinical treatments. Some know very little and may be on their 
first prison sentence with little or no understanding about what addiction means 
or that there is such a thing as drug treatment. 
1.11	 Many recognise that they need help, but are not sure what that it entails or how 
to access it. 
1.12	 Others are in different place in terms of their recovery – some people are totally 
abstinent and have not used for months or years; some are abstinent but lapse or 
relapse from time to time; some are stable whilst maintained on a prescription 
and feel that without this they will use drugs again; and some appear to be going 
through a continuous cycle of drug use, treatment, abstinence and relapse. 
1.13	 One of the key themes to emerge is that people need to feel they have choices. 
This is as important when deciding about treatment options as it is in choosing 
their own route to recovery. 
1.14	 Carers feel very strongly that they should be more involved in decision-making 
about treatment options and better informed about what happens to people 
while they are in prison and prior release. 
1.15	 There is a very strong call amongst service users and carers for greater continuity 
of treatment both within and between prisons and from community to prison. 
1.16	 There is also a very clearly articulated need for much greater support and help on 
release especially with respect to appropriate housing, having enough money and 
co-ordination with community services. 
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2. METHODS 
Background 
2.1	 The script for the service user forums was developed with the Review Group 
service user representative and two service users. 
2.2	 The draft Service User Forum Script was discussed at the Review Group meeting 
in June 2009 and an amended version was approved in July 2009. The first 
version of the script was piloted with the Greenwich Local Addiction Support 
Service (GLASS) service user forum to test for usability. Some questions were 
found to overlap so amendments were made to produce the final version. The 
final version of the Service User Forum Script was tested with service users from 
the London Council and no further amendments were made. 
2.3	 On the 24 July 2009, a letter from Lord Patel, with service user scripts for prisons 
and community attached, was sent to six service user groups, NTA Regional 
Development Managers, Review Group members and Government officials (See 
Annex i). It was also posted on the website (www.pdtsrg.co.uk). 
2.4	 A questionnaire was developed after consultation with the Rehabilitation of 
Addicted Prisoners Trust (RAPt) as this was seen as the best way to consult their 
graduates (See Annex ii). 1,600 questionnaires were sent to RAPt graduates. 
Copies of the questionnaire were also available on the website and were sent 
with copies of Lord Patel’s letter. 
2.5	 Pilot visits were made to HMP Wandsworth, Holloway and Belmarsh with two 
service user facilitators to hold service user forums with 10 people in prison 
receiving drug treatment. Most of the forum participants were selected through 
their attendance of the prisons’ Short Duration Programme (SDP). 
2.6	 The deadline for responses was the 10 September 2009, although responses 
received up until the 10 October 2009 have been included in the analysis. In 
addition to the questionnaire, testing groups and the piloting of a further 25 
Forums were conducted by service user groups involving more than 200 
participants and 553 individual questionnaires were returned. (A full list of 
responding organisations can be found in Annex iii). 
2.7	 All the data has been analysed using methods derived from Grounded Theory 
(Glaser and Strauss, 1967
1
) such as category development and comparison in 
order to identify common thematic groupings. Some limited statistical analysis 
has been undertaken using an Excel spreadsheet on the questionnaires in order 
to provide a detailed breakdown of the sample demographics. 
1 
Glaser, B.G. and Strauss, A.L. (1967) The Discovery of Grounded Theory Chicago: Aldine 
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The Sample of Respondents 
Questionnaires 
2.8	 In total 553 questionnaires were returned. Of these, 299 were from people 
currently in prison and 254 were from people in the community. One 
questionnaire was returned from a carer. The following tables provide the 
demographic breakdown of the prison and community samples. 
Prison sample Community sample 
Gender Gender 
Male 176 58.86% Male 147 58.10% 
Female 97 32.44% Female 90 35.57% 
Blanks 25 8.36% Blanks 16 6.32% 
Trans 1 0.33% 
Prison gender	 Community gender

Prison sample Community sample 
Ages Ages 
18 - 24 12 4.01% 18 – 24 27 10.67% 
25 - 31 119 39.80% 25 – 31 78 30.83% 
32 - 38 83 27.76% 32 – 38 72 28.46% 
39 - 45 38 12.71% 39 – 45 43 17.00% 
46 - 52 14 4.68% 46 – 52 13 5.14% 
53 - 59 6 2.01% 53 – 59 5 1.98% 
60+ 1 0.33% 60+ 2 0.79% 
Blanks 26 8.70% Blanks 14 5.53% 
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Prison ages Community ages

Prison sample Community sample 
Disability Disability 
Yes 43 14.38% Yes 23 9.09% 
No 166 55.52% No 167 66.01% 
Blanks 90 30.10% Blanks 63 24.90% 
Prison disability Community disability
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Prison sample Community sample 
Sexual Orientation Sexual Orientation 
Bisexual 7 2.34% Bisexual 6 2.37% 
Heterosexual 190 63.55% Heterosexual 191 75.49% 
Homosexual 7 2.34% Homosexual 7 2.77% 
Lesbian 2 0.67% Lesbian 0.00% 
Straight 3 1.00% Straight 0.00% 
Blank 89 29.77% Blank 46 18.18% 
Gay 1 0.40% 
Open minded 1 0.40% 
? 1 0.40% 
Prison Sexual Orientation Community Sexual Orientation

Prison sample Community sample 
Ethnicity Ethnicity 
White British 217 72.58% White British 198 78.26% 
White Irish 5 1.67% White Irish 6 2.37% 
Any other WB 3 1.00% Any other WB 3 1.19% 
Mixed W&C 2 0.67% Mixed W&C 0.00% 
Any other 
mixed 9 3.01% Any other mixed 3 1.19% 
Any other 
Asian 3 1.00% Any other Asian 3 1.19% 
Black 
Caribbean 5 1.67% Black Caribbean 1 0.40% 
NOT 
ANSWERED 40 13.38% NOT ANSWERED 20 7.91% 
Any other Black 11 3.68% Any other Black 14 5.53% 
Error 4 1.34% Error 2 0.79% 
Asian British Indian 2 0.79% 
Asian British 
Bangladeshi 1 0.40% 
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Prison ethnicity	 Community ethnicity

Prison sample Community sample 
Religion Religion 
Christian 161 53.85% Christian 91 35.97% 
Muslim 10 3.34% Muslim 12 4.74% 
Buddhist 1 0.33% Buddhist 5 1.98% 
Hindu 0.00% Hindu 0.00% 
Jewish 1 0.33% Jewish 2 0.79% 
Sikh 1 0.33% Sikh 1 0.40% 
Atheist/Non 
belief 61 20.40% Atheist/Non belief 97 38.34% 
Other 7 2.34% Other 13 5.14% 
Blank 57 19.06% Blank 32 12.65% 
Prison religion	 Community religion

2.9	 Amongst prison respondents, the average length of time in prison was 18 months 
ranging from 2.5 months to 22 years. 
2.10	 Amongst community respondents, the average length of time since last being in 
prison was 18 months ranging from 1 week to 19 years. 
Service user and carer forums 
2.11	 More than 200 people took part in the service user and carer forums. 
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Gender 
2.12	 Two service user forums were conducted in women’s prisons and in one of the 
large community forums 40 per cent (40 participants) were female. 
2.13	 The majority of forums were male only and amongst other community-based 
forums there were often only one or two women participants reported. 
Ethnicity 
2.14	 Six forums reported on the ethnicity of participants. Amongst these groups, 
representation of Black and minority ethnic participants varied from 50 per cent 
to single participants. 
Age 
2.15	 Where age is reported it varies from 21 to 45 years. One forum took place with 
younger offenders aged 18 – 21 years and consisted of six participants. 
2.16	 No data was returned on disability, religion or belief, or sexual orientation. 
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3.	 THE FINDINGS 
What is good about drug treatment in prisons and how has this improved? 
3.1	 There is very broad recognition that prison drug treatment has improved: 
“Drug treatment has improved significantly in access to receiving treatment for 
the physical aspects of withdrawal or maintenance in certain cases...” (Prison 
questionnaire respondent) 
“It has improved because there are some staff who are trained in drug treatment 
and they're able to empathise with users. The CARAT workers are very helpful 
and do their best to get you onto a drug free programme as soon as possible.” 
(Prison questionnaire respondent) 
“It has improved a lot because there was only drug awareness but now there are 
SDP, PASRO and 12-step, which go deeper than they ever did. This is what addicts 
need for people to be honest.” (Prison questionnaire respondent) 
“It's come on leaps and bounds since when I first came to jail in 1993.” (Prison 
questionnaire respondent) 
“There are more treatment centres.” (Community questionnaire respondent) 
3.2	 However, even though there is recognition of significant improvements, many 
still do not see this as being enough and there is thought to be too much variance 
across different prisons: 
“I think it is very inconsistent across the prison system. It changes so much from 
one prison to another. It has improved since 20 years ago but I don't think it has 
really come on in the last 10 years.” (Community questionnaire respondent) 
“In some prisons drug treatment has improved dramatically, but others just pay 
lip service.” (Prison questionnaire respondent) 
“Looking back 10 years ago there was very little help available. There is more 
help now but still not nearly enough.” (Prison questionnaire respondent) 
“...there are significant differences in the jail categories.” (Prison questionnaire 
respondent) 
3.3	 When asked to identify those factors, which were seen to be good about drug 
treatment various themes emerge e.g. being seen quickly, receiving the same 
treatment including dose and medication as in the community, being treated 
with dignity and respect, having someone to talk to, group work, access to 12-
step programmes and drug free wings. 
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3.4	 The various categories have been grouped according to two key areas of 
interventions: psychosocial and medical interventions. 
Psychosocial Interventions 
3.5	 The term ‘psychosocial’ is being used for the purposes of this thematic grouping 
very loosely to mean any interventions, which are based around human 
interaction and environment. There are three sub-categories that respondents 
consistently identify: relationships with drug treatment staff, ease of access, and 
transformation. These are discussed below. 
Relationship with drug treatment staff 
3.6	 One of the most frequently praised aspects of drug treatment interventions is the 
relationships formed with staff, especially when this is characterised by being 
listened to, friendly and providing good information: 
“CARAT teams were helpful and easy to approach.” (Community questionnaire 
respondent) 
“The IDTS staff actually listen to you and ask you how you think you are doing on 
the medication you're on.” (Prison questionnaire respondent) 
“Talking to a CARAT worker one-to-one helped, especially when it came near to 
release and I had thoughts of using again.” (Community questionnaire 
respondent) 
“They help you to recognise how and where you have gone wrong and help you to 
deal with the issues that led you to take drugs. Also there is a lot of help and 
support from the staff who run the programme.” (Prison questionnaire 
respondent) 
“The help and support you get from the staff very often is brilliant. They make 
you aware how drugs can destroy you and the people around you.” (Prison 
questionnaire respondent) 
“Approachable staff” (Service user forum) 
“Staff here really listen to you, doesn't feel like I'm just going through the 
motions.” (Prison questionnaire respondent) 
“CARATs really explained things to you, help you, advise you and they do really 
listen to you and do care what your life is about.” (Prison questionnaire 
respondent) 
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Ease of access 
3.7	 Ease of access is a key determinant for respondents in rating their experience as 
good: 
“Feel able to access service without having to worry about possible negative 
repercussions from other non-drug using inmates.” (Service user forum) 
“A CARAT worker was assigned straightaway.” (Service user forum) 
“No waiting list, easy access.” (Prison questionnaire respondent) 
3.8	 Ease of access to group work, intensive programmes and 12-step was viewed as 
very important: 
“The CARAT team were very quick to come and talk to me and offer me a place on 
the PASRO.” (Prison questionnaire respondent) 
“Being able to access courses such as the SDP...” (Prison questionnaire 
respondent) 
Transformation 
3.9	 Many respondents link their experience with CARATs, one-to-one and group 
work with a transformation in attitude and outlook to life: 
“It helps me to focus on turning my life around. It stops me from wanting to use 
drugs in the prison and I can learn to control my addiction problems and move 
forward in life. I think it is the best way forward in tackling drugs and it motivates 
yourself to change your life style.” (Prison questionnaire respondent) 
“It’s intense and makes you look at yourself and your attitudes and behaviours 
and you realise you’re the problem.” (Prison questionnaire respondent) 
“...had the access to the RAPt, so I count myself lucky as I done the RAPt and have 
had the chance to work my life out. This is the first time since 1991 since I've 
been drug free. Without it, I would have gone out committing crime and used 
drugs so it was money well spent.” (Community questionnaire respondent) 
“It saved my life. Set me off on a journey I never wanted to take. Helped me start 
to lose my selfishness and gave me the ability to truly give away what was freely 
given to me.” (Community questionnaire respondent) 
“It was absolutely life changing and I will be forever grateful to the RAPt.” 
(Community questionnaire respondent) 
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“It turned my way of thinking towards the life I was living on the out and the 
harm I caused to family, kids, myself and others. Since I have graduated in ‘08 I 
have remained clean until this date and feel better for doing the programme.” 
(Prison questionnaire respondent) 
Medical Interventions 
3.10	 The factors that most influence whether respondents found medical 
interventions good related to speed of access, choice of treatment, continuity, 
and preventing use of illicit drugs while in prison. These factors are discussed 
below. 
Speed of access 
3.11	 While the ease with which individual CARAT workers or case workers can be 
accessed was deemed a significant factor in rating these services as good, when it 
came to medical interventions it was speed of access that predominated: 
“Quick access to detox...” (Community questionnaire respondent) 
“You receive treatment virtually straight away.” (Prison questionnaire 
respondent) 
“You see a doctor within 24 hours...” (Prison questionnaire respondent) 
“I was seen very quickly.” (Prison questionnaire respondent) 
3.12	 This is often viewed as an essential aspect of reception: 
“Both clients were offered detox immediately and a CARAT worker conducted a 
one-to-one session explaining the different programmes that were available.” 
(Service user forum) 
“Client A (released in July ’09, first time offender) stated upon entering prison he 
was suffering from the effects of withdrawal. It had been approximately 24 hours 
since his last fix (with no attention received when in the custody suite). He was 
immediately seen by a health worker on the first night and given an initial triage 
to ascertain his needs. This, he stated, was a surprise because he had been 
imagining all kinds of unpleasant scenarios.” (Service user forum) 
3.13	 The first night in prison can be a scary and stressful time and at which people can 
be at their most vulnerable. For some it will be their first time in prison and they 
will be unsure what will happen to them. Others may be more experienced, but if 
not provided with the necessary medication withdrawals can make the first night 
uncomfortable for them and those around them: 
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“Normally it’s somebody [sharing a cell with you] that’s got a drug issue, but you 
don’t know what stage they’re at with their issues, where they are on their 
journey and where you are on yours. I’ve found that the guy I was in with, he was 
banging up the wall. He couldn’t sleep at night, he was hallucinating. I spent 
most of the time in the toilet for two days. I didn’t fancy going to sleep with him 
there ‘cos he didn’t sleep. He was fighting the walls and talking to the doors and 
all kinds of s**te.” (Service user forum) 
“The first night was good as you saw a doctor or a nurse when you first arrived. If 
you couldn’t get the treatment that day, they would give you something for the 
first night to keep you stable.” (Service user forum) 
Choice of treatment 
3.14	 One of the most frequently cited improvements in medical interventions is 
around having choice: 
“I am not forced to have my methadone increased.” (Prison questionnaire 
respondent) 
“...you can be maintained on methadone or subutex without being forced to do a 
detox.” (Prison questionnaire respondent) 
“They offer a wide range of treatment and courses.” (Prison questionnaire 
respondent) 
“The drug treatment in prison has improved due to the fact that no-one likes to be 
forced to stop like they did a year ago and before. So now when we get released, 
we can still be on scripts if we choose that we are not ready to stop. Us prisoners 
basically have more choices now.” (Prison questionnaire respondent) 
“They give you what you need and the doctor listens to you and he will give you 
what you’re more comfortable with subutex or methadone.” (Prison 
questionnaire respondent) 
Continuity 
3.15	 The issue of continuity of treatment is very strongly related to choice as many 
respondents reported that it is important to receive the same treatment in prison 
as they were having in the community: 
“I got my methadone script in jail and they gave me the same amount as I'm on in 
the community.” (Community questionnaire respondent) 
“For one there is a choice of subutex and methadone. If you were on say 8ml of 
subutex for example and you put your case across reasonably you will get your 
8ml.” (Prison questionnaire respondent) 
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“Methadone prescribing is more often continued in custody and at the same 
dose.” (Service user forum) 
“They do try to get the treatment you was on in the community and work with 
you.” (Prison questionnaire respondent) 
Prevents illicit use of drugs in prison 
3.16	 One of the aspects of receiving the right treatment that respondents rate as 
being good is not having to use illicit drugs while in prison: 
“Means we don't buy illegal drugs in jail, so we all have money for canteen etc. 
also puts people off bringing in drugs as they struggle to sell them.” (Prison 
questionnaire respondent) 
“To me it has stopped me looking for drugs in prison...” (Prison questionnaire 
respondent) 
“It stops me using in prison...” (Prison questionnaire respondent) 
3.17	 Various related factors are described that cause problems for prisoners when 
they cannot get access to appropriate treatment including bullying and getting in 
to debt: 
“It has helped by cutting down drug trafficking, bullying, taxing as people have an 
alternative drug to help with withdrawal and keep maintaining them on an even 
keel.” (Prison questionnaire respondent) 
“IDTS can help stop bullying...” (Service user forum) 
“Maintenance stops a lot of people getting in debt for drugs they can't afford.” 
(Prison questionnaire respondent) 
3.18	 For some respondents this is directly linked to the amount of substitute 
prescribing: 
“I'm currently on 80ml methadone, the good thing about it is I don't need to use 
other drugs on top of it and it stops me getting into debt by chasing drugs, i.e. 
heroin.” (Prison questionnaire respondent) 
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SUMMARY 
•	 Respondents recognise that drug treatment has improved and many state this is 
significant. 
•	 Amongst the factors that are rated as being good about drug treatment, these 
can be grouped according to two broad categories of treatment psychosocial 
interventions and medical interventions. 
•	 The term psychosocial intervention is used very loosely to refer to all 
interventions based on human interaction and environment including CARATs, 
intensive programmes, 12-step and drug free wings, Therapeutic Communities, 
and group work. 
•	 The factors which are rated as being good about these interventions include the 
quality of relationships, ease of access, and experiencing a transformation in 
which respondents describe their life having being ‘turned around’. 
•	 Amongst medical interventions that respondents report as being good factors 
include speed of access, being able to exercise choice and having continuity of 
treatment both on entering prison and during transfer within the prison estate. 
•	 Respondents also rate good medical treatment as having an impact on reducing 
the need to use illicit drugs in prison and reducing bullying and debt. 
What is not so good about drug treatment in prisons and which needs were not 
addressed? 
3.19	 What is clear from the feedback in questionnaires and discussions in the service 
user forums and from carers is that their experiences of drug treatment vary 
from being very positive to very poor: 
“They felt as though, yes things had improved, but that treatment was so lacking 
in the first place that these improvements still fell very short.” (Service user 
forum) 
“No good aspects of the drug treatment in prison.” (Prison questionnaire 
respondent) 
“I think it is very inconsistent across the prison system. It changes so much from 
one prison to another. It has improved since 20 years ago but I don't think it has 
really come on in the last 10 years.” (Community questionnaire respondent) 
“There is no drug treatment programme in this prison and if you do go with a 
problem they refuse to give you medication to help you overcome the problem.” 
(Prison questionnaire respondent) 
3.20	 The factors that respondents most consistently relate as being poor are in direct 
contrast to those they rate as being good e.g. lack of continuity, poor 
relationships, and lack of choice. In addition, respondents with problems other 
than heroin use such as serious alcohol problems or non-opiate based drugs 
report having a negative experience. 
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Lack of continuity 
3.21	 While some respondents have clearly had a good experience and received on 
entry to prison the same medication and dose that they were used to in the 
community, many reported the opposite experience: 
“I was on 10mg of diazepam & 20mg of Temazepam daily pick up with my 70ml 
of methadone. I am not getting any Diazepam or Temazepam and I'm only on 
50ml of methadone and I am not going to be put up to 70ml which I was 
maintained on for 4 months outside.” (Prison questionnaire respondent) 
“It’s better in some ways with them doing methadone and subutex. It’s improved 
that way but they won't give you what you were on outside which is wrong.” 
(Prison questionnaire respondent) 
“It is really hard at first because I was on 50 ml meth and 40ml valium 
(diazepam). I was really ill and they only give me 15 ml meth and 1<<illegible>> a 
night and meth up to 20mls then 30mls, it was hard.” (Prison questionnaire 
respondent) 
“If on suboxone out here then you should get it in there.” (Community 
questionnaire respondent) 
“Shit they put me on 5mls first day then built it up to 30mls by 5mls a day, I was 
on 85mls on the outside so I don't rate prison as good for drug takers, this is in 
prisons for women.” (Community questionnaire respondent) 
“I was on 85ml in community, then I went to prison and was put on 30ml 
methadone. Reduced 2ml every other day until methadone free, too quick.” 
(Community questionnaire respondent) 
3.22	 Some respondents report this as being due to lack of capacity in the system and 
waiting times: 
“There is both a subutex and a methadone programme. Saying that there is 
limited spaces which creates a lot of problems i.e. people on prescriptions on the 
out don't get a space and are left to rattle (withdraw)!!” (Prison questionnaire 
respondent) 
“Service received was poor and had to wait 4-7 days to see a drug

worker/counsellor.” (Community questionnaire respondent)

“It was crap it took 5 days for my detox to start.” (Community questionnaire 
respondent) 
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“If they’re seeing that many people ‘cos they’re overcrowded, you might be 
bottom of the list you might not be seen the next day. It’s like the lottery. You’re 
a name and a number, that’s all it is.” (Service user forum) 
“The detox was brief and not done properly to free up beds for more intake of 
inmates. 5 days off Heroin - I rattled.” (Prison questionnaire respondent) 
3.23	 There are also issues about the time of arrival e.g. Friday nights: 
“It depends on what day you get in and what time you get in. Because if you get 
in at six or seven o’clock you only get booked in. Then you’re put into what’s 
known as the overnight holding cells. Nothing happens to you till the next day.” 
(Service user forum) 
“Say you’ve landed on a Friday and it has gone passed the times for the chemist 
to check, you’ve got all weekend then until Monday until they arrive before it is 
found out. So if you say well actually I’m on this medication or that medication 
they don’t give it you.” (Service user forum) 
Differences according to category of prison 
3.24	 A related aspect of lack of continuity concerned the differences between 
different categories of prison. As with the general experiences, there is a wide 
variety of responses to the experience of drug treatment in different categories 
of prison from having no treatment to being treated very well. Fewer 
respondents had experience of Category A prisons but amongst those who had, 
they more generally reported the experience of drug treatment as being 
negative: 
“Not much help/support.” (Prison questionnaire respondent) 
“Only been in Cat A and it’s not good they treat everybody as if they're still on the 
street and lying and cheating to get what they can to get high when they really 
just want to feel calm and sleep at night!!” (Prison questionnaire respondent) 
3.25	 The experience of Category B prisons was more positive: 
“B CAT locales have more agencies involved.” (Prison questionnaire respondent) 
“Cat B jails are far better, they have more courses.” (Service user forum) 
3.26	 There were few distinctions drawn between Category C and D prisons and the 
experience was generally reported as being more positive with more options and 
choice: 
“Better access to support (internal and external) better courses.” (Prison 
questionnaire respondent) 
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3.27	 However, a number of respondents said that it was much harder to get 
maintained in Category C and D prisons: 
“No methadone or subutex...” (Prison questionnaire respondent) 
“Would be better if D Cat did provide methadone etc... as it would reduce 
absconding etc....” (Prison questionnaire respondent) 
“They don't give you Methadone (When I was last in Cat C anyway).” (Prison 
questionnaire respondent) 
“They don't usually give out methadone in Cat D prisons.” (Community 
questionnaire respondent) 
3.28	 Some respondents also suggested that Category D prisons were a bigger problem 
because of the amount of illicit drugs available: 
“[About Cat D prisons] Problem is that illegal drugs are too prevalent so why take 
pharmaceutical when drugs are plenty.” (Prison questionnaire respondent) 
3.29	 Smaller prisons were also thought by some to provide a better variety of 
medication and better support. One respondent when talking about a large local 
prison stated: 
“It is felt that the staff do not have the time to offer the care and understanding 
that other prisons offer. Also it is felt that other prisons have a better one-to-one 
care process.” (Service user forum) 
3.30	 The factor most identified with different experiences is length of sentence rather 
than the Category: 
“Long term programmes can be run for long term prisoners.” (Prison 
questionnaire respondent) 
“I think there is more focus on treatment in sentenced prisons whereas in locals it 
is all about detox.” (Prison questionnaire respondent) 
“Courses at Cat B’s should be moved to Cat C’s because I’m nearer to release and 
likely to benefit more from the course.” (Service user forum) 
3.31	 One respondent commented on having a better experience in a private prison. 
Women respondents pointed out that there are no category differences in the 
women’s prisons estate. 
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Lack of choice 
3.32	 The key factors about lack of choice relate to being able to choose between 
different medications e.g. methadone or subutex and being able to choose 
whether to have a detoxification or be maintained: 
“It's terrible. Not enough choice if you don't want methadone, detox there's 
nothing else available.” (Prison questionnaire respondent) 
“Nothing because they try to detox you has soon as they can. I am on remand 
and I should be able to stay maintained whether I am sentenced or not.” (Prison 
questionnaire respondent) 
“There wasn't any [good experience of treatment] it was just maintenance on 
methadone it wasn't helpful.” (Community questionnaire respondent) 
“They prescribed me methadone and I had some support from CARATs but they 
didn't allow narcotics anonymous meetings.” (Community questionnaire 
respondent) 
“Was made to go on methadone when I wanted to have a subutex script.” 
(Community respondent) 
“Wasn't prescribed subutex in prison so I had to go cold turkey because I didn't 
want to go on methadone.” (Community respondent) 
“I think the worst thing, I don’t know, like you said it differs from jail to jail, but if 
...you go in on 50ml they put you straight down to something like 25ml, so you’re 
going to rattle anyway.” (Service user forum) 
“You get 70% of what you’re on.” (Service user forum) 
“The worst experience was being detoxed without any warning or consultation.” 
(Service user forum) 
3.33	 Some respondents reported having to increase their dose when entering prison 
against their wishes: 
“...I was on 4mgs [subutex] when I went in, but they put me on 8mgs and I argued 
saying ‘no I’m on 4mgs and you’re putting me back up to 8mgs’ and they put me 
on three weeks detox. They put me up to 8mgs straight away then dragged me 
all the way back down again. I was like ‘why don’t you start me on 4 and not do 
three weeks worth of detox’. No they’ve got a set way that they’re going to do 
it.” (Service user forum) 
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3.34	 For some the lack of choice extends to their release time: 
“Not a lot, got a quick detox and wouldn't retox me before release.” (Community 
respondent) 
3.35	 Respondents also raise issues about continuity when transferring between 
prisons which have different regimes: 
“The women felt strongly that when a transfer did take place the change in script 
by the receiving prison without discussion with the prisoner or without reviewing 
the case history in most cases was detrimental to their continued progress.” 
(Service user forum) 
“There were differences in detox regimes between prison with different 
timescales and different drugs and doses used.” (Service user forum) 
“Methadone maintenance was only allowed for short term prisoners regardless of 
the person’s personal circumstances.” (Service user forum) 
“Some prisons won’t accept you if you are on subutex.” (Service user forum) 
“Even if you’re on a prescription, if you go there and that jail doesn’t deal with 
that medication, you ain’t going to get it.” (Service user forum) 
“I was on a detoxification and I got shipped to another prison and then that 
particular prison didn’t allow people there who were on medication for the high 
amount I was on. So I had to stay there for two days without anything and they 
sent me back.” (Service user forum) 
3.36	 Particular issues arise when people are transferred unexpectedly from court: 
“It could even happen while you go to court; your space may have been taken 
over by the jail that you have come from and you’re in the middle of a detox 
programme, you get shifted out to another jail and you have to start all over 
again, back to square one. You have to contact a doctor again and all that kind of 
stuff.” (Service user forum) 
3.37	 Transferring was also reported to affect people’s aftercare: 
“The only thing I would say is after I finished the programme and got moved to 
where I am at present, is there is no after treatment available. At the last prison I 
was going to meetings each week and doing shares. At this prison there is no 
aftercare and I feel let down.” (Prison questionnaire respondent) 
3.38	 Respondents report differing experiences for those entering the prison system 
who are not on a prescription but have been using illicit drugs: 
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“I was lucky ‘cos I was scripted before I went in, but other people who weren’t 
scripted were turned away, they just had to go cold turkey.” (Service user forum) 
Provision and timing of sleeping tablets 
3.39	 Problems sleeping often accompany detoxification and other issues related to 
treatment. Respondents frequently report that medications to aid sleep are not 
provided: 
“Wanted sleepers but were not prescribed.” (Prison questionnaire respondent) 
“Only the initial medical needs were sorted to stop cold turkey. I needed extra 
help with sleeping which they wouldn't consider.” (Community questionnaire 
respondent) 
“As I keep saying, one of the worst parts of the detox (for me) is night time, no 
sleep! Why is it that other prisons can give strong sleeping tablets but this one 
can't?” (Prison questionnaire respondent) 
“I was getting sleeping tablets on the out but get none in here.” (Prison 
questionnaire respondent) 
“They will not give you sleeping aids, many new arrivals find it difficult to sleep 
but are refused tablets to help because of the addictiveness of the drugs.” (Prison 
questionnaire respondent) 
3.40	 For others that were prescribed sleeping tablets they reported having no choice 
about the timing of when these were given: 
“...the timings all wrong... sleepers at 4:30 ...” (Community questionnaire 
respondent) 
“When prescribed sleeping tablets, these are often dispensed in the afternoon, 
but saving this medication until the evening so that they can take it to sleep 
during the night is often punished.” (Service user forum) 
“Instead of night-time sleeping medication being given out at 6 p.m., which is of 
no value whatsoever, they could be given at the same time as other medication at 
10.00p.m.” (Service user forum) 
Poor relationships 
3.41	 Most reports of poor relationships and experiences of negative attitudes relate to 
medical treatment and prison officers: 
“They seem to think that inmates are lying to them when undergoing detox and 
withdraw, especially with methadone.” (Community respondent) 
79 
“Every prison I’ve been in they think everyone is on the blag.” (Service user forum) 
3.42	 Negative attitudes amongst prison officers are often reported: 
“Getting things in motion before I leave jail...officers didn't refer me to CARATs for 
this to happen, appointments to see them went missing.” (Community 
questionnaire respondent) 
“Officers could be more polite...” (Community questionnaire respondent) 
“It’s the male prison officers who let you down, their attitudes are degrading and 
wrong - the female staff do not make us feel like we are the dregs of society.” 
(Prison questionnaire respondent) 
“It’s just that battle between CARAT workers and the Screws. It’s like a faction 
you hear them when they get out ‘oh them bloody CARAT workers are here 
again...’ They see them as an interference.” (Service user forum) 
“They [prison officers] think that they [CARAT workers] are wasting their time.” 
(Service user forum) 
3.43	 Some respondents report that there are tensions between prison officers and 
drug workers that arise from the conflict between treatment needs and security: 
“...the Screws are so understaffed, when the CARAT team come on the wing and 
the Screws are like, ‘No we’re not unlocking anybody because we haven’t got the 
staff to supervise you.’ You can see the CARAT team arguing with them saying, 
‘We have to see these people to give them some support and help them for when 
they get out.’ But the Screws are saying, ‘We haven’t got the staff to unlock them 
and supervise you doing this work.’ I only saw them once and that was on my 
second day there, then I didn’t see them after that in the whole six months I was 
there.” (Service user forum) 
“...if there’s only three on duty they’re not going to let sixteen of you out to let 
you wonder into a room [for a group session]... So you’re sat there thinking, 
“Great I’ve got help coming” and you’re waiting for the door to open and all of a 
sudden someone will knock saying “not today mate, they’re not coming”. So you 
have to wait another month maybe or even two weeks before you get that 
assistance again.” (Service user forum) 
3.44	 There was some uneasiness about CARAT workers who are also prison officers: 
“If you tell them [prison officers acting as CARAT workers] what you do while in 
prison they might use it against you.” (Service user forum) 
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Substance use problems other than heroin 
3.45	 Respondents with substance use problems other than heroin report difficulties in 
receiving treatment: 
“The help for heroin addicts is good but I myself need help for depression, crack 
addiction, alcohol and cannabis and as they are not physically as bad so I don't 
get any help...” (Prison questionnaire respondent) 
“I used crack to knock me out at night and they haven't given me anything for this 
and I have trouble sleeping at night if at all BECAUSE CRACK ISN'T PHYSICALLY 
dependant, hell it is for me and I'm now very depressed as well, and time is going 
SLOWER...” (Prison questionnaire respondent) 
3.46	 Alcohol in particular is raised as a major issue by a number of respondents: 
“My problem is alcohol and I don't receive the proper medication I get off my own 
doctor outside.” (Prison questionnaire respondent) 
“There is more visible support for heroin but is this at the expense of alcohol and 
others?” (Prison questionnaire respondent) 
“Alcohol treatment needs were not addressed. Could have given medication and 
more one to one support.” (Community questionnaire respondent) 
Mental health problems 
3.47	 Many respondents stated that they had mental health problems which were not 
addressed: 
“There is not enough attention to mental health problems and it is hard to get the 
treatment you was on before coming to prison or to get any while here.” (Prison 
questionnaire respondent) 
“I am on anti-depressants and I have still not been seen by a member of the 
mental health team to assess my health. They seem to want to throw tablets at 
us to shut us up.” (Prison questionnaire respondent) 
“No mental health provision at all. Get 20% of people who are nuts and are using 
drugs to self medicate.” (Prison questionnaire respondent) 
“I don't feel my mental health needs have been addressed, I've now self harmed 
for 18 months cutting my arms/wrists, hanging myself and taking overdose. I still 
self harm and I feel nobody cares. I've had no counselling at all and I got bullied 
and the suicide liaison officer rewarded of the bullies.” (Prison questionnaire 
respondent) 
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3.48 Some respondents report waiting a long time before their mental health 
problems were addressed: 
“Waited 5 months to get help with mental health problems.” (Prison 
questionnaire respondent) 
“...waiting 4-5 weeks to see mental health stressed me out and impacted on my 
drug use.” (Community questionnaire respondent) 
“Most of the prisoners felt they had to wait a while to speak to someone about 
their mental health needs. However when they did get this help it was very 
valuable.” (Service user forum) 
“There isn't enough help for us...I've been waiting 6 months to see psychiatrist 
and I still ain’t seen one.” (Prison questionnaire respondent) 
“You have to wait months for an appointment to see psychiatrist if you’re lucky in 
this establishment.” (Prison questionnaire respondent) 
3.49	 Where respondents identify their mental health problems with their drug use 
some report their experience as being better: 
“I am currently on IDTS...and I am getting the help I need including mental health 
problems that go hand in hand with 27 years constant use of Class A drugs.” 
(Prison questionnaire respondent) 
3.50	 Other respondents thought that dual diagnosis and related mental health 
problems were not adequately recognised: 
“Yes, mental health issues were not acknowledged or addressed at all...PTSD, 
particularly lack of dual diagnosis.” (Community questionnaire respondent) 
“I suffer with bad depression but wasn't given anything for it just placed on the 
hospital wing... No one seemed to address my mental health needs, if you're on 
methadone they won't give you anything else, that’s what the doctor told me.” 
(Community questionnaire respondent) 
“Needs to be more awareness and training for internal staff to stop and 
understand mental health issues.” (Community questionnaire respondent) 
“If you a mental health problem you are shipped off to the mental health room. 
They don’t have a joint approach. Everything is segregated into mental health 
and substance misuse.” (Service user forum) 
“One service user in this group said that he raised his issue of mental health but it 
seemed as if this would not be addressed properly. He felt that this was because 
healthcare staff are overworked with drug treatment and therefore either miss, or 
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do not respond to, other health issues, primarily mental health.” (Service user 
forum) 
“I am under severe depression whilst been taken off medication without my 
consent. I have asked for mental health but no good. I had to go to extremes to 
see someone about my depression.” (Prison questionnaire respondent) 
3.51	 Respondents reporting mental health problems also identified lack of continuity 
between community and prison: 
“One individual felt their mental health issues were not addressed as they were 
expected to change antidepressant medication when entering custody. This 
person had felt stable on the medication and was forced to get used to a different 
type of medication which gave him unpleasant side effects.” (Service user forum) 
“I need to see psychologists due to mental health issues. Before I came to prison 
my drug councillors and doctor had put me forward for a mental health 
assessment which I still feel the need for. I have and I still am suffering from 
depression.” (Prison questionnaire respondent) 
3.52	 Inconsistencies between different categories of prison were also thought to 
affect mental health treatment: 
“In local establishments the services are limited so problems such as mental 
health are not as established as they are in sentenced prisons.” (Prison 
questionnaire respondent) 
“I was on quitapine at my local prison but when I went to a D Cat they stopped it, 
since being here I told them I need to go back on it.” (Prison questionnaire 
respondent) 
3.53	 One respondent on describing the move to a Category D prison said that: 
“I'm a very paranoid person and suffer with mental health problem and have 
explained this to doctors. I do not come out of my cell much, I find it hard to talk 
and mix with people here. I need my meds sorting but it seems like I'm banging 
my heard against a brick wall.” (Prison questionnaire respondent) 
3.54	 For some this was more related to length of sentence: 
“You’re in prison not long enough to receive mental health treatment. Don’t 
really want to start on counselling if you will be released before you’ve had time 
to deal with all the problems.” (Service user forum) 
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Reception - quality and timing of assessments 
3.55	 Respondents experience of assessment during reception varies in terms of 
quality and timing with many stating that this needs to be more thorough in 
identifying their needs and linked to the community: 
“I don’t think you get assessed properly there once you arrive, to what your needs 
are actually to help you when you do arrive.” (Service user forum) 
“It depends on what day you get in and what time you get in. Because if you get 
in at six or seven o’clock you only get booked in. Then you’re put into what’s 
known as the overnight holding cells. Nothing happens to you till the next day.” 
(Service user forum) 
“One good thing about prison was the introduction. They actually tell you quite 
well what they intend to do with you. They don’t deliver it but they tell you.” 
(Service user forum) 
3.56	 Many respondents report having to undergo repeated assessments which they 
feel should be avoided: 
“The assessment process was too lengthy and repetitive.” (Service user forum) 
3.57	 For some respondents this issue is overcome by having consistency or named key 
workers: 
“...had the same CARAT worker for 3 years which really helped with not having to 
keep talking about my history...” (Service user forum) 
3.58	 Reception can also be a difficult issue for those on transfer where the notes and 
other information does not follow quickly: 
“Medical history notes arrive later than service users into the transfer prison. This 
causes the service user to have to go through all of their history again with the 
next healthcare team. Also the prescribing changes on what is said to be a 
temporary basis until the notes arrive, and then does not get reinstated. This 
prescribing is often different and inadequate. This can make the service user feel 
frustrated that they have to go through their history all over again can feel 
embarrassing and awkward.” (Service user forum) 
“When arriving from a transfer sometimes you only get to see a nurse and have to 
wait to see a doctor in the morning and as meds do not travel with you this 
causes immense discomfort.” (Service user forum) 
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Harm Minimisation 
3.59	 Drug treatment has improved in the area of harm minimisation with lots of drug 
education courses. Some prisons have active harm minimisation awareness 
sessions or months. This is not the case though for all prisons as some service 
users reported that there is still not enough provided in terms of resources and 
information: 
“I had not heard of harm minimisation while in treatment.” (Community 
questionnaire respondent) 
3.60	 Although this person did go on to comment that this may have been a blessing as 
could have prevented them from adopting abstinence – ‘I would of taken that 
option and possibly not be abstinent today.’ 
“More harm minimisation education for those who want it and also education 
around blood borne viruses.” (Community questionnaire respondent) 
3.61	 Some respondents do report using needles in prison and that these were shared: 
“There are a lot of problems with needles in prisons, people making them from 
anything they find (pens for example) or stealing them from clinical waste bins. 
There are people who already have an abscess who are continuing to inject in 
prison.” (Service user forum) 
3.62	 Amongst respondents there were mixed views about the efficacy of providing 
needles in prison: 
“Some participants felt that the availability of sterile equipment would help stop 
the spread of blood borne viruses but others felt it would increase the amount of 
injecting.” (Service user forum) 
3.63	 A service user reported that women on suicide watch plans cannot have razors, 
so they use shared razors in the shower rather than waiting for a prison officer to 
supervise them. In their opinion, they have done riskier things so this is not a 
cause for concern: 
“There are people with hepatitis, people with AIDS and they are shaving their 
heads with the same razor. They have cut marks all over their heads.” (Service 
user forum) 
3.64	 People have seen disinfectant tablets in prisons but they are not always sure 
what they are used for. In some prisons the dispensers are installed but there 
are no tablets in them: 
“No disinfectant tablets as there was no funding identified for it.” (Service user 
forum) 
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CARAT (Counselling, Assessment, Referral, Advice and Throughcare) Services

3.65 CARAT services are very highly valued:

“I think that one thing that is important is you have something called the CARAT 
team and they help you with your drug addictions and stuff.” (Service user forum) 
“That’s why CARATs is so important in jail because you’ve been out on the road 
and because you’re on drugs, so emotionally it’s all cloudy, it’s all blocked out. 
But when you’re in jail it all starts to get a bit clearer and you start to come out of 
the mist a bit.” (Service use forum) 
3.66	 People felt they saw more of CARAT staff now than previously. In one prison 
CARAT workers saw people on reception, which was particularly positive. 
However, this is not consistent across all prisons: 
“The CARAT teams in some prisons are really good, but the general experience 
was that the value and effectiveness of these teams varied from really good to 
really bad.” (Service user forum) 
3.67	 Many respondents report having difficulties in accessing these services: 
“In most prisons it just takes too long to get to see a CARAT worker that would be 
my main concern.” (Prison questionnaire respondent) 
3.68	 Service users were also uncomfortable with CARAT workers and other drug 
workers who were quite obviously fresh out of university and ‘reading out of a 
text book’: 
“We trust the staff and the facilitators on the group, however some staff are 
uneducated in their approach and could benefit from more training and being 
more understanding.” (Service user forum) 
3.69	 It was suggested that in some prisons that CARATs could be advertised better. 
Although there was recognition that people can be referred through various 
means, e.g. one respondent said the prison chaplain told him about CARATs. 
Key working, case management and counselling 
3.70	 The amount of key working and case management that people received varies 
from prison to prison. In some it was very positive: 
“You’re not left alone; even key work is really good. They’re always there for you.” 
(Service user forum) 
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“The case worker visits within three days of women signing up, they get a second 
visit within the 1st month. One woman has had the same case worker for three 
years which really helped with not having to keep talking about her history and in 
getting the right kind of support.” (Service user forum) 
“I completed or participated in the RAPt programme, I addressed and fully 
explored my issues and I am now in a good place and I've benefited by doing RAPt 
as it has helped me by staying focused on my recovery.” (Prison questionnaire 
respondent) 
3.71	 Other people though identified a lack of key working, case management and 
counselling and felt more was needed: 
“I thought counselling services I accessed after RAPt were a long wait to start. I 
would have liked it to be quicker.” (Community questionnaire respondent) 
“There are a lack of counselling sessions and one to one work and a waiting list of 
12 weeks.” (Service user forum) 
3.72	 Being transferred to another prison can also affect key working and treatment 
progress: 
“The only thing I would say is after I finished the programme and got moved to 
where I am at present there is no after treatment available. At the last prison I 
was going to meetings each week and doing shares, at this prison there is no 
aftercare and I feel let down.” (Prison questionnaire respondent) 
“Asked to go on RAPt but this was not available in the prison I was in as they did 
not fall in the catchment area. RAPt programme should be available in ALL 
prisons to those who want and need it.” (Community questionnaire respondent) 
3.73	 Women in particular reported that having to get know a new key worker was 
problematic: 
“The women felt that getting to know a case worker and preparing for 
resettlement then being moved can knock you back in terms of progress. They 
felt that it was better to stay a while and go through the process with the same 
worker as the women felt that they are more likely to complete. Moving means 
having to form new relationships with new workers a bit like starting all over 
again which can sometimes make the women feel like giving up (wounded).” 
(Service user forum) 
Courses and Programmes - PASRO and SDP 
3.74	 The general feedback on these programmes was positive. 
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“Since I have been here I have completed PASRO which has been helpful.” (Prison 
questionnaire respondent) 
“The courses here provide a good foundation for getting clean.” (Service user 
forum) 
“On his last sentence he had gained knowledge regarding addressing his 
addiction from drug awareness programmes.” (Service user forum) 
“I think there are lots of courses to choose from and they're run well in this 
prison.” (Prison questionnaire respondent) 
3.75	 The Short Duration Programme (SDP) was described as a beginners guide to drug 
treatment. What it provided was information on what help is available and an 
introduction to things like triggers and harm minimisation: 
“SDP is a good course. Gives you an eye opener as to what recovery is about. SDP 
is an easy way in, an ice breaker.” (Service user forum) 
3.76	 However, the popularity and restricted number of places on these courses means 
many people did not get access: 
“There is just not enough capacity...smaller more regular groups are needed.” 
(Service user forum) 
3.77	 Some respondents reported that there was poor integration between the various 
interventions e.g. between the intensive programmes, treatment and case work: 
“The SDP group was a good (short duration) CBT/Relapse prevention etc. Well 
facilitated. However the overall strategy and CARATs intercommunication was 
awful.” (Community questionnaire respondent) 
3.78	 Sentence planning in relation to courses can also be a challenge: 
“Like myself, PASRO and SDP only is effective for short term addicts or people 
doing short sentences. What about people who have been in addiction for over 
10 years and have deep-rooted issues. They need RAPt. Also if they are long 
term prisoners PASRO and SDP should be done near to release or RAPt.” (Prison 
questionnaire respondent) 
3.79	 For some it is hard to get to the prison that runs the course requested by the 
sentence plan because it is far away. Other people wanted to do certain courses 
but could not as they did not fit the criteria. 
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12-Step Programmes 
3.80	 There are a number of organisations that provide 12-step programmes in prison. 
12-step received a lot of positive feedback and has helped a lot of people on the 
road to recovery: 
“It's given me the chance to get my life back on track and to live clean and sober.

I can now see a future for myself and all I have to do is keep going to my meetings

and work my recovery daily.” (Service user forum)

“I completed the RAPt programme. It was well run and very helpful as it made me

open up my eyes and there is help.” (Prison questionnaire respondent)

3.81	 Unfortunately 12-step is not available in every prison, limiting choice of 
treatment in some prisons: 
“When I admitted I had a problem was told that I couldn't do the RAPt course 
because of the length of my sentence. I believe this is not good enough because if 
you have a problem you need help.” (Community questionnaire respondent) 
3.82	 In addition, 12-step is not for everyone though and some can find the prospect of 
total abstinence daunting: 
“12-step – whack! and you are in it. The 12-step thing ain’t for everybody.” 
(Service user forum) 
3.83	 12-step can be a particular struggle for people with mental health problems or 
complex conditions, as in some 12-step programmes abstinence extends beyond 
Class A drugs to medication and other psychoactive substances. 
3.84	 One of the key issues identified by respondents relates to aftercare: 
“The most important part of recovery is what happens after. The aftercare 
structure here is non-existent.” (Service user forum) 
3.85	 A suggested solution from a number of people were regular Narcotics 
Anonymous (NA) meetings on the wing, led by more confident or experienced 
service users in the prison. These would need to be supported by the staff 
though to keep the programme going when key service users move on. 
SUMMARY 
•	 Where respondents identified unmet needs these invariably followed the

negative experiences identified in the previous section e.g. continuity in

treatment when entering prison from community or transferring between

prisons; access to additional support e.g. CARATs, group work etc.
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•	 While many respondents do report having their needs fully met, the key issue 
remains lack of consistency across different prisons and, in some cases, between 
different categories of prison. 
•	 Experience is very varied and this reflects the fact that there are different levels 
and quality of service experienced by service users. 
•	 Some key differences are identified with respect to different categories of prison 
in particular variances in access to detoxification or maintenance and availability 
of certain programmes. 
•	 Lack of choice features prominently especially with respect to issues beyond the 
person’s or the prison’s control such as early release form court. 
•	 Transfers are also felt to result in unmet needs when the new prison has a 
different regime that restricts choice about what medication or programme was 
being followed. This was also said to affect aftercare adversely. 
•	 Concerns are raised about poor relationships with prison officers and between 
officers and drug treatment workers. These poor relationships are often 
characterised by security and staffing issues e.g. not enough security staff to 
enable prisoners to be let out of their cells to participate in programmes or key 
working. 
•	 Respondents with substance problems other than heroin state that their needs 
were often unmet e.g. alcohol and crack use were not thought to be treated 
adequately. 
•	 One of the biggest problems cited by respondents as not being met was mental 
health problems. Respondents cited lack of awareness and knowledge about 
dual diagnosis, poor medical responses including long waiting times to see a 
mental health professional, and differences across categories of prison. Length 
of sentence was also said to be a factor as those on short sentences did not see 
the value on starting any counselling. 
•	 Experience of reception and assessments were cited as being problematic 
especially when the person entered prison on a Friday night and could not be 
assessed adequately until Monday morning. Respondents reported having to 
undertake repeat assessments and feeling that it was difficult to keep stating 
their needs. These problems were compounded by notes arriving after the 
prisoner on transfer. 
•	 Harm minimisation was generally thought to be lacking, in particular with respect 
to sharing of needles and razors. Where facilities such as sterilisation machines 
were installed, it was reported that these would lack the actual disinfectant 
tablets. 
•	 CARAT services generally are very well regarded but respondents reported having 
difficulties in access in some prisons and waiting long periods. Respondents 
report varying experiences of quality and cite issues such as training and lack of 
promotion about the services. 
•	 Key working, case management and counselling were reported as varying in 
quality and access across the prison estate and that this could cause particular 
problems on transfer. 
•	 Intensive courses and programmes including 12-step were very highly valued but 
respondents reported difficulties in access resulting from waiting times, lack of 
capacity, and differences across the prison estate. 
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What are the key factors on release that would prevent returning to old habits? 
3.86	 Respondents reported that more aftercare in the community was needed and 
more help in preparation when coming to the end of a sentence or if due to go to 
court (owing to the sudden nature of release in some cases). 
3.87	 There was some recognition that practices have improved in terms of being 
released on a prescription: 
“A positive note was that the medication script is working very well on release.” 
(Service user forum) 
3.88	 However, this is far from being a common experience and many respondents 
identified the issues they faced when being released without access to a 
prescription: 
“I think that’s the problem when they give you a release day, but they don’t do 
anything until you’ve been released. No planning, right. What they do when 
you’re released, as soon as they have signed you out, that’s when they send 
information to your GP for instance, and they post it. So you get released on the 
Monday, the first thing they tell you is ‘You must go to your GP within 24 hours’ 
but when you make your appointment to go and see him he’s not got your 
records.” (Service user forum) 
“I mean for me I found it quite daunting because I didn’t know when I was going. 
I was woken up at five in the morning and told to get my stuff because I was 
leaving and that was it and I was put on the street with a bag.” (Service user 
forum) 
3.89	 Having a prescription for the day of release was seen to be one of the most 
important factors in staying off illicit drugs: 
“Getting your medication the day you get out. Sometimes when you get out of 
jail you have to wait a few days before you can start your script up again ‘cos 
sometimes it takes a while to get in touch with the jail or whatever excuse they’ve 
got. But if you get out and you’ve got your script waiting for you, then it might be 
alright, ‘cos if you haven’t got to go out and do whatever you have to do to make 
the money and then buy the heroin to substitute.” (Service user forum) 
“Ensuring that my script is all set up and ready to collect on release.” (Prison 
questionnaire respondent) 
“If you're still on methadone you need a script there for you the day you're out.” 
(Prison questionnaire respondent) 
“Getting a prescription when released.” (Prison questionnaire respondent) 
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3.90	 Some respondents wanted preparation for release to include retox: 
“It is important to retox people on release as you might use on release.” (Service 
user forum) 
3.91	 Respondents also stated that there should be more availability of drugs like 
Naloxone on release: 
“Naloxone good on release.” (Service user forum) 
3.92	 Release from court which is often unexpected cause particular problems: 
“If you get released from court that’s worse isn’t it? You’re gonna have to start 
fending for yourself, which is why it is best to take your time especially if it’s a 
Friday. You ain’t going to get to see someone till the Monday again.” (Service 
user forum) 
“If you’re scripted up on medication and you get released from court, you’re 
basically F****d again, ‘cos everything just stops.” (Service user forum) 
3.93	 Many respondents said that not having any identification created problems in 
sorting out their prescriptions on release: 
“You’ve got to have ID for yourself in the first place, what if you ain’t got any ID 
you won’t be able to register yourself at the Doctors.” (Service user forum) 
“You should get a letter written for ID – it is hard without any ID.” (Service user 
forum) 
“Well it took me a while [to register with a GP] ‘cos I hadn’t got any ID.” (Service 
user forum) 
3.94	 However, although continuity of medications was seen as very important, most 
respondents identified social and economic factors as being the most significant 
in preventing them from returning to old habits e.g. appropriate housing, access 
to adequate funds and having something to do. These issues are discussed 
below. 
Appropriate housing 
3.95	 Most respondents cited having somewhere appropriate to live on release as 
being very important to them. This was due to the fact that they often lost their 
previous accommodation once they went to prison: 
“When I went to prison I had a flat and then they took it off me.” (Service user 
forum) 
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“Yeah I lost my flat. They said I made myself intentionally homeless, and I said 
‘How have I done that?’ by going to prison. So then they said that I wasn’t 
entitled to anywhere.” (Service user forum) 
3.96	 Respondents felt that without accommodation they were more likely to return to 
their old habits of drug use and crime. This was often said to be due to having 
little choice but to live with previously known drug using friends: 
“You’ve got to think, you’re coming out of prison, you’ve got nowhere to go, 
you’re a crack user all you’re thinking is drugs. The crack house is a place to go.” 
(Service user forum) 
“You’re going back into the jungle that you’ve come from.” (Service user forum) 
“It’s a waste if you don’t get any accommodation.” (Service user forum) 
3.97	 Hostel accommodation was reported to be unhelpful due to the amount of drug 
use that goes on: 
“You can do all of the work in prison only to be left with nowhere to live leaving 
you to go to a hostel which is full of drugs. We need more help in resettlement.” 
(Service user forum) 
3.98	 For some people it is important that they do not go back to the same area, where 
they end up hanging out with the same drug users and being stopped by their old 
dealers. Women in particular felt this was significant: 
“The women felt strongly about being re-housed away from their original home 
address in decent accommodation which would help to give a feeling of 'a fresh 
start' and make a move away from old habits. This can often be hampered by the 
requirements of some housing associations to have a family connection in order 
to live in a particular area.” (Service user forum) 
3.99	 For others though it is important to go back to the same areas on release as it is 
where their friends, family and support are. Each person needs to be assessed as 
to where it is most appropriate for them to find accommodation. For people who 
are located in a prison that is far from home organising accommodation and 
other resettlement needs is more of a challenge. 
3.100	 Residential rehabilitation was also identified as important for people in ensuring 
that they continued with the progress that they had started in prison: 
“I need to go to secondary rehab so that I can keep the work that I'm doing in 
here. It's my last chance to stay drug free and I can't afford to waste it.” (Prison 
questionnaire respondent) 
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“I intend to go straight into second stage residential rehab so I'll avoid habits, 
high risk situations as I want to keep myself safe.” (Prison questionnaire 
respondent) 
Access to adequate funds 
3.101	 Many respondents cite the lack of money as a significant factor in returning to 
offending. This is often reported to be the result of a delay between benefit 
claims submitted and the date of payment. 
3.102	 Respondents say that they need adequate funds on release to help out with 
clothes and food during the delay waiting for benefits: 
“Some people suggested more money should be available to those on the day of 
release to set up a new life with accommodation, clothes and food. Many people 
leave prison with nothing and the money given is not sufficient.” (Service user 
forum) 
“Lack of money was identified as a cause to returning to offending, often caused 
by the time period between benefit claims being submitted and the date of 
payment.” (Service user forum) 
“Some kind of help with benefits before release, so that there are some benefits in 
place. This prevents people leaving with just a gate grant and being expected to 
then survive one or two weeks before benefits are sorted out, with just this 
money.” (Service user forum) 
“What annoys me is when you get released you get £47 but a weeks giro for 
someone our age is £65. It’s a big difference from £47 to £65. What’s the first 
thing you do when you get out? Fried breakfast and a beer, you ain’t got any 
money left after that.” (Service user forum) 
3.103	 One respondent contrasts the experience of prison to being on the outside with 
no money: 
“They say to you that there is a thing called a crisis loan, and they don’t even give 
you that. You’re sitting there saying I’ve got no food in my house. When I’m in 
prison I get three meals a day. I’m now out of prison and I’m not eating.” (Service 
user forum) 
3.104	 Family members and carers also cited the risk of not having enough funds: 
“...the gap between leaving prison and receiving benefit payments can be a 
dangerous one, as a lack of funds can result in resorting to crime again, which 
brings the offender back into prison and takes them full circle.” (Carer forum) 
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Having something meaningful to do

3.105	 Another key factor that respondents cite as being a cause of returning to old 
habits is having nothing meaningful to do. This may mean employment, 
education, or being able to participate in structured programmes: 
“Boredom is a big thing.” (Service user forum) 
“You need something for your time. Your most vulnerable time is the day that 
you leave prison.” (Service user forum) 
3.106	 Many respondents had gained qualifications while in prison but on the outside 
found that this did not help them to gain employment: 
“The group identified that gaining vocational qualifications in custody was useful, 
however often they lack the work experience that is required to successfully gain 
employment.” 
3.107	 It was felt that more help could be given with finding employment: 
“More help with getting employment so that you have something to focus on 
upon release then you would not be going back to the same old routine.” (Service 
user forum) 
“It would have been better to come out to employment and have the chance to 
apply for jobs prior to release.” (Community questionnaire respondent) 
3.108	 For some employment and housing were linked: 
“Have an established pattern/routine on release, like employment and a place to 
live, because in my experience these are probably the two most difficult aspects of 
release.” (Prison questionnaire respondent) 
Integrated care planning 
3.109	 Lack of communication and integration between prison services and community 
services including drug services, probation, housing and benefits was seen to be a 
critical factor on addressing all of the above issues: 
“There’s three things that are important when you get released and they are the 
three things that are least supported. When you get released the first thing that 
you need is a GP. There’s no link between the prison and the local health service. 
There’s no link between prison and your benefits, there’s no link at all with those 
people. So when you actually leave you know you’re released, they know you’re 
released, nobody else does... And all the people that you would probably rely on 
to get you up and running back in the community have no knowledge of you.” 
(Service user forum) 
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3.110	 Having a more comprehensive structured plan on release was thought to be 
helpful in addressing these issues: 
“A structured plan from leaving the gates accompanied, being brought home or 
family's home to ground myself to the outside world, daily contact with peers 
until settled, help with changing old lifestyle to a new one, work, training, 
employment.” (Community questionnaire respondent) 
3.111	 Others called for a more integrated approach to addressing the different areas of 
need: 
“Going directly into employment or structured education. Direct link with 
housing. Support network in place – one-to-one support groups, structure...on 
the day of release and if they've got none of the above all of the good progress 
they've done in prison becomes void.” (Community questionnaire respondent) 
“‘End to end’ management by community workers even when the clients are in 
prison should be encouraged. This would mean more involvement of the 
community worker with the client whilst they are in prison - so that the same 
worker can continue working with the client on release.” (Service user forum) 
3.112	 Having a more integrated approach was thought to include being met at the 
prison gates by a community worker: 
“It would be nice to get picked up by your drug worker so you don't end up getting 
drugs on the way home. This [end-to-end case management] could facilitate 
being picked up from the prison by community workers to ensure appointments 
were kept.” (Service user forum) 
“Someone to meet you from either the local DIP teams or a trusted person to 
make sure you are not going to slip straight back to your old habits.” (Service user 
forum) 
3.113	 Some respondents thought this role should be undertaken by peer support 
workers, family or friends from within NA or AA: 
“Get a sponsor to meet you from either NA or AA again to help prevent the 
slippery slope.” (Service user forum) 
Family and carer perspectives 
“Families can play a vital role in treatment programmes in general, but their 
importance is especially evident in criminal justice settings and the context of 
release from custody. In many cases families are the main – or only – source of 
support for offenders, be it with accommodation, money, emotional help, 
company or the search for a new and productive life. Although families have a 
critical role to play in the treatment of drug and alcohol users, they are also 
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deserving of support for their own needs: they can improve treatment outcomes, 
but care should be taken that they are not seen merely as a resource in achieving 
this end.” (Carer forum) 
3.114	 There were positive feelings expressed by families about drug treatment in 
prison, particularly in that they see prison as a potential place of safety where 
people are able to address their drug taking. Families commented that the prison 
environment can actually provide the opportunity and incentive to change: 
“[Prison treatment] is away from the [drug-taking] lifestyle and a place of safety... 
[prisoners] have a proper detox which they may be unable to get within the 
community. All the services are close by and linked up with each other.” (Carer 
forum) 
3.115	 Both prisoners and families commented that the prison environment can actually 
provide the opportunity and incentive to change: 
“It’s easier to stay clean in prison.” (Carer forum) 
“Being in prison is the only way to come off drugs.” (Carer forum) 
“Prison is the only place in the last 16 years where [a partner] is able to keep off 
drugs.” (Carer forum) 
3.116	 Many commented that prison could provide a level of structure that treatment in 
the community cannot. However, the most common complaint from 
families/carers is that they are locked out both physically and emotionally from 
what is happening to their family member, friend or partner and are left feeling 
uninvolved and ill-informed: 
“Coming out [of prison], the date and what was going to happen was an 
uncertainty.” (Carer forum) 
“I wasn’t even informed that [a partner] had completed the SDP course...I didn’t 
feel part of the process.” (Carer forum) 
3.117	 There is a strong feeling that carers should be more involved in treatment 
decisions, especially prior to release: 
“On release it is important if there is someone interacting with family and friends 
to let them know that you will need support.” (Carer forum) 
“The support of my family, that's what would prevent me from coming back to 
prison as we got too much to lose out there in the real world.” (Community 
questionnaire respondent) 
97 
“Families should have increased involvement in care plans, especially as they 
often provide accommodation for recently released offenders; there should be 
continued liaison with, and support for, the family. There was a perceived lack of 
continuity between treatment in prison and treatment outside, and an offender’s 
trusting and productive relationship with a CARAT worker can be lost upon 
release.” (Carer forum) 
“Better information sharing and dialogue with families would facilitate a 
smoother release process and make the family feel more engaged in an issue they 
invariably have a large stake in.” (Carer forum) 
3.118	 Being better informed at the early stages of treatment can also reduce stress and 
worry: 
“The fact that people were withdrawing had a detrimental effect on their early 
visits from friends and family – he was so emotional and this was very distressing, 
it made me worry about him a lot more.” (Service user forum – family member) 
3.119	 Respondents who had been in prison also felt there should be more 
communication with family members: 
“Communication between family connections was not addressed in my treatment 
jail.” (Service user forum) 
“Help with relationships with family and loved ones before release to help build 
ties, and continued help in the community with this.” (Service user forum) 
“Being given time to help re-establish family relationships.” (Prison questionnaire 
respondent) 
“Someone interacting with family and friends to let them know you’re gonna 
need support.” (Prison questionnaire respondent) 
3.120	 This was particularly evident for the 18 to 21s where family was the main source 
of support on release: 
“Most felt that their family and friends would be their main source of support.” 
(Service user forum) 
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SUMMARY 
•	 Amongst the factors that respondents stated would prevent them from returning 
to old habits was continuity of prescription on release by which they meant 
having one on the same day. 
•	 Pre-release preparation in the form of retox was thought by some to be

important.

•	 Respondents thought that having greater choice about medication options such 
as opiate blockers would help them. 
•	 The need for identification or a formal letter was cited as a block to gaining a 
prescription from a GP in the community. Many respondents linked this with 
other problems such gaining access to benefits and housing. 
•	 Appropriate housing was identified as one of the main factors that would prevent 
returning to old habits. This was especially linked to not having to return to old 
friends and drug users and being in drug free environments e.g. going straight to 
rehabilitation centres. 
•	 Hostels were frequently cited as being places where drug use was common and 
as such a risk to those who had been released drug free. 
•	 Women in particular identified the need to be able to be re-housed way from 
their old areas as significant to their ongoing progress and remaining drug free. 
•	 Many respondents cited inadequate access to funds as being a factor that would 
lead them back to old habits, especially offending. Respondents described being 
unable to meet their basic needs for food, clothes, and warmth. 
•	 Carers also identified lack of access to adequate funds as a key factor in

preventing relapse.

•	 Having something meaningful to do including employment, education, and 
structured programmes was cited as a key determinant in remaining drug free. 
Boredom was often cited as a reason people drifted back to old habits. 
•	 Respondents described having trained for various qualifications while in prison 
but having difficulty finding any employment on the outside and they needed 
more help with this. 
•	 Respondents identified lack of or poor care planning on release as a factor that 
could influence their progress. More integrated care planning and greater joined 
up services between prison and community, including end-to-end management, 
were cited as improvements that respondents would like to see. 
•	 This extended to being met at the prison gates on release by a key worker. 
Though some respondents felt this role could be taken by friends or peers in NA 
or AA. 
•	 Carers identified themselves as the major support for someone leaving prison 
and yet they often felt left out of the treatment process. 
•	 Carers did recognise that improvements had taken place but they wanted to see 
carers receive more information early on in treatment and to be more involved 
prior to release. 
•	 Early involvement was felt to be especially important with respect to younger 
offenders for whom family support was more significant. 
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4. ONGOING CONSULTATION 
4.1	 From the outset, Lord Patel has made service user and carer consultation and 
involvement a key aspect of the work of the Review Group. This consultation 
exercise in part demonstrates that commitment. 
4.2	 The extent of responses and involvement of such a wide range of groups and 
agencies in addition to all the individual respondents, is testament to the level of 
interest that there is in the work of the Review Group and in improving the 
quality of drug treatment services. 
4.3	 The consultation took a number of measures to ensure as wide a representation 
as possible could take part. Responses were monitored to determine if there was 
differential responding from different groups. Concern had originally been raised 
that questionnaires were not a good way to engage with prison drug treatment 
service users as it would restrict the number of responses from people with 
learning difficulties. This was overcome by holding forums but a number of 
questionnaires returned identified that the respondent was dyslexic and that 
someone had assisted the person with filling out the questionnaire. 
4.4	 It is also apparent that questionnaires were distributed in the prison system 
through various means, some of which may have affected the responses e.g. 
some of the services distributing questionnaires made changes to some 
questions believing that the respondents might not know how to answer the 
question or want to provide the information. This is despite the fact that the 
questionnaire was developed by service users themselves. 
4.5	 Although this was done with the best of intentions, this fits in with service users’ 
feedback that they often feel that their thoughts and views are second-guessed 
rather than people asking them openly what they think and what they need. 
4.6	 In fact, in one prison service users were discouraged from handing out 
questionnaires themselves. This may have been due to legitimate security 
concerns, but it demonstrates some of the challenges involved in ensuring 
meaningful service user involvement and consultation. 
4.7	 Adfam provided a written submission that summarised the results from various 
carer forums they were in contact with. This was invaluable as there were very 
few carers, friends and family represented in the service user forums. 
4.8	 It was welcomed that specific attention had been given to families in this 
consultation, which is in keeping with the family’s crucial role in supporting 
people not just during their time in prison but also during their reintegration into 
the community. However, it was noted by families that the questionnaire and 
process itself was not particularly family-friendly. 
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4.9 Respondents were asked if and how they would want to remain involved with the

work of the Review Group and whether they wanted to be part of further 
consultations. Amongst prison questionnaire respondents, 202 (67 per cent) 
replied: 
• 32 (11 per cent) were unsure 
• 31 (10 per cent) said no. 
• 127 (42 per cent) said they would 
4.10	 Amongst community questionnaire respondents, 62 per cent replied: 
• 20 (8 per cent) were unsure 
• 24 (9 per cent) said no 
• 110 (43 per cent) said yes. 
4.11	 The main way in which people expressed their interest in being involved was to 
receive written and verbal information and to be kept informed of developments. 
Some requested personal visits or meetings with Review Group members and 
others wanted to be involved in regular group meetings on these subject areas. 
4.12	 A very similar response was received from participants in the service user and 
carer forums. 
4.13	 In general, people found the opportunity to feed into the Review Group a 
positive one. Those given the opportunity to feedback in the forums thoroughly 
enjoyed them, found them a helpful experience and hope they could have more. 
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5. CONCLUSIONS 
5.1	 The key messages from service users and carers is that while they recognise the 
improvements that have been made to drug treatment in prisons it does not yet 
go far enough. 
5.2	 Respondents may vary in their experiences of treatment and their needs, but 
there is a widespread call for more overall consistency and continuity both 
between prisons and community and across the prison estate. 
5.3	 Choice of treatment options, including medical interventions such as 
detoxification, maintenance, and abstinence programmes are highly valued. 
Respondents expressed clear opinions on their preferred treatment options 
whether this is for different medications used in detoxification and maintenance 
or choice of psychosocial interventions. Choice is a key factor in respondents 
determining the quality and value of treatment. 
5.4	 Amongst those needs that respondents said were not met, mental health 
problems and support for alcohol and drug problems other than heroin 
predominate. Many respondents report having mental health problems that are 
related to their drug use ranging from depression and anxiety to cutting and 
feeling suicidal. 
5.5	 Not only do respondents state that their medical needs for mental health 
problems were not met but they also identify a lack of understanding about 
mental health problems and poor access to trained professionals. 
5.6	 Interventions such as those provided by CARATs, PASRO, SDP, etc. are very highly 
valued but respondents report having varied experiences of access. Problems 
identified include waiting times, capacity issues, and the variance across the 
prison estate. There is also a call for greater integration between different 
services and treatment responses e.g. IDTS, CARATs and DIP. 
5.7	 Carers including friends, family and partners feel strongly that they are too often 
left out of the process, and yet they are often the main support on release. 
Carers would like to be given more information about treatment that is being 
given and to be more involved prior to release. Service user respondents also call 
for more involvement of their family and friends stating that they would like 
them to be able to better understand their support needs. 
5.8	 The response rate to the consultation was very good and there is a clear interest 
amongst many people to remain involved and be consulted further on these 
issues. There is learning from this consultation that can aid further work e.g. 
targeted questionnaires for carers and involvement of community groups to 
ensure greater diversity amongst respondents especially amongst younger 
offenders, women and Black and minority ethnic respondents. 
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Annex i 
22 July 2009 
To: All Drug Treatment Service User Groups 
Drug Treatment Service User Forums 
In 2008 I was asked by Ministers to chair an independent review group tasked with 
overseeing a programme of work to consider the recommendations of the Price 
Waterhouse Coopers (PwC) report, Review of Prison-Based Drug Treatment Funding. 
The Prison Drug Treatment Strategy Review Group (PDTSRG) was formed to review the 
quality, availability and fairness of drug treatment in prison. 
Of particular importance to me is that the views of people who need or have accessed 
drug treatment in prison are heard and included in the strategy. I have tried to ensure 
that the Review Group is as open and accessible as possible. The PDTSRG website 
www.pdtsrg.co.uk went live in February 2009 and includes access to minutes and 
documents from each meeting. People can also provide comments, feedback and discuss 
the PDTSRG on the forums. 
Trying to get the views of people in prison or people who have been in prison requires 
active communication. Established Service User groups are in a good position to tell 
service users about the PDTSRG and to collect information and feedback to the PDTSRG. 
To obtain this information I am wondering if your service user group would be happy to 
conduct a service user forum about the PDTSRG and write back to us with your findings. 
The PDTSRG Project Team, with the help of Greenwich Local Addiction Support Service’s 
(GLASS) service user group have written and piloted a script for the forum that we would 
like you to use to feedback. The script should take no more than 1 ½ hours to run 
through with your service user group. 
The PDTSRG is moving fast so if you can help we need you to write back with any 
findings from your forum by the 10 September 2009. There will future consultation 
opportunities on other aspects of the PDTSRG, but we would like to ensure that we 
capture the views of service users now so that they inform the current work. I have 
attached to this letter two versions of the forum script, one for communities and one for 
prisons. Please choose the one best suited to your service user group. Instructions on 
how to facilitate the forum and feedback are included in the script. If you need any 
financial or administrative help (someone to write up your findings for instance) please 
contact Rachael Hunter at rachael.hunter@dh.gsi.gov.uk , or you can phone 020 7972 
4860. We are happy to help you cover the cost of reimbursing service users (through 
vouchers or lunch) for their time. 
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The Project Team have also developed a questionnaire, which is attached. Although we 
would prefer you to write back to us about the results of a forum, there is the option of 
completing a questionnaire for people who cannot feedback at a forum. An electronic 
version on the questionnaire can be found on the website. 
Thank you for taking the time to consider the PDTSRG. Your views and the views of 
service users are important to me and the Review Group and may help to shape the 
future of drug treatment in English prisons. 
Kamlesh 
Professor Lord Patel of Bradford OBE 
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Instructions for Service User Forum Facilitators 
COMMUNITY FORUMS 
Below is a script for service user forums to use to feed back to the Lord Patel Prison Drug 
Treatment Strategy Review Group. We would appreciate if you could use the 
introduction and list of questions to hold a forum on drug treatment in prison for service 
user groups for people in the community who have been in prison sometime in the last 
two years. The forum should take approximately 1 ½ hours. 
Some of the themes we would like you to try to address in the forum include: 
•	 Quality of treatment, 
•	 Service user preferences, and 
•	 Meeting the needs of the client (including housing, training, employment and 
mental health treatment). 
Please write back to us with what was discussed at the forum, putting responses under 
each of the questions asked. If possible please include specific quotes of what people 
have said, and if you do please make sure that they are totally anonymous – please do 
not include any individual’s names or identifying information. 
If you could advise what the make up of your group was we can examine themes in line 
with the following: 
•	 Men/women 
•	 Ethnicity 
•	 Disability 
•	 Sexual Orientation and/or 
•	 Age (older prisoners or prisoners under 21). 
Although we are interested in a range of drug treatments in prison, we are primarily 
interested in the treatment of substance misuse for illicit drugs. Alcohol and tobacco, 
although relevant and can be included, should not make up the core of the conversation. 
Thank you for taking the time to ask for service user views for us. It is greatly appreciated 
and will help to feed into the development of our strategy. We expect that we will do a 
second consultation process on our draft strategy. 
Please mail responses back by September 10 2009 to: 
Rachael Hunter 
Wellington House 
133-155 Waterloo Road 
London 
SE1 8UG 
Or e-mail rachael.hunter@dh.gsi.gov.uk 
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Script for Service User Forums

Introduction about the Lord Patel Prison Drug Treatment Strategy Review Group 
•	 Lord Patel’s Review Group is an independent review of drug treatment practices 
in prisons. 
•	 The Review will look at the quality, availability and fairness of drug treatment in 
prison. It will also look at whether the same quality of drug treatment is available 
in all prisons. 
•	 There is also a focus on the service user’s treatment journey, particularly from 
prison into the community and between prisons. 
•	 Lord Patel would like to hear the views of people in prison, people who have 
been in prison and their families and friends about drug treatment for people in 
prison. Your views may help shape the future of drug treatment in prison and will 
form part of the process of writing a prison drug treatment strategy. 
•	 Lord Patel and the Review Group value your views and appreciate you taking 
time out to input into today’s discussion. Any comments you do make will be fed 
back to the Review Group but will be confidential. Your names will not be 
associated with any of the views you express during today’s discussion. 
Facilitator to discuss and ensure the understanding of the group 
Questions: 
1)	 What, if anything, was good about the drug treatment you had in the last prison 
you were in? 
2)	 If drug treatment in prison has improved how do you think it has improved? 
3)	 Has your drug treatment experience differed between different categories of 
prison or when being transferred between prisons? 
4)	 Did you have any drug treatment needs in prison that you feel were not 
addressed? (NOTE to Facilitator: Themes in this question to try to draw out 
include mental health problems and interactions with drug treatment, harm 
minimisation and treatment preferences) 
5)	 It is the day of your release from prison – what help would most likely prevent 
you from returning to old habits? 
6)	 What other support do you need on release from prison? 
7)	 After today’s session, how would you like to stay involved with the work of Lord 
Patel’s Review Group? 
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Instructions for Service User Forum Facilitators 
PRISONS 
Below is a script for service user forums to use to feed back to the Lord Patel Prison Drug 
Treatment Strategy Review Group. We would appreciate if you could use the 
introduction and list of questions to hold a forum on drug treatment in prison for service 
user groups in prison. The forum should take approximately 1 ½ hours. 
Some of the themes we would like you to try to address in the forum include: 
•	 Quality of treatment, 
•	 Service user preferences, 
•	 Meeting the needs of the client (including housing, training, employment and 
mental health treatment). 
Please write back to us with what was discussed at the forum, putting responses under 
each of the questions asked. If possible please include specific quotes of what people 
have said, and if you do please make sure that they are totally anonymous – please do 
not include any individual’s names or any identifying information. 
If you could advise what the make up of your group was we can examine themes in line 
with the following: 
•	 Men/women 
•	 Ethnicity 
•	 Disability 
•	 Sexual Orientation and/or 
•	 Age (older people or people under 21). 
Although we are interested in a range of drug treatments in prison, we are primarily 
interested in the treatment of substance misuse for illicit drugs. Alcohol and tobacco, 
although relevant and can be included, should not make up the core of the conversation. 
Thank you for taking the time to ask for service user views for us. It is greatly appreciated 
and will help to feed into the development of our strategy. We expect that we will do a 
second consultation process on our draft strategy. 
Please mail responses back by September 10 2009 to: 
Rachael Hunter 
Wellington House 
133-155 Waterloo Road 
London 
SE1 8UG 
or e-mail rachael.hunter@dh.gsi.gov.uk 
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Script for Prison Service User Forums 
Introduction about the Lord Patel Prison Drug Treatment Strategy Review Group 
•	 Lord Patel’s Review Group is an independent review of drug treatment practices 
in prisons. 
•	 The Review will look at the quality, availability and fairness of drug treatment in 
prison. It will also look at whether the same quality of drug treatment is available 
in all prisons. 
•	 There is also a focus on the service user’s treatment journey, particularly from 
prison into the community and between prisons. 
•	 Lord Patel would like to hear the views of people in prison, people who have 
been in prison and their families and friends about drug treatment for people in 
prison. Your views may help shape the future of drug treatment in prison and will 
form part of the process of writing a prison drug treatment strategy. 
•	 Lord Patel and the Review Group value your views and appreciate you taking 
time out to input into today’s discussion. Any comments you do make will be fed 
back to the Review Group but will be confidential. Your names will not be 
associated with any of the views you express during today’s discussion. 
Facilitator to discuss and ensure the understanding of the group 
Questions: 
8)	 What is good about the drug treatment in this prison or any other prison you 
have been in? 
9)	 If drug treatment in prison has improved how do you think it has improved? 
10) Has your drug treatment experience differed between different categories of 
prison or when being transferred between prisons? 
11) If anything is not working well now, what could happen to make it better? 
12) Do you have any drug treatment needs in prison that you feel have not been 
addressed? (NOTE to Facilitator: Themes in this question to try to draw out 
include mental health problems and their interaction with drug treatment, harm 
minimisation and treatment references) 
13) It is the day of your release from prison – what help would most likely prevent 
you from returning to old habits? 
14) What other support do you need on release from prison? 
15) After today’s session, how would you like to stay involved with the work of Lord 
Patel’s Review Group? 
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Annex ii 
Your Experience of Prison Drug Treatment 
Lord Patel Prison Drug Treatment Strategy Review Group 
(Service users, families and carers consultation questionnaire) 
PLEASE RETURN BY SEPTEMBER 10 2009 
Please mail your response to (no postage stamp required): 
FREEPOST RRLX-ALSB-HJLL 
RAPt Aftercare Team 
Riverside House 
27-29 Vauxhall Grove 
London 
SW8 1SY 
Or e-mail to: 
admin@pdtsrg.co.uk 
Information 
•	 Lord Patel’s Review Group is an independent review of drug treatment practices 
in prisons. 
•	 The Review will look at the quality, availability and fairness of drug treatment in 
prison. It will also look at whether the same quality of drug treatment is available 
in all prisons. 
•	 There is also a focus on the service user’s treatment journey, particularly from 
prison into the community and between prisons. 
•	 Lord Patel would like to hear the views of people in prison, people who have 
been in prison and their families and friends about drug treatment for people in 
prison. Your views may help shape the future of drug treatment in prison and will 
form part of the process of writing a prison drug treatment strategy. 
•	 Lord Patel and the Review Group value your views and appreciate you taking 
time to fill out this form. Any comments you do make will be fed back to the 
Review Group and will be confidential. Please try to avoid using names or any 
information that could identify a person when filling out this form. Try to answer 
as many questions as possible. If you do not feel comfortable answering a 
question you do not need to answer it. 
•	 If you have access to the internet you can go to www.pdtsrg.co.uk for more 
information or to contribute to the forums. 
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Questions (If you do not feel comfortable answering a question please leave it blank): 
16) PLEASE TICK A BOX: 
Are you currently:

In prison? □ (Go to question 2)

In the community? □ (Go to question 4)

A family member or carer for a person that has received drug treatment in prison?

□ (Go to question 6 – please answer any prison related questions providing 
information about what would have helped you or your family member/person 
you care for) 
17) How long have you been in prison this time? 
________ months _______years 
18) What is good about drug treatment in this prison? (Then go to question 6) 
19) How long ago were you last in prison? 
________ months ________years 
20) What was good about drug treatment in the last prison you were in? 
21) If drug treatment in prison has improved how do you think it has improved?
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22) Does the drug treatment provided differ between the following categories of 
prison? If so how? 
Local: 
Cat A: 
Cat B: 
Cat C: 
Cat D: 
Other comments:

23) Thinking about prison, did you have any drug treatment needs that you feel were 
not addressed? How would you have liked them to be addressed? This can include 
mental health problems and their interaction with drug treatment, harm 
minimisation and treatment preferences. 
24) It is the day of your release from prison – what help would most likely prevent you 
from returning to old habits? (or your family member or person you care for 
returning to their old habits) 
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______________________ 
25) How would you like to stay involved with the work of Lord Patel’s Review Group?

Personal Information (Optional – If you do not want to answer a question please leave 
it blank). 
1) Gender □ Male □ Female (Please tick one) 
2) Age __________ 
3) Ethnicity ___________ 
4) Religion________________ 
5) Sexual Orientation _________________ 
6) Do you have a disability? If yes please provide details: 
PLEASE RETURN BY SEPTEMBER 10 2009 
FREE MAIL RETURN (no postage stamp required) 
FREEPOST RRLX-ALSB-HJLL 
RAPt Aftercare Team 
Riverside House 
27-29 Vauxhall Grove 
London 
SW8 1SY 
Or e-mail to: 
admin@pdtsrg.co.uk 
If you have any questions please contact Rachael Hunter at: 
E-mail: admin@pdtsrg.co.uk 
Phone: 020 7972 4860 
Or send a letter to the free post address above. 
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Annex iii 
Thank you - A big thank you to RAPt for receiving the majority of the questionnaires for 
this work. This would not have been as successful as it was without you. 
Thank you to Robert Marshall for helping with some prison service user forums. 
Service User Forums: 
• Greenwich Local Addiction Support Service (GLASS) 
• London Regional User Council 
• Action Housing and Support Ltd Sheffield 
• Adfam 
• BAC-IN 
• Barnsley DAAT 
• Community Voice 
• Fulham Life Action Group 
• Gloucestershire Service User Office 
• Halthon Cheshire Forum 
• HMP Belmarsh 
• HMP Birmingham 
• HMP Brixton 
• HMP Chelmsford 
• HMP Featherstone 
• HMP Haverigg 
• HMP Holloway 
• HMP Hull 
• HMP Styal 
• HMP Wandsworth 
• Lifeline – HMP Moorland 
• Northallerton 
• North East Regional Service User Forum 
• Revolving Doors 
• Telford User Group 
• Torquay Service User Consultancy 
• User Feedback Organisation (UFO) Safer Bristol 
• Wirral DAAT 
Questionnaires: 
• Cheshire DAAT 
• Devon DAAT 
• NACRO - Chester 
• Northumbria Probation 
• Nottinghamshire Probation 
• Shrewsbury 
• Solihull Integrated Addiction Services 
• South Yorkshire 
• Suffolk County Council 
• Sussex Probation 
• Warrington Service User Groups 
• Winchester Drug Service 
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Appendix B

Prison Drug Treatment Strategy Review Group

The Evidence Base Review Report 2009
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1. INTRODUCTION 
1.1. There is consensus amongst providers and commissioners of prison drug treatment 
that it should be evidenced based. However, there is an absence of high quality 
research addressing effectiveness of drug treatment in prisons and there are a 
number of complex issues with respect to the evidence that does exist. Therefore, 
the desired approach is a multi-modal or flexible approach to treatment that is 
aligned to or influenced by published evidence for effectiveness. The implications of 
this approach are that to follow a particular treatment regimen in a dogmatic 
fashion may not always be practical or indeed desirable. 
1.2. For example, most of the studies on effectiveness are either from community 
settings or are international and the same results may not necessarily translate to 
the UK prison system. There is also a general lack of clarity in the way that 
psychosocial interventions are categorised e.g. sometimes this is by treatment type, 
sometimes by characteristics of participants and sometimes in relation to 
programme intensity or the combination of delivery. Terms are used inter-
changeably which makes it difficult to understand exactly what is being compared. 
1.3. This paper attempts to clarify these issues and set the context for an assessment of 
the evidence base for drug treatment in prisons. The paper is in four parts: 
•	 Background context 
•	 Current drug treatment interventions provided in prisons 
•	 An overview of evidence for effectiveness by treatment modality 
•	 Discussion of the issues that influence effectiveness and interpretation of 
evidence 
1.4. The paper is intended to be read in conjunction with the paper on outcomes as both 
evidence and outcomes are inter-related. This is especially important in the context 
of prison drug treatment as outcomes may relate to both drug use and offending 
behaviour and there needs to be a similar approach to the rigour by which 
effectiveness is assessed. 
1.5. The paper identifies a series of treatment modalities that should in principle be 
delivered in prisons. 
2. BACKGROUND CONTEXT 
“A comprehensive framework of drug treatment services, spanning Tiers 1–4, should be 
available in prisons to address the varying needs of drug users. In principle, delivery of 
drug treatment in prisons is very similar to providing treatment in the community. 
However, there are specific factors that need to be taken into account, given the different 
environment in which prison treatment is provided”. (NTA, 2006. 3.4 p. 14) 
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2.1 Price Waterhouse Coopers (PwC) examined best practice models to inform their 
report, which reviewed prison-based drug treatment funding. This was not a 
systematic review of the literature in the research sense. They considered the 
evidence base for: 
•	 Detoxification for Opioid Users 
•	 Maintenance Prescribing for Opioid Users 
•	 Pharmacological Interventions for Cocaine/Amphetamine Users 
•	 Psychosocial Programmes 
•	 Intensive Drug Treatment Programmes (DTPs) 
2.2 Their conclusion about the evidence was that there was no gold standard drug 
treatment intervention identified in the literature and that there are several key 
research gaps in drug treatment effectiveness e.g. 
•	 Evidence on the effectiveness of brief psychosocial interventions that focus on 
advice, information and support alone is weak and more research is needed 
•	 More research is required on the effectiveness of the 28-day psychosocial

intervention package offered by CARATs for PDUs

•	 The evidence base for maintenance prescribing is borrowed from community 
research (although there is an Australian (RCT) and Canadian prisons study 
evidence for its effectiveness). 
•	 More information is needed to support UK policy for maintenance prescribing in 
prisons 
•	 There is limited evidence to support any pharmacological interventions for

substances other than heroin in both a community and prison setting.

(PwC, 2007 A3. p. 55 – 56)

2.3 PwC acknowledged several limitations within the existing literature on effectiveness 
of prison drug treatment e.g. 
• Variations in the definition used for a problem drug user e.g. whether this was 
restricted to dependence or included problematic use without dependency 
•	 The relative reliance on research on effectiveness that comes from either an 
international source or is based on community settings e.g. fails to take adequate 
account of the specific UK context of prison based drug treatment 
•	 Failure to take adequate account of the unique operating issues within UK prisons 
•	 Difficulties in assessing effectiveness of care pathways due to the multiplicity of 
treatment options and services 
•	 Relative weighting in consideration of the evidence base towards interventions 
that lend themselves well to measurement e.g. pharmacological and clinical 
interventions at the expense of psychosocial and other interventions 
(PwC, 2007 A3. p. 67) 
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2.4 The United Kingdom Drug Policy Commission (UKDPC) has since published a review 
of evidence for problem drug-using offenders: Reducing Drug Use, Reducing Re-
offending. Are programmes for problem drug-using offenders in the UK supported by 
the evidence? (UKDPC. March, 2008) 
2.5 The UKDPC review found that: 
There is reasonable evidence to support: 
•	 Drug courts; community sentences such as DTTOs and DRRs; prison-based 
•	 Therapeutic communities; opioid detoxification and methadone maintenance 
within prisons; and the RAPt 12-step abstinence-based programme. 
•	 However, there is no cost-benefit analysis of the two UK drug courts; the 2008 
Ministry of Justice review of drug courts was relatively positive, but it noted that 
continuity of judiciary appeared to be a key factor for the enhancement of good 
outcomes. The Bradley Report of people with mental health problems or learning 
disabilities in the criminal justice system (2009) also noted that the Ministry of 
Justice report did not address dual diagnosis. 
There are no published evaluations of the effectiveness of: 
•	 CARAT interventions; drug-free wings; programmes based on cognitive 
behavioural therapy, such as short-duration programmes and PASRO (Prison 
Addressing Substance Related Offending) programmes; conditional cautions; 
diversion from prosecution schemes; and Intervention Orders. 
There is mixed evidence for: 
•	 Criminal Justice Integrated Teams; Restrictions on Bail; and the added value of 
drug testing as part of a community order. 
(pp. 11 – 12) 
2.6 UKDPC concluded that: 
•	 The principle of using criminal justice system based interventions to encourage 
engagement with treatment is supported by the evidence. 
•	 Following a period of expansion and a focus on quantity, attention should now 
focus on quality. 
•	 Net-widening to include additional groups of drug-using offenders in criminal 
justice system based interventions may have negative consequences. 
•	 Community punishments are likely to be more appropriate than imprisonment 
for most problem drug-using offenders. 
•	 Prison drug services frequently fall short of even minimum standards. 
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•	 Given the sizeable investment in criminal justice system interventions for drug-
dependent offenders, we know remarkably little about what works and for 
whom. 
(pp 12 – 15) 
3. A DECSRIPTION OF PRISON DRUG TREATMENT IN ENGLAND AND WALES 
3.1 The configuration of prison drug treatment and the terminology used to describe it 
differ slightly from the community. There are three basic categories: clinical 
substance misuse services; CARAT teams; and Accredited Drug Treatment 
Programmes. 
Clinical substance misuse services 
3.2 These are provided or under introduction in 117 adult prisons in England and 3 in 
Wales. These are medical services restricted largely to detoxification, maintenance 
and Naltrexone prescribing. Clinical drug treatment services link to wider healthcare 
services. 
CARAT (Counselling Assessment Referral Advice and Throughcare) Services 
3.3 These are provided in 129 of the 135 establishments in England and Wales. CARAT 
services are essentially key working, care planning and low-intensity interventions 
for adult and young offender (18+) prisoners. 
3.4	 CARATs may refer clients to more intensive accredited drug treatment programmes 
in prison. CARATs represent the key through-care link with the community through 
the Drug Intervention Programme (DIP). 
3.5	 These two components of drug treatment, clinical and CARATs, are combined to 
form the Integrated Drug Treatment System (IDTS). IDTS is funded in all adult 
prisons in England. The main features of IDTS are: 
•	 Improved clinical management with greater use of maintenance prescriptions 
•	 Intensive CARATs support and interventions during the first 28 days of intense 
clinical management for all patients 
•	 Greater integration of drug treatment generally but a particular emphasis on 
clinical and CARAT services, with the objective of creating multi-disciplinary 
teams. 
Accredited Psychosocial Drug Treatment Programmes 
3.6 These are exclusively psychological drug treatment programmes. They cover a range 
of therapeutic approaches 
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a) Cognitive Behavioural Therapy (CBT) Programmes: 
3.7 There are four types of CBT drug treatment programmes in prisons: 
i) Short Duration Programme (SDP) 
3.8 Provided in 43 prisons, SDP is a medium-intensity CBT programme that 
incorporates harm minimisation and relapse prevention. The programme targets 
prisoners who are on remand, or those who have been sentenced to 12 months or less. 
It aims to motivate and direct offenders to remain in treatment or seek further support. 
3.9 SDP can also be delivered in Category D prisons as a ‘booster’ programme to 
those prisoners who want to prepare themselves sufficiently to cope on release. SDP 
consists of twenty, two–and-a-half-hour sessions delivered over a period of four weeks. 
ii) Prisoner – Addressing Substance Related Offending (P-ASRO) 
3.10 Provided in 40 prisons, this is a low- to medium-intensity programme. All 
participants need to be serving sentences of 12 months or more, with a low to medium 
risk of re-offending, and with a score of between four and seven on the Significance of 
Dependence Scale (SDS). P-ASRO aims to reduce the likelihood of drug related re-
offending. 
3.11 P-ASRO for male adult and young offenders consists of twenty, two-and–a-half-
hour sessions delivered over a five- to six-week period. For female adult and young 
offenders, the programme consists of twenty-four, two-and–a-half-hour sessions 
delivered over a period of eight weeks. 
iii) Substance Treatment & Offending Programme (STOP) 
3.12 Operating in 7 prisons, this programme adopts a cognitive behavioural approach 
to understanding and treating problem behaviour associated with substance-related 
offending. The aim of STOP is to achieve abstinence, and targets male adults of 21 years 
and above, serving sentences of over 12 months with medium to high risk of re-
offending and a score of seven or more on SDS. STOP comprises 76 one-hour sessions 
delivered over a period of 11 to 13 weeks. 
iv) FOCUS 
3.13 Provided in five prisons, FOCUS is founded on a social learning perspective for 
the development of adult substance use problems that incorporates a strategic 
combination of behavioural and cognitive behavioural treatment modalities and 
techniques. The programme is designed specifically to target male adults aged 21 and 
above, serving sentences of over 12 months with medium to high risk of re-offending 
and a score of seven or more on SDS. Individual are required to have an IQ of at least 80 
and score 30 or more on the Hare PCL-R psychopathy test. The programme comprises 62 
sessions delivered over a period of 18 weeks. 
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b) 12-Step Approach 
3.14 There are currently two accredited 12-step programmes provided in a total of 12 
prisons: 
•	 Prison Partnership Twelve-Step Programme (PPTSP) This programme takes 
between 15 and 19 weeks 
•	 Rehabilitation of Addictive Prisoners trust (RAPt) Substance Abuse Treatment 
Programme (SATP) Completion can take up to 23 weeks 
c) Therapeutic Communities (TC): 
Prison Partnership Therapeutic Community Programme (PPTCP) 
3.15 This programme is currently available in five prisons, and is based on a 
hierarchical Therapeutic Community (TC) model. It is designed for prisoners aged 21 and 
over with a medium and high risk of reconviction and level of dependence on drugs. A TC 
for women prisoners received accreditation in April 2008 and is currently being run at 
HMP Drake Hall. 
3.16 As a rule, therapeutic community programmes are based on the principle of 
social learning, with new residents given instruction in the means to a drug-free life by 
more established residents (‘peers’ history and in getting the right kind of support.” 
(Service user forum)). In practice, there can be variation in treatment philosophy, from a 
strictly behavioural hierarchical model of treatment, to a 12-step or cognitive-founded 
approach, or an eclectic mix of interventions. 
4.	 OVERVIEW OF EVIDENCE BY TREATMENT MODALITY 
4.1 The following evidence is not intended to be an exhaustive review but rather is 
presented in order to give the reader a sense of the key issues when considering the 
evidence for drug treatment in prison. The evidence is structured according to the 
treatment modalities used in Models of Care (update July 2006) whilst recognising that 
some modalities such as structured day programmes are not provided in the same way 
within prisons. 
•	 Substance misuse related advice and information 
•	 Harm reduction interventions 
•	 Prescribing interventions including specialist prescribing 
•	 Structured day programmes 
•	 Structured psychosocial interventions 
•	 “Other structured treatment” 
•	 Drug treatment within specialist areas 
•	 Residential rehabilitation 
•	 Aftercare 
(Adapted from Models of Care update 2006 (NTA, 2006)) 
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4.2 The evidence cited has been chosen because it reaches a high standard of quality 
(e.g. 3 or 4 on the Maryland scale of scientific methods). However, as discussed in the 
final section of the paper there are issues when considering the quality and 
appropriateness of the evidence base and there is a need to agree the level of quality 
and standards which should be applied for prison drug treatment. Where this review 
draws evidence from offender or prison studies, the corresponding reference is 
underlined [e.g. (Boys, 2002)]. 
Substance misuse related advice and information 
4.3 There is not a great deal of evidence, either within or outside prisons on the 
effectiveness of substance misuse related advice and information. Although there is 
some support for brief interventions for those not engaged in formal treatment. 
4.4 In their review of the evidence base, NICE (2007a) concluded that people who 
misuse cannabis or stimulants, and are not in formal drug treatment, appear to respond 
well to brief interventions, both in terms of increased abstinence levels and reduced 
drug use. 
4.5 By contrast, for people already receiving formal drug treatment, an additional 
brief intervention did not appear, in the view of NICE (2007a), to have much effect on 
abstinence or drug use. 
4.6 CARAT services do include elements of advice and information and this is 
generally reported as being valued by prisoners. There is insufficient evidence to link this 
to evidence of outcomes as no such studies or formal evaluation has yet been 
undertaken. However, this is one element of CARATs which needs to be viewed in a 
broader context of the range of interventions provided e.g. key working and case 
management. 
Harm reduction interventions 
4.7 There is a range of harm minimisation and prevention strategies in prisons 
currently for example, harm reduction interventions such as hepatitis B vaccination and 
hepatitis C treatment. Prison presents an opportunity and a challenge to address these 
issues amongst drug users. In fact, prison is now the most common place for injecting 
drug users to be vaccinated against hepatitis B and a range of leaflets and DVDs are 
available to prisoners informing them how to reduce the risk of contracting blood borne 
viruses. 
Rates of drug use and injecting 
4.8 Drug use in prisons fluctuates across sites and time. Individual prisons may 
experience short-lived drug inundations, or have a more persistent serious problem with 
drug smuggling. However, research evidence shows that drug use amongst prisoners 
generally falls dramatically compared to pre-prison levels of misuse. The best national 
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indicator of drug use in prisons is provided by the random mandatory drug testing (MDT) 
programme. For a number of reasons, random MDT results cannot be a complete 
measure of the prevalence of drugs-misuse in prisons. However, independent research 
carried out by the Office for National Statistics in 2005 concluded that random MDT 
provides a reliable and statistically valid way of measuring patterns and trends of drug 
use in prisons at national and regional level. The random MDT positive rate has fallen by 
68 per cent since 1996/97 – from 24.4 per cent to 7.7 per cent in 2008/09. 
4.9 Injecting drug use carries a high risk to personal and public health. One UK study 
(Judd, 2005) found a baseline prevalence of antibodies to hepatitis C virus was 44 per 
cent and of antibodies to HIV 4 per cent among injecting drug users. The majority of 
injecting drug users are sent to prison (Dept Health 2002). Approximately half of all 
prisoners are problematic drug users. 37 per cent of problematic drug users entering 
prisons report injecting drug use within the 28 days preceding custody (Home Office, 
2003). Imprisonment in the UK is also related to a reduction in the prevalence of 
injecting drug use (Bellis, 1997; Shewan, 1994), but cases of initiation into injection in 
prison have been identified (Boys, 2002). Although it reduces in custody, injecting drug 
use in prison is more likely to involve the use of shared equipment (Bellis, 1997). 
Imprisonment is associated with higher rates of blood borne virus infection among 
injecting drug users (Weild, 2000). 
Blood Borne Viruses 
4.10 The Health Protection Agency monitors levels of infections amongst Injecting 
Drug Users (IDU). Their report Shooting Up
2 
shows there is cause for concern with this 
group as they continue to be affected by various infectious diseases associated with 
injecting: 
Hepatitis C: The prevalence of hepatitis C infection among IDUs remains high overall 
with prevalence in England broadly stable in recent years at 43 per cent but with very 
marked regional variations, following a rise since the beginning of the decade (the UK 
prevalence in 2000 was only 33 per cent). In 2006, the number of confirmed hepatitis C 
infections reported in England rose to 8,346, 10 per cent higher than in 2005. Injecting 
drug use remains the single most important reported risk factor for acquiring hepatitis C 
infection (HPA, 2007).Crack cocaine injectors show rates of 59 per cent compared to 
non-crack injectors with rates of 34 per cent. 
Overall, almost half of IDUs in the UK have been infected with hepatitis C. However, 
there are marked variations in hepatitis C prevalence within the UK, with low prevalence 
found in some areas. There are indications that current levels of hepatitis C transmission 
remain elevated. 
HIV: HIV infection among IDUs has remained relatively uncommon in the UK, probably as 
a result of prompt community and public health responses. The annual number of HIV 
diagnosis among IDUs in recent years has been low and relatively stable. The overall 
2 
Shooting Up – Infections among injecting drug users in the United Kingdom 2006 – An update: October 
2007. Health Protection Agency 
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prevalence of HIV seen among IDUs in 2006 was similar to that seen in recent years, and 
remains higher than that seen in the late 1990s. In London, the prevalence was 5.0 per 
cent, whilst elsewhere in England it was 0.66 per cent. 
The prevalence of HIV among the ‘recent initiates’ has remained higher than it was prior 
to 2003, with the prevalence being 0.77 per cent in 2006 (in 2002 it was 0.25 per cent). 
Vaccination: Hepatitis B infection is a vaccine-preventable disease. Vaccination requires 
three doses that can be given over a period of three weeks to those in high-risk groups 
such as IDUs. The proportion of IDUs who have taken up an offer of the hepatitis B 
vaccination has increased markedly over time, rising from around quarter (25 per cent) 
in 1998 to two thirds (65 per cent) in 2006, with almost two-thirds self-reported 
receiving three or more doses (61 per cent) compared with 42 per cent in 1998. 
This improvement in uptake of the vaccine probably reflects improved provision through 
drug services and, in particular, the prison vaccination programmes. However, there is 
still a great deal of work to be done in effectively targeting those problem-drug users 
with hepatitis B vaccine programmes delivered in the community, including through 
enhanced needle and syringe exchange (NEX) programmes, drug treatment units and 
GPs. 
Injecting in prisons – needle exchange and disinfecting tablets 
4.11 The sharing of needles and syringes (direct sharing) is a key route by which 
infections may be transmitted amongst IDUs. In England, direct sharing was reported by 
23 per cent in 2006. Whilst this is lower than the rate of around a third seen in 2002, it is 
still higher than the level seen in the mid 1990s. The sharing of filters, mixing containers 
and flushing water can also pass on infections. In England, 45 per cent of current 
injectors reported sharing these items in 2006. 
4.12 Although we know that there is far less injecting behaviour in prisons where it 
does occur, there is a potentially much higher risk of sharing injecting equipment due to 
its scarcity. The Singleton survey in prisoners conducted in 1997 found that 26 per cent 
of prisoners had injected at some time, but only 2 per cent had injected during their 
current prison sentence. 
4.13 Prison Service Instruction 34/2007 makes it mandatory that disinfecting tablets 
are available across the adult prison estate. Although this is an evolving area, there is 
increasing evidence of the effectiveness of disinfectant tablets and there is as yet no 
evidence on what effect introducing needle exchange into an environment where 
injecting is reduced might have on injecting behaviour. NICE published guidance on 
Needle and Syringe programmes however it reports that: ‘There is a lack of good quality 
UK research on the effectiveness of prison-based interventions. As a result, they have 
been omitted from the recommendations’ (NICE, 2009) http://www.nice.org.uk/PH18 
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4.14 In community settings the most common intervention designed to reduce 
injection and sexual risk behaviour is psycho-education. This approach commonly 
combines education about blood borne viruses (such as HIV or hepatitis C) with skills 
training in areas such as assertiveness. NICE (2007a) reviewed 15 trials of psycho-
educational programmes, concluding that they had little or no effect on injection risk 
behaviour and a limited and inconsistent impact on the reduction of sexual risk 
behaviour in people who misuse drugs. 
Prescribing interventions including specialist prescribing 
Opioid substitution 
4.15 Marsch (1998) conducted a meta-analysis review of the effect of methadone 
maintenance on opiate use, HIV risk and criminal activities. Of 43 studies, 24 (23 from 
USA or Canada, 1 UK) measured the impact of methadone maintenance treatment on 
criminal activity. The results demonstrated a consistent, statistically significant 
relationship between methadone maintenance treatment (MMT) and the reduction of 
illicit opiate use, HIV risk behaviours and drug and property-related criminal behaviours. 
The effectiveness of MMT was found to be highest in its ability to reduce drug-related 
criminal behaviour. 
4.16 In a systematic review of drug and alcohol interventions in prison and community 
criminal justice settings, Roberts et al. (2007) reported that: 82 per cent of all findings 
presented indicate that this intervention was more effective than at least one 
comparison intervention in reducing criminal behaviour. 55 per cent of findings showed 
that it was more effective than all other comparisons included in the study. 
4.17 In a literature review of substitution treatment in prisons, Stallwitz and Stover 
(2007) concluded that prison-based methadone is effective across health and offending 
domains, and that higher dose treatment was more effective than lower dose. Mitchell, 
(2005) in a meta-analysis of 26 evaluations of prison-based drug treatment programmes, 
did not find that methadone programmes reduced offending. 
4.18 Dolan (2003; 2005), in a randomised controlled trial, found statistically significant 
evidence that a prison methadone programme can reduce re-incarceration and fatal 
overdose upon release. Gordon (2008), in a prison methadone RCT, found that the 
programme reduced re-incarceration to a statistically significant effect, 
Naltrexone 
4.19 Naltrexone is recommended by NICE (2007b) as a treatment option in detoxified 
formerly opioid-dependent people who are highly motivated to remain in an abstinence 
programme. There are now long-acting forms of Naltrexone (e.g. sustained release 
implants) which may be of value as a new formulation of this drug. However, as yet 
these remain unlicensed and there is no UK research data for prisons. They also fell 
outside the scope of the 2007 NICE Naltrexone Technology Appraisal 115. 
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4.20 There is some evidence (e.g. Carroll et al. 2001) that contingency management, 
behavioural couples therapy and family-based interventions may all be beneficial 
adjuncts to Naltrexone treatment as a consequence of improved prescription 
compliance. 
Structured day programmes 
4.21 Structured day programmes for drug treatment are not provided in prisons, 
although there are structured interventions that are provided on an intensive basis and 
therapeutic communities where there is a day programme approach. It should also be 
noted that much of the evidence for support of structured interventions is predicated on 
the requirement of aftercare to ensure that benefits are sustained. 
Structured psychosocial interventions 
4.22 It is not always clear what constitutes a structured psychosocial intervention and 
this should be borne in mind when considering the evidence as it is likely that terms used 
may not be interchangeable. The above point regarding sustaining benefits with 
aftercare also applies. For example, Cognitive Behavioural Therapy (CBT) may involve a 
range of methods and the emphasis on these could differ between particular 
programmes. Some of the common methods used in CBT are: 
•	 Skills training - for example, assertiveness skills or social skills to implant and 
practice new behaviours. This will involve instruction, modelling, role-play, 
feedback and coaching. 
•	 Self instructional training (SIT) - clients are taught a series of instructions to 
repeat to in order to control their behaviour. The statements which the client 
makes to himself during the problematic behaviour are then elicited and 
attempts are made to replace them with more adaptive self-statements. 
•	 Behavioural analysis - which places great emphasis on the need to educate the 
subject and provide him with a framework to understand his behavioural 
problems. This will often involve self-monitoring over a prolonged period. 
•	 Problem solving skills - clients are taught a simple step by step approach to 
identifying and resolving social and inter-personal problems which they then 
apply to their own situation. 
•	 Emotional management – clients are taught a range of techniques such as 
relaxation training, thought stopping, time out and distraction to assist them in 
managing states of arousal. 
•	 Motivational strategies - motivation to change is not a fixed personality trait and 
varies from time to time. Most CBT programmes include exercise based on the 
decisional balance technique, and exercises to create cognitive dissonance in 
order to increase and motivate clients to change. 
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•	 Relapse prevention - clients are taught strategies to cope with the set backs that 
inevitably occur in the process of change. These are rehearsed in advance so that 
when a minor lapse occurs this does not lead to complete abandonment of new 
way of behaving. Relapse prevention also includes identifying the environmental 
triggers which might lead to relapse and making plans to avoid these. 
4.23 Holloway et al. (2008) found positive effects for psychosocial interventions for 
both drug use and offending. Although they also conclude that: “more needs to be 
known about variations in effectiveness and the influence of programme type, intensity, 
and context on crime outcomes”. 
Psychosocial interventions for problematic stimulant use 
4.24 Knapp et al. (2001) carried out a Cochrane review of psychosocial interventions 
for problematic use of cocaine and other psycho-stimulants. They included 27 
randomised controlled trials, covering a total of 3,663 participants, where psychosocial 
interventions were compared with other behavioural or psychosocial treatment. The 
authors concluded that they could determine “Little significant behavioural changes with 
reductions in rates of drug [cocaine] consumption following an intervention”. 
Standard CBT studies for the treatment of problem stimulant use considered by NICE 
4.25 These studies are of the treatment of cocaine and the findings are not directly 
applicable to treatment of heroin dependence. This was not done in the NICE document 
and has led to some misinterpretations of its recommendations. It is also important to 
note that these studies are also specifically relevant to the issue of aftercare since they 
tend to support continuing aftercare as the key factor in effectiveness rather than 
Therapeutic Communities. (See also section on Aftercare.) 
4.26 Crits-Cristoph and colleagues (1999) carried out a multi-site randomised 
controlled trial, involving 487 participants. They compared the effectiveness of two 
psychotherapies (psychodynamic and cognitive treatments) with individual drug 
counselling and individual plus group counselling approaches. These individual and group 
counselling approaches were based on a 12-step approach. Both of these modalities 
were found to be superior to cognitive therapy. 
4.27 Maude-Griffin et al. (1998) randomly assigned 128 participants to either a CBT or 
12-step treatment programme. CBT was found to be superior to a statistically significant 
extent across a range of client variables. 
4.28 Putting together these two studies (Crits-Cristoph 1999 and Maude-Griffin 1998) 
produces a combined result of nil treatment effect from CBT versus standard care. As a 
principle consequence of this result, NICE (2007a) have recommended; “Cognitive 
behavioural therapy and psychodynamic therapy focused on the treatment of drug use 
should not be offered routinely to people presenting for treatment of cannabis or 
stimulant misuse [or those receiving opioid maintenance treatment]”. 
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CBT and cannabis use 
4.29 A comparison, based on economic modelling, of CBT with waiting list control for 
cannabis users has suggested that CBT is not a cost-effective intervention (NICE 2007a, 
reviewing Stephens 2000; Stephens 2002). 
CBT programmes for women 
4.30 Compared to no treatment and no treatment plus parole supervision, Hall (2004) 
found that women engaged in a CBT programme in prison showed statistically significant 
reductions in re-incarceration. This effect was enhanced by a CBT programme plus 
parole supervision. 
CBT generalised drug dependence 
4.31 Johnson and Hunter (1992) found a reduced level of re-offending as a result of a 
cognitive behavioural approach against a more generic treatment programme for drug-
dependent offenders at one year-follow up. Participants rated social skills training first, 
assertiveness training second and options appraisal third as the most useful elements of 
the treatment programme. 
Drug-focused counselling 
4.32 Pearson and Lipton (1999) reviewed 1,606 evaluations of prisons-based drug 
treatment programmes reported from 1968-1996. They found that drug-focused 
counselling was largely ineffective. 
“Other structured treatment” 
Multi-modal short programme 
4.33 Hughey & Klemeke (1996) compared re-offending rates for completers of a five 
week prison treatment programme, non-completers, and a matched control group. Re-
incarceration rates were lowest among the completer group, but these did not reach 
statistical significance 
12-step meetings 
4.34 Several studies have found that attendance at 12-step meetings positively 
influences alcohol and illicit drug use (Fiorentine 1999; Gossop et al. 2003; Humphreys 
and Moos 2001; Moos et al. 2001; Morgenstern et al. 1997; Morgenstern et al. 2003; 
Project MATCH Research Group 1997). It should be noted that attendance might not 
improve other outcomes such as quality of life and psychosocial functioning (Humphreys 
2004). 
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4.35 Morgenstern et al. (2003) found that 12-step meeting attendance was the best 
single predictor of positive outcome following treatment for substance use disorders, a 
factor that increases in conjunction with severity of dependence (Tonigan et al. 1996). 
4.36 There is also evidence that the probability of stable remission increases with the 
number of meetings attended early on (Pisani et al. 1993; Humphreys, Moos, and Cohen 
1997). 
Contingency Management (CM) 
• CM and families 
4.37 Lewis and Petry (2005) studied the effect of contingency management on 
encouraging participation in family activities. Clients who participated (N= 29) remained 
in treatment longer, were abstinent for more weeks, and reported greater reduction in 
family conflict compared to participants who did not engage in family activities (N= 130). 
The significance of the finding is diluted potentially by the fact that 72per cent of the 29 
engagers were female, women having on average better outcomes to drug treatment 
per se than men (Dennis, Foss & Scott, 2007; Scott et al. 2005). 
4.38 NICE (2007a) also concluded that contingency management for cannabis misuse 
did not appear to be effective during treatment as for cocaine misuse. 
• Duration of CM Effect 
4.39 Petry et al. (2006) found that contingency management was superior to standard 
treatment in reduction of drug use (largely cocaine) over the first 3 months of treatment, 
but they found no difference in abstinence rates (CM v standard treatment) at 6- and 9-
month follow-ups. A similar pattern of dilution of beneficial CM effect over time was 
reported by Epstein et al. (2003) in a study of cocaine use by methadone-maintained 
patients. 
4.40 There is one robust study (Higgins et al. 1994) of the efficacy of contingency 
management in managing cocaine use over the course of a full year. Cocaine users in the 
contingency management group received a £3 voucher for each week they remained 
abstinent from cocaine during the first 6 weeks in treatment, a £5 voucher for each week 
of abstinence during the next 6 weeks in treatment and a £10 voucher each time they 
were found to be abstinent in checks performed at 26, 39 and 52 weeks. This voucher-
based trial produced a Relative Risk of 1.42 in favour of CM over a ‘standard care’ 
intervention. 
• CM and value of rewards 
4.41 Sindelar et al.(2007) measured the cost effectiveness of lower-value versus 
higher-value reward contingency management treatment for problematic cocaine users. 
The higher payout contingency management was calculated to be more cost-effective. 
128 
Psychodynamic interventions 
4.42 NICE (2007a), in reviewing five RCT studies (Catalano 1999, Woody 1983, Woody 
1983, Fals-Stewart 2001, Woody 1995), concluded that the evidence suggested mostly 
limited benefits from psychodynamic interventions. 
Behavioural Couples Therapy 
4.43 NICE (2007a) looked at three trials of couples-based interventions (Fals-Stewart 
1996, Kelley 2002, Winters 2002). The evidence from these studies suggests that for 
individuals who have contact with a family member or carer, and who are receiving 
methadone maintenance treatment, the addition of behavioural couples therapy can 
lead to reduction in the use of illicit opioids or cocaine. 
4.44 Additionally, Fals-Stewart 1997, found that behavioural couples therapy was 
more cost effective than individual-based treatment across a range of outcomes (e.g. 
days of abstinence, health and offending) for methadone maintenance patients. 
Drug treatment within specialist areas of the prison or prison hospital setting 
Therapeutic Communities 
4.45 As a rule, therapeutic community programmes are based on the principle of 
social learning, with new residents given instruction in the means to a drug-free life by 
more established residents (‘peers’). In practice, there can be variation in treatment 
philosophy, from a strictly behavioural hierarchical model of treatment, to a 12-step or 
cognitive-founded approach, or an eclectic mix of interventions. 
4.46 Wexler et al. (1999) studied the effectiveness of Therapeutic Community drug 
treatment provided to offenders in a California prison. There were three study groups: 
(no treatment; TC only; TC plus a community-based aftercare programme following 
release). At three-year follow up, only 27 per cent of prison programme graduates who 
also completed community aftercare were re-incarcerated, contrasting strongly with 
around 75 per cent of the subjects in all other study groups who returned to prison. 
There has been a lower-level of return to prison among TC attendees versus non-
treatment at 2 year follow-up, but this effect had eroded by the end of year 3. 
4.47 A study of a Texas prison TC (Knight et al. 1999) reported similar findings. 
Participants were divided between Therapeutic Community attendance only, TC plus 
aftercare, and non-treatment [non-randomised] control group. The aftercare completers 
again had a lower return-to-prison rate after three years than both the TC + aftercare 
non-completers and the control (25 per cent vs. 41 per cent and 42 per cent, 
respectively). 
4.48 In a Sacks et al. (2004) study of Therapeutic Community, clients were assigned 
randomly to either modified therapeutic community (MTC), or mental health (MH) 
treatment programmes. 43 of the 75 entrants to the MTC programme also entered an 
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aftercare programme. The results at 12 month follow-up favoured strongly MTC + 
aftercare (5 per cent re-incarceration) over MTC only (16 per cent) and MH (33 per cent 
return to custody). 
4.49 As with Wexler (1999) and Knight (1999) prison TC studies, voluntary entry to 
aftercare represents a potential selection bias. It should also be noted that this was a 
study of interventions for prisoners with dual diagnosis. Smith (2006) commented that 
the mental health intervention group were younger, more likely to be unemployed in the 
year prior to imprisonment, to have used alcohol at an earlier age, and were less likely to 
report drugs as the principal reason for their offending 
4.50 Nielsen et al. (1996) studied the impact of a combined Therapeutic Community 
and resettlement (work release) programme for problem drug users in a Delaware 
prison. Compared to non-participants, programme completers showed significant 
improvement in self-reported drug use and offending behaviour at 12-month follow-up. 
There appeared to be no appreciable difference in outcomes for course drop-outs v. 
non-participants. 
4.51 Chanhatasilpa (2000) examined fifteen studies of outpatient drug treatment to 
determine the overall effectiveness of treatment programmes for chemically dependent 
offenders in reducing recidivism. Programmes that combined in-prison Therapeutic 
Communities with follow-up community treatment were regarded as effective in 
reducing recidivism, a finding echoed by Perry et al. (2006), in their Cochrane review of 
drug treatment for offenders. 
4.52 NICE (2007a) judged that only two RCTs, providing data on 673 participants, 
(Greenwood 2001; Nemes 1999), met the eligibility criteria for inclusion in the 
psychosocial guidelines CG51. 
4.53 NICE agreed with the conclusion reached by Smith et al. (2006), in their 
systematic review of TCs, that there is a lack of research assessing the effectiveness of 
Therapeutic Communities, or whether one type of Therapeutic Community is superior to 
another. They also concluded, however that: “Prison TC may be better than prison on its 
own or Mental Health Treatment Programmes to prevent re-offending post-release for 
in-mates”. 
4.54 The finding from NTORS was that longer times in residential treatment were 
related to better treatment outcomes (Gossop et al. 1999) and that treatment retention 
was related to better methadone treatment outcomes (Gossop et al. 2001). 
4.55 Farrell (2000) studied the effectiveness of therapeutic community versus a work-
release programme for drug-dependent women in prison. Other than a reduction in 
alcohol consumption, the TC programme was found to have had no statistical significant 
influence on drug consumption, or on re-offending. 
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Residential rehabilitation 
•	 12-step Treatment Programmes 
4.56 NICE (2007a) assessed the effectiveness of 12-step-based residential treatment. 
Only one trial (Finney et al. 1998), met their inclusion criteria. This was a large 
prospective cohort (n=3,018) study that compared 12-step-based residential treatment 
with relapse-prevention CBT and eclectic (combined elements of 12-step and CBT 
approaches) residential treatments (Finney, 1998). 
4.57 NICE concluded that the study demonstrated those in the 12-step group were 
more likely to remain abstinent and had fewer substance use problems than participants 
in the other two arms of the study, but noted that this treatment differential was 
modest. 
Aftercare 
4.58 Continuity of treatment and aftercare from prison drug treatment are extremely 
important from a number of perspectives. These include the short-term nature of prison 
sentences and rapid movements between prisons and areas; post release morbidity and 
recognition that risk and protective factors are managed best within a release package 
that addresses wrap-around resettlement services such as education, employment and 
housing. 
National Treatment Outcomes Research Study (NTORS) 
4.59 The relationship between drug use and crime is complex and makes 
interpretation of the drugs-crime link inherently problematic. Even so, NTORS (Gossop 
2005) reviewed changes in offending behaviour after drug treatment and its findings 
indicate the important role that drug treatment may play in reducing some types of 
criminal behaviour among drug users. 
Key findings include: 
•	 There were substantial reductions in crime at all follow-up points after treatment, 
both for acquisitive crimes and drug selling crimes. Acquisitive and drug selling 
crimes after five years were reduced to about a quarter of the levels at intake. 
•	 Clients from residential and methadone maintenance programmes, who remained in 
treatment for longer periods of time, achieved better crime and other outcomes 
than those who left earlier. Heroin users who were facing pressure from the criminal 
justice system when commencing treatment had worse outcomes, in terms of illicit 
heroin use, than other clients after treatment. 
•	 The reductions in crime provide substantial and immediate benefits to society 
through the reduced economic costs of crime. 
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•	 Crime and addiction do not inevitably go together. Half of the NTORS clients 
reported committing no acquisitive crimes and more than two-thirds reported 
committing no drug offences during the period before admission. 
4.60 Brown (2001) compared outcomes for an aftercare intervention comprising 
individual counselling, case management, skills building, family relations, harm 
minimisation skills and peer support provided to offenders (both newly released and 
those on community sentences). A no-aftercare group were followed up a control. There 
was a statistically significant reduction in offending at six-month follow-up; the effect 
became attenuated at 12 months. 
Independent Factors 
4.61 Studies across a number of years have identified an extensive list of external and 
independent risk factors for the emergence and persistence of drug dependence, and for 
its resistance to treatment. These indicators are: 
Personal Social 
Family factors, including family history of substance abuse Life stressors 
Neighbourhood disorganisation Substance using peers 
Parental psychological problems Homelessness 
Risk taking and sensation-seeking Low income 
Lack of social support Availability of drugs 
Psychiatric co-morbidity and low social attachment 
4.62 McLellan et al. 2000; Hser 2007; Weisner et al. 2003 identified low 
socioeconomic status, co-morbid psychiatric conditions and lack of family and social 
supports among the most important predictors of relapse following treatment. 
4.63 Hser at al (2007) found that relapsed drug users differed from their ‘recovered‘ 
peers in their tendency to use substances in coping with stressful conditions, to have 
spouses/partners who also abused drugs, and to lack non-drug-using social support. 
Stable recovery among the study cohort 10 years later was predicted only by ethnicity, 
self-efficacy, and psychological distress. 
4.64 Conversely, (Hawkins, Catalano, and Miller, 1992; West, 2001) identified external 
and internal protective factors (e.g., family factors such as supportive relationships, 
individual factors such as academic involvement and self-esteem) 
4.65 Cloud & Granfield, (2004) found that the principal strategies employed by 46 
formerly dependent alcohol and drug users for sustaining the cessation of addiction 
included engaging in alternative activities (e.g., religious conversion, returning to 
education, community service), relying on relationships with family and friends, and 
avoiding drug users and the social cues associated with use. However, the applicability of 
this study is limited, as participants were well educated with a history of employment. 
4.66 In a review of 124 studies of recovery, White and Kurtz (2006) reached two 
conclusions: 
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1. Locating clients with high problem severity and low recovery capital within sober living 
communities can enhance long-term recovery outcomes 
2. Post-treatment check-ups and support and assertive linkage to communities of 
recovery and other recovery support services can enhance significantly long-term 
recovery outcomes. 
4.67 On this second assertion, the authors cite the finding of McKay (2005) that 
beneficial effects can be achieved through relatively inexpensive interventions such as 
telephone-based check-ups and support. 
Life Skills 
4.68 A review by Moos and Moos (2007) of 48 studies reporting that the odds of 
sustaining abstinence was positively associated with abstinence ‘self-efficacy’, approach 
coping styles, vocational engagement, income, having clean and sober friends, and 
having ‘social and spiritual support’. 
Treatment outcome indicators 
4.69 Weisner, Ray, et al. (2003) and Scott, Foss, and Dennis (2003) found that long-
term effects of treatment were predicted by the client’s short-term response to 
treatment plus participation in aftercare and self-help. 
4.70 These findings are consistent with developing understanding other findings in 
recent years that suggest strongly that a longer-term approach to drug dependence 
brings better outcomes than short-term (McLellan 2002; McLellan et al. 2005; Moos 
2003; Weisner and Schmidt 1993, 1995; Weisner et al. 2001; Weisner 2002; Wexler et al. 
1999). 
4.71 Abstinence is also associated with a more ‘approach’ coping style (such as logical 
analysis, seeking guidance, problem solving, seeking alternative rewards, and positive 
reappraisal) (Carpenter and Hasin 1999; Chung et al. 2001; Finney and Moos 1995; 
Holahan et al. 2003; Moggi et al. 1999; Moos and Moos 2005). 
4.72 Using a multinomial logistic regression of data from other studies, Scott et al. 
(2005a) found that the odds of ‘sustaining recovery another year’ were higher for 
females, those with more legal involvement, those having more clean and sober friends, 
and weeks of treatment but lower for those with more treatment episodes or who were 
homeless. 
4.73 Dennis et al. (2007) studied 1,132 people entering prison, and followed up more 
than 94 per cent of them over the course of eight years to determine the amount of 
abstinence that each had been able to achieve over that time. Very similar levels of 
lifetime physical abuse, emotional abuse, sexual abuse and homelessness at the 
commencement of the study (i.e. at baseline) were found among those who eventually 
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managed less than one year‘s abstinence and the group that managed five years or more 
‘clean time’. 
4.74 Many of the participants required several episodes of treatment across the eight 
years. Dennis‘s findings appear to support the observations of McLellan et al. (2005) that 
a more extended treatment approach is required for the management of many cases of 
dependence. 
4.75 Falck, Wang, and Carlson (2006) and Scott, Foss, and Dennis (2003) reported 
persistent use or high relapse rates among drug users in their long-term follow-up 
studies. Hser, Hoffman, et al. (2001) found that even among those abstinent from heroin 
for as long as 15 years, a quarter had eventually relapsed during the course of the next 
18 years. 
4.76 Hser et al. (2007) in a regression analysis of a thirty-three year study, reported 
that although some heroin-dependent individuals will stop relatively early in their 
careers, they constitute only a minority of opiate-dependents; even among this sub-
group, it takes 8 to 10 years before stable recovery is reached. Patterns of stimulant use 
are less well understood, but frequent use can persist over decades (Hser et al. 2007). 
4.77 Dolan et al. (2003; 2005) found that retention after release in prison-initiated 
methadone maintenance treatment was associated with reduced mortality, re-
incarceration rates and hepatitis C infection. 
4.78 Simpson (1997) found that retention in treatment, (a general indicator of good 
outcome), was significantly associated with the quality of a relationship with the 
counsellor, satisfaction with treatment, attendance at education classes while in 
treatment (a six-fold indicator of retention), and engagement in continuing care and 12-
step and other support groups in the follow-up phase. 
4.79 Studies by Martin and Scarpitti (1993) and Deschenes et al. (1995) reported 
evidence to support intensive supervision following release. (See also section below on 
combining modalities.) 
5. FACTORS THAT INFLUENCE EFFECTIVENESS 
5.1 The factors that affect evidence are varied and complex including intensity of 
treatment programme; combination of treatment modalities; infrastructure support 
including interventions to support participation and engagement in treatment; and 
variables such as gender and ethnicity. 
Intensity of treatment programmes and/or supervision 
5.2 Taking the term ‘programme’ to mean either a pharmacological or psychological 
intervention for the treatment of problematic drug use, Holloway (2005), in her review 
of the effectiveness of treatment programmes in reducing drug-related crime, stated 
that: 
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‘The meta-analysis showed that higher intensity programmes were 50% more likely to 
reduce criminal behaviour than their low intensity equivalents…..This applies to dosage 
levels, whether the programme is continuous or interrupted, time in treatment, whether 
the subject completes or terminates the programme, and whether treatments are 
combined in some way (e.g. detoxification plus aftercare)’. 
5.3 Coviello et al. (2001) found that 12-week day treatment programme more 
effective (to a statistically significant extent) than six-week programme. Ghodse et al. 
(2002) found ‘intensive’ aftercare more effective than ‘non-intensive’. 
5.4 Turner (1992) investigated the effect of intensive probation or parole for 
offenders versus standard supervision. She found that the intensive group secured a 
higher (statistically significant) rate of employment, but were returned to prison at a 
higher rate. The type of offences that led to breaches were of a more technical, less 
serious nature, suggesting to the author that this was a consequence of a higher level of 
probation scrutiny. 
5.5 Holloway and colleagues (2005), in a systematic review of 52 studies of drug 
interventions for offenders, concluded that ‘The evidence for treating dependence on 
substances other than opioids shows very limited success to date in community settings, 
and is non-existent in offender settings’. The report did, however, find that ‘Higher-
intensity programmes were more likely to result in reduction of criminal behaviour than 
low intensity equivalents’. These ‘higher-intensity programmes’ included clinical, 
psychological and aftercare elements, either as single discrete interventions, or any 
combinations of the three components. 
5.6 In a follow-up meta-analysis, Holloway et al. (2008) concluded that the two most 
effective interventions for the reduction of crime among drug-using offenders were 
Therapeutic Communities and supervision. 
5.7 A major meta-analysis (Prendergast 2002) of comparison group studies found 
treatment reduced illicit drug use and reduced crime significantly and to clinically 
meaningful levels. 
Combining interventions and programmes 
5.8 One of the criticisms of the evidence base is that it does not sufficiently recognise 
comparisons between different treatment modalities and the potential for there to be 
mutually enhancing affects on outcomes. 
5.9 NICE (2007a) compared studies from three different types of multi-modal 
programmes: 
i. Intensive outpatient treatment (four trials – Coviello 2001; McClellan, 1993; Volpicelli 
2000, Weinstein 1997) 
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ii. Intensive outpatient treatment with reinforcement-based treatment (Jones 2005, 
Silverman 2001, Silverman 2007) 
iii. Structured day treatment (Avants1999, Marlowe 2003) 
NICE (2007a) concluded that: 
‘The evidence related to intensive outpatient treatments and day treatments (defined 
respectively as at least 9 and 20 hours of group work per week) does not support the 
notion that “‘more is better” when comparing more intensive treatments to standard 
outpatient treatment in relation to drug-use outcomes’. 
None of the above studies related directly to prisons or probation. 
5.10 There are also studies that have addressed the combination of prescribing either 
for substitution therapy or as an adjunct to detoxification with various other treatment 
modalities. 
Opioid substitution plus CBT 
5.11 NICE (2007a), in an analysis of four randomised controlled trails, concluded that 
relapse-prevention CBT (Epstein 2003; UKCBTMM 2004; Rawson 2002) and standard CBT 
(Woody, 1983) do not appear to be effective treatment options for people undergoing 
methadone maintenance treatment. They added, however that there was some 
evidence that: ‘Standard CBT may be beneficial for a sub-sample who experienced high 
levels of psychiatric co-morbidity’. 
Opioid substitution plus Contingency Management 
5.12 In reviewing the evidence related to opioid treatment plus CM (incorporating 
Petry et al. 2005; Silverman et al. 2004), NICE (2007a) concluded that contingency 
management for people undergoing methadone maintenance treatment is strongly and 
consistently associated with longer, continuous periods of abstinence during treatment 
and point abstinence at 6- and 12-month follow-up. These findings were consistent for 
studies using vouchers, prizes and privileges as reinforcers. However, NICE found no 
evidence to support CM for people undergoing buprenorphine maintenance treatment. 
Opioid detoxification plus psychosocial interventions 
5.13 Amato et al. (2004), in reviewing outcomes from opioid detoxification with 
adjunctive psychosocial interventions against unsupported detoxification, found that 
stand-alone detoxification was the poorer treatment option in terms of retention in 
treatment, completion of treatment and average time elapsed prior to relapse. The high 
rates of treatment drop-out and relapse (Mattick and Hall, 1996), suggest that 
complementary psychosocial interventions are indicated to sustain early recovery from 
opiate dependence. NICE, in reviewing 7 RCTs, found significant evidence in support of 
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family interventions (Yandoli 2002), Contingency Management (McCaul 1984), and social 
network interventions (Galanter 2002). 
Complex needs (dual diagnosis) 
5.14 Charney et al. 2001; Hesse 2004 and Watkins et al. 2006 all reported evidence 
that integrated mental health and drug interventions for people with combined drug and 
mental health problems can reduce their drug use. (See also ‘Opioid substitution plus 
CBT’ above). 
Infrastructure and interventions to support participation and engagement in treatment 
5.15 Amongst the factors that influence effectiveness are the infrastructure to support 
treatment programme delivery and interventions that are designed to support 
participation and engagement in treatment. 
Support for carers/families 
5.16 From an evaluation of three studies, (Kirby et al. 1999; Meyers et al. 2002, 
Copello et al. 2007) NICE (2007a) concluded that self-help interventions appear to be as 
effective as more intensive psychological interventions in reducing stress and improving 
psychological functioning for carers and families of problem drug users 
Alternative therapies 
5.17 Roberts et al. (2007) reviewed a Bowen 2006 study of the effect of vipassana 
meditation (VM) compared with a substance use treatment as usual control group 
(n=78). The VM group showed significantly lower levels of alcohol use after the 3 month 
follow up period, but no difference in re-offending was found between the groups. The 
authors concluded that Vipassana Meditation was effective as a treatment for alcohol-
related problems, but not effective in reducing later criminal activity. 
Case management 
5.18 Evidence for case management as an intervention in its own right is not 
favourable, for example, one study assessed the effectiveness of a community-based 
offender case management intervention. Participants were randomly assigned to ACT 
(assertive community treatment) case management or to routine parole. No impact on 
drug use or criminality was found (Martin 1993). Also, NICE (2007a) in reviewing ten 
studies from the USA (e.g. Morgenstern, 2006; Needels, 2005), decided that case 
management has very little impact on drug use, but some effect in assisting people to 
access more formal treatment. 
5.19 However, it is also important to recognise the potential role and contribution of 
case management as a supportive intervention to increase participation and 
engagement in treatment, especially with respect to aftercare. 
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Infrastructure 
5.20 Aside from modality or intensity of treatment approach, Simpson (2006) found 
evidence that innovation adoption based on training for improving treatment 
engagement was significantly related to client self-reports of improved treatment 
participation and rapport recorded several months later, suggesting that effort to change 
and improve programmes may have a beneficial effect on client outcomes. 
Other therapeutic factors 
5.21 The therapist and client’s working relationship has been shown to be significant 
in relation to outcomes from treatment. Orford (2008) reported that the most common 
positive factor attributed by UKATT (2005) clients to positive changes they had made 
was to relationship they had with their therapist. This was statistically superior to the 
clients’ assessments of the beneficial impact of either of the two studied interventions. 
5.22 There is evidence from Project MATCH (Connors 2000) and from other 
psychotherapy studies (Hanson, 2002; Martin 2000), that better treatment outcomes are 
associated with the rating of more positive ‘working alliance’ by both clients and 
therapists. See also Connors et al. (2000); Martin D et al. (2000); Hanson et al. (2002) and 
UK Alcohol Treatment Trial (UKATT) Research Team (2005). 
6. FACTORS THAT INFLUENCE INTERPRETATION OF EVIDENCE 
6.1 In addition to the factors that influence effectiveness there are a number of 
factors that influence interpretation of the evidence for effectiveness. These include 
methodological questions such as extrapolating evidence from community settings to 
the prison environment; having sufficient clarity and shared understanding of the 
different definitions used by researchers for particular types of interventions; having 
sufficient appreciation of the full range of evidence to be included and finally having a 
methodology by which evidence can be scored and assessed. 
Extrapolating community studies to the prison setting 
6.2 There is a lack of high quality research into prison drug treatment, so important 
evidence from community studies has been included. However, it is by no means clear 
that findings from these studies can be extrapolated to prison settings where there are 
numerous factors that would affect the delivery of the same interventions. 
Clarity and understanding around definitions of various interventions 
6.3 There is a need for greater clarity and understanding about the various terms 
used by researchers to describe psychosocial interventions and cognitive therapies e.g. 
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•	 There is a general lack of clarity in the way that psychosocial interventions are 
categorised. Sometime this is by treatment type, sometimes by characteristics of 
participants and sometimes in relation to programme intensity or the 
combination of delivery. 
•	 Terms are used inter-changeably which makes it difficult to understand exactly 
what is being compared. 
•	 It is not always clear what constitutes Cognitive Behavioural Therapy (CBT) as 
opposed to cognitive therapy or psychodynamic approaches. 
6.4 One of the main implications for this is that services such as CARATs and IDTS, 
which use a range of psychosocial interventions including CBT are often deemed to have 
a negative or very low scoring evidence base. Roberts et al. (2007) asserted that: ‘The 
28-day [IDTS] psychosocial intervention recommended for prisoners with problematic 
drug use does not have a strong evidence base behind it and should be evaluated as a 
priority’. The UK Drug Policy Commission (2008) offered a similar opinion. 
6.5 PwC also concluded that ‘more research is required on the effectiveness of the 28-
day psychosocial intervention package offered by CARATs for PDUs’ (p.55). While it is 
true that there needs to be specific research on CARATs and effectiveness it is not 
straightforward to make conclusions based on related research of one element of the 
service. CARATs provide a range of interventions including information, advice and most 
importantly linkages with other treatment service within and outside the prison 
environment. Effectiveness of CARATs and IDTS should be considered within this broader 
context of infrastructure support and engagement with treatment (see below). 
The lack of a comprehensive coverage of the entire research base 
6.6 This paper is not intended to cover the entire evidence base and many of the 
reviews cited are similarly focused on specific sets of research. This is arguably true of 
any area of research and review of evidence; it would not be possible to include the 
entire evidence base in any single paper. The key issue for prison drug treatment is that 
there are research studies from the perspective of health that focus on drug related 
outcomes and there is also an evidence base from the perspective of offending 
behaviour that includes drug related outcomes. 
6.7 Although some of the studies covered by this paper did not measure re-offending 
rates, reductions in drug use have often been found to be associated with rapid 
reductions in criminal activity (Dismuke et al. 2004; Gossop 2003). It was not the purpose 
of this paper to focus solely on offender outcomes but it is important that both these 
perspectives are included in any consideration of the evidence base. 
Drug treatment, crime and coerced treatment (summarised from McSweeney, Stevens 
and Hunts)
3 
3 The quasi-compulsory treatment of drug-dependent offenders in Europe – Final National Report, England. 
McSweeney T., Stevens A. & Hunt N. February 2006 
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6.8 Large proportions of arrestees and criminals are regular users of illicit drugs. In 
addition, many regular users of illicit drugs also commit crimes. Drug users tend to 
commit more crime during periods of heavy use. However, the causal nature of the 
drugs-crime connection is not clear. It is likely that drug users commit crimes (and 
criminals take drugs) for a variety of reasons. There is a large body of literature that 
shows that drug treatment is effective in reducing drug use and crime, and in increasing 
health and employment of dependent drug users. 
6.9 There was, until the 1970s, a long history of failure in coerced drug treatment. 
More recent efforts appear to have been more successful, although problems of high 
drop-out and inadequate comparison limit confidence in the findings to date. They tend 
to show that legally coerced treatment produces similar or better outcomes than 
treatment entered without legal pressure. 
6.10 Hall and Wild et al. both also criticise these studies for methodological 
shortcomings and argue that the benefits of coerced treatment have been overstated 
(Hall 1997; Wild 1999). 
6.11 The relationship between drug use and crime is complex and makes 
interpretation of the drugs-crime link inherently problematic. Even so, NTORS reviewed 
changes in offending behaviour after drug treatment and its findings, along with the US 
studies mentioned above, indicate the important role that drug treatment may play in 
reducing some types of criminal behaviour among drug users. 
Key findings include: 
•	 There were substantial reductions in crime at all follow-up points after treatment, 
both for acquisitive crimes and drug selling crimes. Acquisitive and drug selling 
crimes after five years were reduced to about a quarter of the levels at intake
4
. 
•	 Clients from residential and methadone maintenance programmes, who remained in 
treatment for longer periods of time, achieved better crime and other outcomes 
than those who left earlier. Heroin users who were facing pressure from the criminal 
justice system when commencing treatment had worse outcomes, in terms of illicit 
heroin use, than other clients after treatment. 
•	 The reductions in crime provide substantial and immediate benefits to society 
through the reduced economic costs of crime. 
•	 Crime and addiction do not inevitably go together. Half of the NTORS clients 
reported committing no acquisitive crimes and more than two-thirds reported 
committing no drug offences during the period before admission. 
Use of Meta-analysis and consensus on scoring methods 
4 
Gossop M., Trakada K., Stewart D. and Witton J. (2005). Reduction in criminal convictions after addiction 
treatment: five-year follow-up. Drug and Alcohol Dependence, 79, 296-302. 
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6.12 The standard approach to assessing the efficacy of various treatment modalities 
through study of the available research is meta-analysis. This is the most common 
method employed in producing NICE guidelines and is commonly used for Cochrane 
reviews. 
6.13 The evidence presented in this paper is based on a number of large-scale reviews 
of drug treatment, related principally to people in prison, which have evaluated research 
studies of a high standard of academic rigour, scoring at either levels 4 and 5 on the 
Maryland scale of scientific methods (Sherman 1997). The Maryland scale describes 
increasing methodological quality as follows: 
Level 1: 
Observed correlation between an intervention and outcomes at a single point in time. A 
study that only measured the impact of the service using a questionnaire at the end of 
the intervention would fall into this level. 
Level 2: 
Temporal sequence between the intervention and the outcome clearly observed; or the 
presence of a comparison group that cannot be demonstrated to be comparable. A study 
that measured the outcomes of people who used a service before it was set up and after 
it finished would fit into this level. 
Level 3: 
A comparison between two or more comparable units of analysis, one with and one 
without the intervention. A matched-area design using two locations in the same 
country would fit into this category if the individuals in the research and the areas 
themselves were comparable. 
Level 4: 
Comparison between multiple units with and without the intervention, controlling for 
other factors or using comparison units that evidence only minor differences. A method 
such as propensity score matching, that used statistical techniques to ensure that the 
programme and comparison groups were similar would fall into this category. 
Level 5: 
Random assignment and analysis of comparable units to intervention and control 
groups. A well-conducted Randomised Controlled Trial fits into this category. 
6.14 Only evidence drawn from either Maryland scale levels 4 or 5 has been scored 
Table 1. The scoring is based on the following: 
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1 Point: 
(a) Limited level 4 or level 5 finding for effectiveness, or 
(b) Single level 5 study demonstrating statistically significant evidence of 
effectiveness, but one or more other level 5 studies demonstrate ineffectiveness. 
2 Points: 
(a) Single level 5 study demonstrating statistically significant effectiveness – no 
study demonstrating contrary findings, or 
(b) Multiple level 4 findings demonstrating statistically significant evidence for 
effectiveness: 
3 Points: 
Statistically significant evidence of effectiveness drawn from two or more level 5 
studies 
Table 1: Scoring Matrix for evidence of effectiveness 
Interventions already available in some prisons are set in light grey. Interventions not 
currently available in prisons are set in dark grey. 
Treatment Type Reduced Reduced Use Reduced Re- Total Value 
Drug Use in Prison Offending 
12-step Programme 2 2 
12-step Meetings 3 3 
Therapeutic Communities 2 2 4 
Case Management 1 1 
Brief Interventions 3 3 
Drug-Focused Counselling 1 1 
Intensive Support on 
Release 
3 3 6 
Psychodynamic 1 1 
Harm Reduction (Group) 0 
Opioid Substitution 3 2 3 8 
Naltrexone 2 2 
Opioid Detox without 0 
Psychosocial Support 
Cognitive Behavioural Therapy 
For Stimulant Use 1 1 
For Cannabis Dependence 0 
For Methadone 0 0* 
Maintenance Clients 
For Generalised Drug 1 1 
Dependence 
For Women Drug Users 1 0 1 
Contingency Management: 
For Stimulant Use 3 3 
For Methadone 3 3 
Maintenance Clients 
For Opioid Detoxification 3 3 
Couples / Family Interventions: 
For Opiate Detoxification 3 3 
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Treatment Type Reduced Reduced Use Reduced Re- Total Value 
Drug Use in Prison Offending 
For Methadone 
Maintenance Clients 
3 2 5 
Social Network Therapy 2 2 
for Opioid Detoxification 
Self-Help Support For 0** 
Carers / Families 
Other Categorisations: 
Vipassana Meditation 2 2 
Higher-Intensity (All 
Treatment Types)*** 
2 2 4 
Beneficial Non-Treatment Factors: 
Enhanced Life Skills 3 2 5 
Sober Living Communities 2 2 4 
* Evidence for effectiveness in the treatment of dual diagnosis 
** Evidence for improved psychological well-being among carers and families 
*** Includes clinical and psychosocial programmes, and combinations of both 
6.15 Although meta-analysis is a commonly used methodology and seeks to ensure 
that a fair and impartial evaluation is being undertaken there are nevertheless issues 
with respect to prison drug treatment that may need additional consideration. For 
example: 
•	 Meta-analysis is dependent on there being sufficient scale to judge effects which 
is not always the case with drug use studies 
•	 Meta-analysis tends to be over-reliant on studies that use Randomised Control 
Trials (RCTs) to judge effectiveness which can have the effect of under-valuing 
alternative methodologies 
•	 Treatment effectiveness is often demonstrated in studies where a no-treatment 
control group is used but the same is not demonstrated when different 
treatment modalities are compared with each other 
•	 RCTs will score well in meta-analysis but these studies are often not good at 
demonstrating interactive effects between treatments and between variables 
within treatments e.g. specific characteristics of the prison setting 
•	 The results of meta-analysis are strongly influenced by the search strategies 
employed by the researchers . So two meta-analytic studies may well produce 
conflicting results depending on the peer review journal searched and the source 
materials included. 
6.16 While the analysis used to compile table 1 provides a useful and approach to 
assessing the evidence, it does not take into account the above issues. It will be 
important in considering the evidence to find some consensus on the most suitable basis 
for assessing evidence that does not weaken the quality of the assessment. 
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7. CONCLUSION 
7.1 It is well established that drug treatment for offenders can reduce both drug use 
and rates of re-offending. Therapeutic Communities, opioid substitution and intensive 
support/supervision on release have particularly strong evidential support. 
7.2 Recognition of the importance of a wide range of individual, family and social 
risk/vulnerability factors in addiction, points to the need for a wide range of specific 
treatment interventions (pharmacological and psychosocial as well as other supportive 
‘wraparound’ interventions) to achieve positive outcomes (McLellan 1993). The 
appropriate combination of such interventions helps individuals to re-establish their lives 
and integration within the community. 
7.3 The specific treatment approaches used in community and prison treatment 
programmes address the substance use itself or address other relevant contributory 
factors. For example, interventions used in prison treatment include motivational 
approaches and positive reinforcement approaches to support abstinence. Substitute 
drugs are used to manage detoxification and as maintenance. Other interventions are 
used to address more directly the impact of particular underlying risk factors in 
individuals. These could include interventions to address childhood sexual or physical 
abuse, or to control anger management problems, or could include use of specific 
treatments for co-morbid disorders such as depression or psychosis. 
7.4 In addition, particularly for those stabilised on medication or those working to 
sustain abstinence, housing, training and employment support can also help to address 
risk factors for relapse. 
7.5 Combination of appropriate pharmacological and psychosocial interventions and 
other support is most likely to provide enhanced responses over individual approaches 
alone. However, there is a need to use the evidence base to determine the best ways in 
which to combine these approaches within the context of prison drug treatment and 
aftercare. 
7.6 Having an evidence based effective treatment and aftercare system for prisons 
essential. Where interventions are known to be ineffective or to have negative impacts 
they should cease to be provided. However, the key issue is that the existing evidence 
base for UK prison based drug treatment is incomplete and there is a need for a national 
strategic approach to commissioning new evidence where this is required and agreeing a 
shared basis by which evidence is used and assessed that encompasses both health and 
offender outcomes. 
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Appendix C 
Prison Drug Treatment Strategy Review Group

Outcomes Review Report 2009
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1. TASK FOR THE REVIEW GROUP 
The Prison Drug Treatment Strategy Review Group are asked to determine and agree 
the key outcomes needed for prisoners and offenders, both in prison and on release 
into the community. 
2. BACKGROUND CONTEXT 
2.1 In considering the above, the Review Group must take into account and have an 
understanding of the national context and the key factors that are currently shaping the 
drug treatment sector and which may have an impact in determining outcomes for drug-
using prisoners and offenders. These are briefly summarised below: 
The 2008 Drug Strategy 
The National Drug Strategy, Drugs: protecting families and communities (2008), provides 
the policy context within which the work of the Review Group, including work on 
outcomes, must be considered. The Drugs Strategy features an undertaking to get drug-
misusing offenders into effective treatment and to improve prison treatment 
programmes. The strategy also concentrates more on families, addressing the needs of 
parents and children, and working with whole families to prevent drug use, reduce risk, 
and get people into treatment (see Sections 6 and 7 of this paper). 
Treatment Effectiveness 
2.3 National and international evidence shows that good quality drug treatment can 
be effective in reducing illegal drug use, improving the health of drug users, reducing 
drug-related offending, reducing the risk of death due to overdose, reducing the risk of 
death due to infections (such as blood borne viruses) and improving social functioning. 
2.4 With the development of the National Treatment Agency’s (NTA) Models of Care 
for the treatment of adult drug users: Update 2006, there has been a greater focus on 
improving drug users’ experience across the treatment system. It is recognised that drug 
treatment is not so much a singular event as a process, usually involving engagement 
with different drug treatment services, perhaps over many years. Every drug user’s 
treatment needs are different and depend on a range of factors that often vary across 
time, including health status, relationships, accommodation, nature of the drug problem 
and the quality of the drug treatment or treatments they receive. 
2.5 Drug treatment use is also often episodic, with drug users dipping in and out of 
treatment over time. Evidence indicates that entry into treatment often has an 
immediate positive impact on drug use and crime. However, this may not be sustained if 
the drug user is not retained in treatment. Optimised treatment usually involves 
retaining drug users in treatment for a minimum of three months. This is the point at 
which treatment begins to accrue generalised long-term benefits. 
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The ‘Recovery’ Debate 
2.6 There is an ongoing debate in the UK that has misleadingly portrayed abstinence 
and maintenance approaches to drug treatment as an antagonistic ‘either/or’ issue, with 
little reference to the evidence on treatment effectiveness, which indicates a treatment 
system should be composed of a range of different services to meet different needs. 
2.7 This debate appears to be diverting attention away from key issues such as 
whether drug users in need of treatment have enough choice, the variability in quality of 
services, and the focus on outputs such as numbers in treatment, rather than outcomes. 
2.8 The UK Drug Policy Commission established a consensus group to agree a 
definition and published a vision statement in their document The UK Drug Policy 
Commission Recovery Consensus Group. A vision of recovery (July 2008): 
‘The process of recovery from problematic substance use is characterised by 
voluntarily-sustained control over substance use which maximises health and 
wellbeing and participation in the rights, roles and responsibilities of society.’ 
Effective Drug Treatment in Prisons 
2.9 There is no doubt that prison presents a great opportunity to help those who 
want to be drug free. There are now increasing opportunities for drug-using offenders in 
prison who are assessed as requiring drug-replacement for a period of time. Effective 
drug treatment raises considerably the quality of prison life, for example, reduced illicit 
drug use by an offender can result in better health outcomes for that individual. 
2.10 Prison treatment goals have a key influence on the treatment modalities 
available in prison and on defining prison treatment outcomes. Treatment goals will 
depend very much on individual need at the time. The effectiveness of prison 
treatment, when judged against most potential outcomes, is influenced by Prison Service 
treatment policy, which is to provide appropriate treatment and support for those who 
have the goal to be drug free (this may be a less realistic goal for those in prison for only 
a short length of time). 
Reintegration/Continuity of care 
2.11 The effectiveness of prison treatment is influenced as much by the interventions 
and support received in the community and the extent to which reintegration needs are 
met. If accommodation needs, benefits support, education and training, family linkage 
and ultimately, employment needs are met, most drug treatment modalities, wherever 
delivered, are far more likely to be effective. If these needs are not met this will reduce 
considerably the likelihood of successful reintegration. 
2.12 This effect is much more pronounced for those staying in prison for short periods 
of time (the majority of prisoners). 
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2.13 The above issues are discussed in more detail in the attached Annex A. 
3. ESTABLISHING OUTCOMES IN PRISON 
3.1 The range of existing outputs data, outcomes, surveys, etc. presents potentially a 
very complex picture that creates difficulties in establishing and measuring prison 
treatment outcomes. Whilst some treatment outcomes may be common to all 
prisoners, outcomes may vary considerably and in a way that is not always readily 
quantifiable. Factors that will have an impact include: 
•	 Gender, age, ethnicity; 
•	 Nature/severity of drug dependency; 
•	 Treatment goals; 
•	 Type and quality of treatment provided; 
•	 Extent of co-morbidity; 
•	 Levels of accommodation and support post release 
•	 Length of time in prison; and 
•	 Discharge distance from home. 
3.2 Thought clearly needs to be given to establishing an outcome based model or 
framework, which should be considered appropriate for use. 
3.3 Arguably, the key outcome measure of interest to the public will be of sustained 
stability post-release (however, this is measured e.g. reduction in illicit drug use, 
sustained abstinence, reduction in crime, etc.). However, other measures, such as 
health outcomes should also be considered, including prevention of the spread of blood 
borne viruses. 
3.4 Another key question to consider is whether it is best to focus on developing a 
few high-level outcomes that apply universally to all prisoners or develop a more 
complex matrix of outcomes, which more closely reflects prisoner segmentation. 
Thought also needs to be given to how all potential outcomes are measured. 
3.5 The Review Group will need to make decisions as to what can be used as 
‘evidence’ i.e. there is a risk that if the Review Group is too restrictive as to what is 
evidence they may miss the opportunity to develop key outcomes but if the Review 
Group is too flexible they may lead to straying from effective, evidence-based practice. 
3.6 Therefore, the Review Group need to consider a programme of work that 
determines: 
•	 What are the key outcomes for offenders in prison and for offenders on release into 
the community (i.e. continuity of care); 
•	 What are the factors that will impact on potential prison and community-based 
outcomes; 
•	 What can be learnt from the existing evidence-base and what are the gaps; 
•	 What outcomes can be measured (including what output and outcome monitoring 
tools already exist in the community and in prisons); 
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•	 What are the existing initiatives and strategies that would have an impact on this 
work, such as the Reducing Re-offending National Action Plan, the Drug System 
Change Pilots, The NHS Operating Framework, Treatment Outcomes Profile (TOP), 
etc.; and 
•	 Users and carers views on what constitute desirable outcomes. 
3.7 There is a wide range of literature on outcomes, so to assist the Review Group 
the attached paper in Annex 1 is intended to provide a summary of the issues to help 
inform discussions, but it is important to note that the information provided is in no way 
definitive. The attached summary paper includes: 
•	 Background information on outcomes measures; 
•	 Factors that affect outcomes in prisons; 
•	 An outline of Government targets; and 
•	 An outline of existing relevant output data/information, outcome measures 
and surveys, etc. 
3.8 The attached paper (Annex 1) needs to be read in conjunction with the paper on 
the evidence-base. 
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Annex 1 
REVIEW GROUP SUMMARY PAPER ON OUTCOMES 
1.	 INTRODUCTION 
1.1	 The last ten years have seen significant improvements in the provision of drug 
services. There are now far more people in treatment than ten years ago, 
waiting times have fallen sharply and there is a range of good practice in multi-
agency working. 
1.2	 The Drug Strategy acknowledges that while there have been successes 
particularly in fast-tracking people into treatment, there is a need to focus more 
upon the outcomes of treatment, including its impact on crime, health, and 
harms caused to families. 
1.3	 Treatment to address drug use can take many forms. The evidence base informs 
national policy and the regional and local decisions that are made to provide the 
best outcomes for those using drugs, both in prisons and in the community. 
There is evidence that interventions, which aim to reduce offending by 
addressing the drug use of dependent users who offend, do work to reduce 
offending. Research shows that drug treatment can achieve reductions in 
offending behaviour. 
1.4	 The Drug Strategy also states that aftercare and wraparound provision are 
associated with better outcomes for prisoners. Treatment is often most effective 
when combined with additional support to tackle the underlying contributory 
issues such as homelessness, long-term unemployment or mental health 
problems. Evidence cited by the Drug Strategy, for example, demonstrates that 
mental health problems suffered by drug users, left unaddressed, can impact 
negatively on drug treatment outcomes. 
1.5	 The Price Waterhouse Cooper (PwC) report, Review of Prison-Based Drug 
Treatment Funding (2007) was conducted within the policy context of the Drug 
Strategy. The PwC report considered what realistic, achievable and measurable 
outcomes could be set for the provision of drug treatment in prisons. The 
report’s recommendations on outcomes are to: 
•	 Articulate and agree the key outcomes for prisoners and offenders in prison 
and in the community; 
•	 Demonstrate how the partner organisations will work together to 
successfully deliver those outcomes; 
•	 Identify measures (key performance targets) which will help the partner 
organisations understand how their performance contributes to the 
achievement of the outcomes; and 
•	 Set out how current activities (initiatives) align with key outcomes and 
design others to fill gaps. 
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2.	 BACKGROUND CONTEXT ON OUTCOMES 
2.1	 Outcomes are simply the effects or changes brought about by the activities of an 
organisation or individuals. An outcome is the measurement of the effectiveness 
of an activity, rather than its size, efficiency or productivity. 
2.2	 It must be noted that outputs and outcomes are often imposed by Government, 
so they are rarely within the control and influence of the organisations to which 
the outcomes are assigned. 
2.3	 That said, an outcomes approach can help organisations deliver more effective 
services for their client group by making services more user-focused and needs 
led, identifying what works well in services and what could be improved. Other 
benefits include: 
•	 Improved and shared clarity of what organisations, Government Departments 
or services are trying to achieve; 
•	 Assists services in creating structure and focus to client-worker interactions 
through regular reviews that cover outcomes areas; 
•	 Encourages staff and clients by providing evidence of progress; and 
•	 A means to reviewing whether funding allocations are cost-effective and 
needs based. 
2.4	 Drug treatment outcome studies, such as the National Treatment Outcomes 
Research Study (NTORS), have played an important role in improving our 
understanding of treatment effectiveness. They provide information about drug 
users and their problems as well as the nature of their involvement with 
treatment services. They can also help us to understand the changes that occur 
in drug use and other problem behaviours after treatment. These studies tend to 
group drug treatment outcomes into four key domains: 
•	 Drug and alcohol use 
•	 Physical and psychological health 
•	 Social functioning 
•	 Offending and criminal involvement 
2.5	 These domains should already be used in care planning and in care plan reviews. 
Some validated tools to measure outcomes in drug treatment do already exist. 
However, these are relatively long and complex and there is no widespread 
agreement on which is the most suitable and in what context. The challenge has 
been to develop a simple but effective, validated tool that can be incorporated 
into national monitoring systems such as the National Drug Treatment 
Monitoring System (NDTMS) and regular care plan reviews by keyworkers. 
2.6	 Moreover, the interventions taking place during treatment are just part of a 
much wider range of factors that can influence outcomes. In many cases, 
treatment may be neither the most important nor the most powerful influence 
upon outcomes. Environmental supports and stresses can influence outcomes. 
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Peer and family relationships, unemployment and living arrangements can all 
have an important effect. The gains produced by an effective treatment 
programme can be undermined or neutralised by adverse social and environment 
factors. 
2.7	 The National Treatment Agency for Substance Misuse (NTA) has developed the 
Treatment Outcomes Profile (TOP), which is being used by drug services in the 
community in England. TOP is an instrument for drug treatment service 
outcomes monitoring and related research applications. However, it is too early 
to assess the effectiveness of TOP as a national outcome monitoring tool and in 
its current form may not be appropriate for use in prisons (more details on TOP 
can be found in section 5.15). 
2.8	 While there are data on outputs on drug-using offenders in prison, there is 
currently little evidence or data that indicate the positive outcomes for drug-
using offenders in prison of treatment programmes i.e. prescribing programmes 
or psychosocial programmes for drug-using offenders aiming to remain drug free. 
3.	 OUTLINE OF GOVERNMENT TARGETS 
3.1	 One of the difficulties of establishing national outcomes measures arises from the 
fact that each government department has its own aims and objectives, for 
example: 
•	 Ministry of Justice – To protect the public and reduce re-offending 
•	 Department of Health – Improve the health and well-being of people in 
England 
•	 Home Office – Reduce the harm that drugs cause to society, to 
communities, individuals and their families. 
3.2	 These aims are monitored through Public Service Agreements (PSAs). The PSA 
target that measures drug treatment in the community and prison is PSA Delivery 
Agreement 25: Reduce the harm caused by alcohol and drugs. 
3.3	 Each Government Department also has departmental Strategic Objectives 
(DSOs), for example, the Ministry of Justice’s DSO is to Support the efficient and 
effective delivery of justice. 
3.4	 Local Area Agreements (LAAs) are the mechanism by which central Government 
sets improvement targets for outcomes to be delivered through local 
government in England. These targets are selected from a set of 198 national 
indicators (NIs) for local authorities and their partners. There are a number of 
national indicators (NIs) relevant to drug users such as NI 40: number of drug 
users recorded as being in effective treatment. The relevant PSAs and NIs are 
outlined in Annex 2. 
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3.5	 PSAs, DSO and NIs may be an effective way to measure activity but they are not 
effective at measuring outcomes due to the limited range of information 
provided. PSAs are restricted in that they only count episodes of care and hence 
do not provide much information on the quality of treatment or other important 
information about the client experience. Moreover, although local areas do have 
to act on all the 198 national indicators, they choose which 35 indicators they will 
prioritise based on local needs assessments and priorities. For example, only 74 
of the 149 local areas in England have included NI 40 as one of their priority 
areas. 
3.6	 That said, the provision of drug treatment is not an optional activity within the 
NHS in England: all primary care trusts have to ensure the provision of effective 
treatment as one of the Tier 2 Vital Signs indicators within the 2009/10 NHS 
Operating Framework. Tier 2 indicators are ranked as national priorities for local 
delivery, to be signed off by the regional Strategic Health Authority. The 
indicator, VSB14: Number of Drug Users Recorded as Being in Effective Treatment 
is overseen by the NTA, supported by Strategic Health Authorities and by the 
Care Quality Commission. It is underlined and informed by three National 
Institute for health and Clinical Excellence [NICE] guidance documents: Drug use: 
psychosocial interventions (Clinical Guideline 51), Drug use: opioid detoxification 
(Clinical Guideline 52) and Interventions to reduce substance misuse among 
vulnerable young people (Public Health Intervention 4)
5
. 
3.7	 PSAs can cover distinct quantities and measurements of a service being provided, 
for example, PSA 25 and NI 40 also refer to “effective treatment”, which is 
defined as: 
• Discharged from the treatment system 12 weeks or more after triage; 
• Or that remain in treatment 12 weeks after triage; 
• Or that were discharged in less than 12 weeks in a care planned way. 
3.8	 Whilst time in treatment is important, it is not the only measure of interest for 
drug treatment. There are other metrics that can provide additional information 
on whether Government Departments are achieving their aims, but some 
important areas, such as well-being and re-offending are more difficult to 
measure in terms of distinct episodes of care. Moreover, definitions around 
quality may not always be clear. 
3.9	 Finally, it is important to note that in terms of target setting within LAAs, local 
authorities and their partners also need to take into consideration two aspects of 
the Race Relations Act 1976 (as amended), as the majority of bodies involved in 
LAAs are public bodies, and as such have obligation under this Act. Specifically, 
they need to be mindful of what is known as the General Duty under the Act, 
which is, (a) to eliminate racial discrimination, (b) to promote equal opportunities 
5 
http://www.nice.org.uk/guidance/index.jsp?action=byTopic&o=7281&set=true 
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and (c) to promote good relations between different racial groups. The Act also 
requires public bodies to monitor the impact of their activities in relation to racial 
equality where that is relevant. In the context of LAAs, local authorities and their 
partners will need to consider how the delivery of the LAA commitments is 
impacting upon different minority groups. 
4.	 FACTORS THAT AFFECT OUTCOMES IN PRISON 
4.1	 As previously mentioned, the interventions taking place during treatment are 
part of a much wider range of factors that can influence outcomes. In many 
cases, treatment may be neither the most important nor the most powerful 
influence upon outcomes. Accordingly, outlined below are some of the factors 
that will have an impact on outcomes in prison. 
Characteristics of the Prison Population 
4.2	 The majority of prisoners spend a short time spent in custody. The average time 
served, excluding remands and determinate sentences in 2005 was eight months. 
Such short lengths of stay in prison mean that access to prison drug treatment 
interventions is also short. Those needing most help with a drug problem often 
seem to fit into the short stay category, as they are either on remand or have 
received a short sentence, only half of which is spent in custody. Length of stay 
in prison has a particular impact on outcomes. The shorter the time spent in 
prison, the more constrained the range of outcomes. 
4.3	 Short length of stay means offenders can access the 28 days clinical 
interventions, CARATs support, and PASRO and Short Duration Programmes 
(SDP). However, access to longer programmes such as 12-step programmes 
would be unlikely in this length of time. 
4.4	 There are also around 100,000 inter-prison transfers annually. This places 
additional pressure on ensuring treatment continuity and additional demands on 
treatment teams who have to engage frequently with new clients. 
Substance Use 
4.5	 Data shows that substance misuse affects 50 per cent of the male and 65 per 
cent of the female prison population (Singleton et al. 1997). Patterns of drug use 
and depth of dependency determine treatment need and can have a 
considerable impact on treatment outcomes. Figures published in the Psychiatric 
Morbidity Study paint a similar picture to new ADAM studies and the Criminality 
Survey 2000 (table below). The CARAT drug service research database reported 
that 36 per cent of CARAT clients reported injecting behaviour in the 30 days 
before custody. The ADAM study reported that 14 per cent had injected in the 
last month, with 22 per cent of injectors reporting the sharing of equipment. 
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4.6	 Injecting drug use carries a high risk to personal and public health. One UK study 
(Judd 2005) found a baseline prevalence of antibodies to hepatitis C virus was 44 
per cent and of antibodies to HIV 4 per cent among injecting drug users. In 2006, 
the number of confirmed hepatitis C infections reported in England rose to 8,346, 
10 per cent higher than in 2005. Injecting drug use remains the single most 
important reported risk factor for acquiring hepatitis C infection (HPA 2007). The 
number of years of injecting has been found to be associated with hepatitis B and 
hepatitis C infection (Noble 2000). 
4.7	 The majority of injecting drug users are sent to prison (DH 2002). Approximately 
half of all prisoners are problematic drug users. 36 per cent of problematic drug 
users entering prisons report injecting drug use within the 28 days preceding 
custody (Home Office 2003). 
4.8	 Drug use in prisons fluctuates across sites and time. Individual prisons may 
experience short-lived drug inundations or have a more persistent serious 
problem with drug smuggling. Randomised mandatory drug testing (rMDT) is the 
best national indicator of drug use in prisons. rMDT indicates that, as a national 
average, drug use reduces markedly in prison, from 55 per cent at point of arrest 
to 8.9 per cent during prison custody (NOMS 2008). 
4.9	 Imprisonment in the UK is also related to a reduction in the prevalence of 
injecting drug use (Bellis 1997; Shewan 1994), but cases of initiation into injection 
in prison have been identified (Boys 2002). Although it reduces in custody, 
injecting drug use in prison is more likely to involve the use of shared equipment 
(Bellis, 1997). Imprisonment is associated with higher rates of blood borne virus 
infection among injecting drug users (Weild 2000). 
4.10	 McLellan et al. 2000; Hser 2007; and Weisner et al. 2003 identified low 
socioeconomic status, co-morbid psychiatric conditions and lack of family and 
social supports among the most important predictors of relapse following 
treatment. In a UK study, Gossop et al. (2002) found that clients who relapsed to 
heroin use after treatment were more likely to have had pre-treatment legal 
problems, and that those who relapsed were more frequent users of heroin prior 
to treatment. The study found that relapse typically occurred very soon after 
leaving treatment, with more than half of the relapses occurring within three 
days of leaving treatment, and three-quarters within one week. 
4.11	 Hser at al (2007) found that relapsed drug users differed from their ‘recovered’ 
peers in their tendency to use substances in coping with stressful conditions, to 
have spouses/partners who also misused drugs, and to lack non-drug-using social 
support. Stable recovery among the entire study cohort 10 years later was 
predicted only by ethnicity, self-efficacy, and psychological distress. 
168 
Women and Substance Use 
4.12	 Plugge et al. (2006) published results of a study of the health of women in prison. 
It investigated the important role prison played in the treatment of the women’s 
substance misuse. They found that prison was a time for them to become 
abstinent and to address previously untreated physical health problems. Women 
said that their physical and mental health problems had been ignored previously 
‘on the outside’. There was evidence of self-medicating in the community – using 
drugs to relieve or block out feelings. These feelings would return during 
detoxification, resulting in extreme emotions, which is one of the causes of 
suicide and self-harm in prisons. 
4.13	 The study also highlighted the importance of throughcare and having the care 
required on release. Women who had support on release were more likely to 
have successful drug treatment outcomes in the community. Women who 
accessed drug treatment early in custody had the most improvement in physical 
and psychological wellbeing. 
4.14	 Appropriate identification and treatment of women with substance misuse 
problems coming into prison can result in healthier pregnancies that progress to 
full-term and fitter babies. 
Dual Diagnosis 
4.15	 Drug dependency is often complicated by co-morbidity of substance misuse and 
mental health problems. The Office of National Statistics (ONS) Survey of 
Psychiatric Morbidity among Prisoners in England and Wales reported that over 
three quarters of those prisoners in the ONS study who were drug dependent 
before prison, were assessed as having two or more other mental disorders 
(Singleton et al. 1999). Potentially, this could have a significant impact on drug 
treatment outcomes. 
Self-Harm 
4.16	 There is a high rate of self-harm in prison. Self-harm is particularly prevalent in 
the women’s estate, as demonstrated by the table below. 
A review of self-harm incidents by the Safer Custody group in 2003 
No. of Incidents 
No. 
Individuals 
of Incident 
(IR)* 
Ratio 
OVERALL 16,221 5,430 3.0 
Gender 
Female 7,408 1,347 5.5 
Male 8,813 4,083 2.2 
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4.17	 Twenty-seven individuals self-harmed over 50 times during the year: 25 of whom 
were female, and four women (no men) self-harmed more than 100 times in one 
year. The 1997 ONS Survey of Psychiatric Morbidity Among Prisoners in England 
and Wales found that 10 per cent of women had self-harmed without suicidal 
intent during their current prison sentence. The prevalence of self-harm during 
their current prison term is higher amongst women with neurotic disorders (20 
per cent) and those with post-traumatic stress disorder (25 per cent). The 
prevalence of self-harm also increased the longer the time in prison - only 3 per 
cent of women who spent less than a month in prison having self-harmed 
compared to 23 per cent for those who spent two years or more in prison 
(Singleton et al. 1997). A NOMS Safer Custody group analysis made similar 
findings - women who self-harmed did so more than five times each time they 
were in custody. Men that self-harmed did so more than twice. 
Suicides 
4.18	 The National Confidential Inquiry (NCI) has completed a comprehensive analysis 
of six years of suicides in prison, from January 1999 to December 2004. Their 
findings were as follows: 
•	 529 self-inflicted deaths occurred among prisoners in 96 prisons, averaging 88 
deaths per year. 
•	 Thirty-nine (7 per cent) deaths occurred within 24 hours of reception into 
prison; 147 (28 per cent) were within one week. 
•	 Self-inflicted death was significantly more likely to occur within 28 days in 
prisoners with a primary diagnosis of drug dependence (86 per cent) than 
those with a primary diagnosis of schizophrenia (27 per cent) or affective 
disorder (38 per cent). 55 (43 per cent) of those with a primary diagnosis of 
drug dependence died within the first week of custody. 
4.19	 This is in line with the initial analysis of suicides in prison from 1999-2000, which 
noted that self-inflicted deaths for those drug dependent prisoners peak in the 
first week in custody (Shaw et al. 2003). The six-year review has found a 
downward trend in self-inflicted deaths for drug dependent prisoners. This would 
concur with an increased investment of clinical drug treatment and CARATs in 
prisons. 
4.20	 Self-inflicted deaths of prisoners with a recorded history of substance misuse can 
be used as a measure of the effectiveness of interventions. If interventions were 
effective, it would be expected that deaths would reduce. The NCI continue to 
collect information on self-inflicted deaths in prison. The PPO is developing a 
database of deaths to look at trends over time. 
Length of treatment and aftercare/support systems for offenders 
4.21	 Weisner, Ray, et al. (2003) and Scott, Foss, and Dennis (2003) found that long-
term effects of treatment were predicted by the client’s short-term response to 
treatment plus participation in aftercare and self-help. 
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4.22	 These findings are consistent with other findings in recent years that suggest 
strongly that a longer-term approach to drug dependence brings better 
outcomes than short-term (McLellan 2002; McLellan et al. 2005; Moos 2003; 
Weisner and Schmidt 1993, 1995; Weisner et al. 2001; Weisner 2002; Wexler et 
al. 1999). A UK study (Gossop et al. 1999) showed that drug dependent patients 
who remained in treatment in residential programmes for longer periods of time 
achieved better outcomes than those who left earlier, in terms of abstinence 
from opiates, abstinence from stimulants, reductions in injecting drug use, and 
reductions in both drug selling and acquisitive crimes. 
4.23	 Scott et al. (2005a) found that the odds of “sustaining recovery another year” 
were higher for females, those with more legal involvement, those having more 
clean and sober friends, and weeks of treatment, but lower for those with more 
treatment episodes or who were homeless. 
4.24	 Dennis et al. (2007) studied 1,132 people entering prison, and followed up more 
than 94 per cent of them over the course of eight years to determine the amount 
of abstinence that each had been able to achieve over that time. Very similar 
levels of lifetime physical abuse, emotional abuse, sexual abuse and 
homelessness at the commencement of the study (i.e. at baseline) were found 
among those who eventually managed less than one year’s abstinence and the 
group that managed five years or more ‘clean time’. Many of the participants 
required several episodes of treatment across the eight years. Dennis’s findings 
appear to support the observations of McLellan et al. (2005) that a more 
extended treatment approach is required for the management of many cases of 
dependence. 
Recovery Factors 
4.25	 Cloud & Granfield, (2004) found that the principal strategies employed by 46 
formerly dependent alcohol and drug users for sustaining the cessation of 
addiction included engaging in alternative activities (e.g., religious conversion, 
returning to education, community service), relying on relationships with family 
and friends, and avoiding drug users and the social cues associated with use. 
However, the applicability of this study is limited, as participants were well 
educated with a history of employment. 
4.26	 In a review of 124 studies of recovery, White and Kurtz (2006), reached two 
conclusions: 
•	 Locating clients with high problem severity and low recovery capital within 
sober living communities can enhance long-term recovery outcomes (Jason et 
al. 2001). 
•	 Post-treatment check-ups and support, and assertive linkage to communities 
of recovery and other recovery support services can enhance significantly 
long-term recovery outcomes. . 
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4.27	 On this second assertion, the authors cite the finding of McKay (2005) that 
beneficial effects can be achieved through relatively inexpensive interventions 
such as telephone-based check-ups and support. 
Transmission of Blood Borne Viruses (BBVS) 
4.28	 Prisoners as a population are more vulnerable to viral hepatitis than the general 
population because of higher levels of risk taking behaviour, including 
intravenous drug use, tattooing and the sharing of potentially blood 
contaminated items such as razors and scissors. 
4.29	 The last extensive study of the prevalence of hepatitis B and C in the prison 
population was Weild et al. (2000). Prisoners in eight prisons were surveyed in 
1997 and 1998 to determine prevalence of risk factors in the transmission of 
BBVs in prison. Of those tested, 8per cent were positive for hepatitis B 
antibodies and 7 per cent for hepatitis C. High levels of intravenous drug use 
were found – 24 per cent having ever injected and 30 per cent of whom injected 
in prison. The percentage of intravenous drug users testing positive to hepatitis B 
and C was 20 per cent and 31 per cent respectively. 
Teeth 
4.30	 Poor oral health is linked to the misuse of opiates and other drugs. Prolonged 
drug use is often associated with self-neglect and the adoption of a diet which 
promotes tooth decay. In 2002, a Scottish prison survey was conducted to 
provide accurate and up-to-date information on the dental health of the Scottish 
prison population. 559 prisoners from the men’s, women’s and young offenders’ 
estates participated in the survey. The results showed that on average the prison 
population had more decayed but fewer filled teeth than the Scottish population. 
4.31	 The severity of tooth decay was also considerably worse in the prison population, 
especially for female prisoners. Reported length of stay data showed that it took 
two years to improve the dental health of prisoners. An Oral Health Impact 
Profile found that poor dental health resulted in painful aching in the mouth, 
feeling self-conscious, tense, embarrassed, irritable, psychological discomfort, 
psychological disability and social disability (Jones et al. 2002). 
5.	 OUTLINE OF EXISTING DATA/INFORMATION 
5.1	 The information below outlines primarily the output data/information (and a few 
outcome measures) currently collected on offenders in prisons and on release. 
This is not intended to be a definitive list, but outlines some of the key 
monitoring and survey measures currently available. 
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In Prison 
Measuring the Quality of Prison Life (MQPL) 
5.2	 Liebling and Arnold (2002) developed a survey of measures for prison life and 
quality in addition to those already in place (such as KPIs and Standards Audits). 
The Prison Service Standards Audit Unit (SAU) administers the MPQL in each 
adult and young offender institution in England and Wales once every two years. 
5.3	 Questionnaire statements are grouped into 16 dimensions, which address various 
aspects of prison life. Dimensions are based on relationships and regime and 
include respect, humanity, trust, fairness, order and security, and safety. 
Prisoners are asked to rate their level of agreement on a 5 point scale, from 
strongly agree to strongly disagree to a list of statements. From this, mean 
scores are produced for each dimension. The questionnaire survey: 
•	 Provides a detailed assessment of life in an individual prison 
•	 Identifies and measures differences between prisons 
•	 Measures differences over time on particular establishments 
The Offender Assessment System (OASys) 
5.4	 This is a joint risk-needs assessment instrument in use across the National 
Probation Service and Prison Service. It identifies and classifies offending related 
needs, such as anger management, potential drug dependency and poor literacy. 
OASys also provides a structured risk assessment and if appropriate, suggests 
areas for further assessment. The results of these assessments are used in the 
development of sentence plans. OASys is made up of the following sections: 
•	 Offending related factors: This part of OASys has 13 sections. The first 12 
examine factors that are related to risk of reconviction. 
•	 Risk of Harm: This covers risk of serious harm, risks to the individual and 
other risks. 
•	 Sentence Planning: This section is made up of an initial plan and a review 
plan. 
5.5	 OASys may be useful in determining an individual’s needs and the extent that 
these have been met during their prison term. It also provides a measure of risk 
of re-offending in both the overall OASys score and Offender Group Reconviction 
Scale’s (OGRS) scores. However, its usefulness is limited as many prisoners will 
never receive OASys assessment and for those that do, the assessment may take 
place too far down the line to influence the direction of treatment or determine 
need, or to serve as a post-treatment measure. 
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Levels of Bullying and Violence Reduction 
5.6	 Prisons now have a violence reduction strategy as set out in Prison Service Order 
2750. Each prison has a violence reduction coordinator who monitors trends 
over time and reasons for change in that prison, and can provide source data on 
levels of bullying and violence. 
Random Mandatory Drug Testing 
5.7	 Monthly figures are available for random mandatory drug testing by prison and 
by drug type; this includes opiates, cannabis and benzodiazepines. Universal 
buprenorphine testing was introduced from 1 April 2008. 
Deaths Database 
5.8	 The Safer Custody prison service individual information has provided data on all 
deaths in prison custody since 1 January 1978. 
Incident Data (IRS) 
5.9	 Information has been collected and analysed by HM Prison Service’s Safer 
Custody Group on 27 types of incidents including self-harm, assaults and drugs 
since 2000 (data on self-harm was included in 2004). 
Hepatitis B Vaccinations 
5.10	 The Health Protection Agency monitors the number of hepatitis B vaccinations in 
prisons. Data is available by prison on a monthly basis. 
On Release – Reducing Re-Offending 
Measurement of Re-Offending 
5.11	 Re-offending can be inherently difficult to measure as identifying people who 
have re-offended requires working within a number of complex systems and will 
only capture those caught and convicted. For example, Dolan et al. (2005) used 
re-incarceration rates. The UK study NTORS (Gossop et al. 2003; 2001; 1999) 
looked separately at crime both in terms of reductions in offending behaviour 
and in reductions in convictions and found that the results were consistent with 
both of these measures, indicating improved outcomes after treatment. 
5.12	 The link between crime/re-offending and drug dependency is well established, 
but the relationship is a complex one. On average, around 50per cent of 
offenders (eg ADAM, Criminality Survey 2000) report their crime is linked to drug 
dependency. This generates or fuels a substantial volume of crime. 
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5.13	 This raises the question of how drug treatment should be targeted. If a key 
outcome is to reduce re-offending, careful attention needs to be paid to identify 
the target group at greater risk of re-offending and consideration is required as 
to how re-offending will be defined and measured. 
On Release – Health and Well-Being 
Deaths of Recently Released Prisoners 
5.14	 Information on deaths on release from prison is an indicator of the quality of 
contact that ex-prisoners have with the services they need. However, the 
information is not routinely collected. Further surveys would be required to 
collect information on deaths on release, but could be done by comparing IIS 
database with NCI and ONS databases to identify all those who have died in a 
given period. 
Treatment Outcomes Profile (TOP) 
5.15	 TOP [see Annex 3] is the national outcomes monitoring instrument for drug 
treatment in the community in England established by the NTA. Prior to TOP, the 
NTA had relied upon process and proxy outcome measures – such as waiting 
times and retention – to indicate the effectiveness of drug treatment. 
5.16	 The NTA developed TOP to be used at the start of treatment and in care plan 
reviews. TOP is reported through the National Drug Treatment Monitoring 
System (NDTMS). 
5.17	 TOP contains a set of questions based on the four domains established 
internationally, which are drug and alcohol use, physical and psychological 
health, offending and criminal involvement, and social functioning. TOP allows 
key workers and service users to track progress on measures within these 
domains, and compare pre-treatment functioning and behaviour with these 
phenomena at stages in (and even beyond) treatment. 
5.18	 TOP has been designed with the following principles and requirements in mind: 
•	 It must reflect the main problems (risks and harms) that clients in 
structured substance misuse interventions experience 
•	 It must be straightforward to complete 
•	 It should be in a form that is useful in clinical practice and can provide 
helpful feedback to clients to build and maintain change motivation 
•	 It must be as brief as possible, to minimise the time taken to collect the 
information 
5.19	 While TOP may be a useful tool in measuring the outcomes of offenders released 
into the community, it is too early to assess the effectiveness of TOP as a national 
outcome monitoring tool. In its current form TOP may not be suitable for use in 
prisons (the TOP questions, for instance about shoplifting and risk of eviction are 
not relevant to a prison environment). 
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National Drug Treatment Monitoring System (NDTMS) 
5.20	 The NDTMS collects, collates and analyses information from, and for those 
involved in the drug treatment sector in the community. The NDTMS is a 
development of the Regional Drug use Databases, which have been in place since 
the late 1980s. It provides data on the progress of the drug treatment PSA 
target. Drug treatment agencies provide information to the NDTMS on their 
activities each month – known as the Core Data Set. The data items are gathered 
under the following headings: 
•	 Client details 
•	 Episode details 
•	 Treatment modality/interventions details 
•	 TOP details 
•	 Local/regional fields whose usage depends on local/regional requirements 
5.21	 NDTMS has been used by prisons from April 2009, as part of an updated Drug 
Interventions Record. 
Drug Interventions Record (DIR) 
5.22	 The DIR is used by criminal justice drug workers in the community, and CARATs 
and clinical workers in prison as: 
•	 The key tool for continuity of care and monitoring and research in relation to 
the Drug Interventions Programme (DIP) – used by Criminal Justice 
Intervention Teams (CJITs) and CARATs; and, 
•	 The Substance Misuse Triage Assessment form – used in prisons only. 
5.23	 The DIR has three main roles, which are to: 
•	 Facilitate and improve standards of continuity of care for drug users, and 
minimise duplication of assessment, especially when they are moving 
between custody and community but also when information is passed 
between case managers and/or treatment providers; 
•	 Support the monitoring and research functions around DIP, in line with the 
programmes’ and other related performance management frameworks; 
•	 Be the Substance Misuse Triage Assessment form used for all CARAT clients 
(and clinical clients where Integrated Drug Treatment System (IDTS) is in 
operation), whether or not they are likely to become clients of the CJIT in 
their home area of residence. 
5.24	 Data fields gathered by the DIR include: 
•	 Problem substances 
•	 Regularity of substance misuse 
•	 Treatment modalities in prison 
•	 Referral to community drug services on release 
•	 Offence 
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Prison Health Performance & Quality Indicators 
5.25	 There is one specific PHPQ indicator dedicated to prison substance misuse 
treatment – PHPQI 1.19. It takes the traffic light rating given to the Integrated 
Drug Treatment System clinical provider by the National Treatment Agency for 
Substance Misuse quarterly review (4th Quarter, January–March 2009). 
5.26	 The Royal College of GP’s Quality Practice Award, an outcome-focussed 
workforce approach, is being piloted in HMP New Hall. The 12 modular reflective 
practice toolkit has been adapted from the GP QPA, which is open to practices 
with high-performing systems. The QPA culminates in an external audit by a 
multi-agency team. 
Care Quality Commission and World Class Commissioning 
5.27	 The Care Quality Commission is the new integrated regulator for health and adult 
social care, established as part of the NHS Next Stages review. The audit 
processes the QCA develop will potentially contribute to quality outcomes. 
5.28	 Similarly, the World Class Commissioning assurance handbook outlines a five-
stage process that is designed to concentrate on outcomes. 
5.29	 Although there are often discernable differences in the effectiveness of one 
treatment modality over another (ref PDTSRG Evidence Base Paper), other 
factors can have an equal or more profound influence on treatment outcomes. 
These include: 
Operational Governance – Poor financial and administrative governance 
can mean that resources are wasted and fewer people can access and 
enter treatment; 
Inequality – Treatment systems may provide a good service to some 
clients (e.g. white males), but fail to reach a significant proportion of the 
wider population (eg women, Black and Asian drug users, people with 
learning disabilities or serious mental health problems) 
Staff quality, competence and motivation – Some services are not good 
at retaining clients in treatment. Rigid and outmoded approaches can 
cause clients to leave prematurely, whilst innovation in services, however, 
6
can engender positive outcomes 
5.30	 The World Class Commissioning System recognises this need for a broad 
outcomes perspective. It therefore incorporates health outcomes, competencies 
and governance. It is important to set and measure outcomes that cover all of 
the above. Outcomes that concentrate on client response to treatment will, for 
instance, fail to detect a service’s failure to bringing into treatment some 
individuals from under-represented communities. 
6 
Simpson D, Joe G and Rowan-Szal G (2007). Linking the elements of change: Program and client responses to 
innovation, Journal of Substance Abuse Treatment 33, 2, 111-120 
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Prison Surveys 
5.31	 Surveys offer a good means of measuring the range of prisoners’ problems and 
needs on reception and how these change over time. In the case of the mental 
and physical health of the population, surveys are the only pooled source of 
information. Each primary care trust conducts a health needs assessment on the 
level of health care need in the prison, but this information is never reported or 
combined. The disadvantage of surveys is the cost and time associated with 
conducting them. Examples of key surveys are outlined below: 
•	 Survey of physical health: The last survey of the physical health of the prison 
population was conducted in 1994, prior to the NHS taking on the 
responsibility for commissioning health care for prisons. It showed that 
prisoners have worse physical health than their equivalents for age and 
gender in the general population (Bridgwood & Malbon 1995). 
•	 Survey of mental health problems: The last major survey of prisoner mental 
health problems was the ONS survey Psychiatry and Morbidity Among 
Prisoners In England and Wales, conducted in 1997. It showed that prisoners 
have more adverse mental health problems than an equivalent member of 
the population (Singleton et al. 1998). 
•	 Newly sentenced prisoners survey: The Home Office commissioned a cohort 
study of 1,457 newly sentenced prisoners from 49 prisons in England and 
Wales, between November 2005 and November 2006. The prisoners are 
being followed for four years. Some of the information collected by the 
cohort study is the same information as for the ONS prison Survey of 
Psychiatry Morbidity. A draft document from this study suggests increased 
prevalence of psychosis and substance misuse in the prison population since 
the ONS survey in 1997. 
Outcome Studies – Community-based 
National Treatment Outcome Research Study (NTORS) 
5.32	 This study recruited 1,075 clients from 54 treatment programmes during 1995. 
Forming the largest prospective longitudinal cohort study of treatment outcome 
for drug users to be conducted in the UK, NTORS investigated problem drug users 
in four treatment modalities: specialist inpatient treatment, rehabilitation 
programmes, methadone maintenance and methadone reduction. 
5.33	 NTORS investigated treatment outcomes in existing services under day-to-day 
circumstances. Such studies are rare because of the high cost involved and the 
degree of effort and organisation required to implement, coordinate and sustain 
data collection systems over a number of years. 
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5.34	 The main outcome measures used were: 
•	 Substance misuse behaviour (including substance type, frequency and quality 
of use) 
•	 Health (psychological and physical health problems) 
•	 Social functioning (employment, accommodation and crime) 
•	 Harm (injecting and sharing injecting equipment) 
Drug Treatment Outcomes Research Study (DTORS) 
5.35	 Funded by the Home Office, DTORS seeks to update existing knowledge on the 
effectiveness of drug treatment in England. Within the context of changing 
patterns of drug use and an expansion in criminal justice referrals, this study aims 
to measure the outcomes experienced by those seeking drug treatment. 
5.36	 The study comprises of three key elements: a quantitative study of outcomes, a 
qualitative study of treatment-related issues, and a cost benefits analysis. This is 
a three-year study, which is currently ongoing. Outcome measures used include: 
•	 Levels of drug use 
•	 Offending 
•	 Social circumstances 
•	 Physical and mental health problems 
•	 Risk taking behaviours 
6. Additional desirable outcome indicators 
6.1	 Some key factors identified in Section 4 of this paper are not measured via 
the tools set out in Section 5. These are set out below. 
6.2	 Children and families - The well-being of children and families is an important 
aspect of the 2008-18 Government Drug Strategy Protecting families and 
communities. 
6.3	 The outcomes should be both immediate, (i.e. successful re-integration of 
families upon release) and longer term (children safeguarded). Treatment 
activities most likely to achieve these objectives and therefore bring about 
desired outcomes are: 
•	 Inquiry as to whether patient has child care responsibilities 
•	 Use of multi-agency working to the fullest extent where patients are parents 
•	 Document information given to patient when take-home doses 
•	 Involvement of families in treatment wherever appropriate 
•	 Number of parents accessing parenting support interventions 
•	 Common Assessment Frameworks completed where there is a substance 
misuse link and 
•	 Involvement in Safeguarding children board , and children and young people’s 
services involvement 
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6.4	 The Review Group evidence base paper identified three interventions and 
provisions that have proven reducing re-offending potential: 
� Opioid substitution 
� Enhanced life skills 
� Sober living communities 
All of these three depend to a substantial extent on the design of services that 
integrate with community provision and facilities. 
6.5	 There are potential benefits to be drawn from the alignment of drug treatment 
service outcomes with the objectives of companion services, particularly where 
such services provide a very important health or social care need for some of the 
same service users. Mental health and learning disabilities services are perhaps 
the best example of this: 
Outcome (PSA 16) Data Source 
Adults with learning disabilities in settled Care Quality Commission special data 
accommodation collection 
Adults with learning disabilities in Care Quality Commission special data 
employment collection 
Adults in contact with secondary mental Mental Health Minimum data set 
health services in settled accommodation 
Adults in contact with secondary mental Mental Health Minimum data set 
health services in employment 
6.5	 The alignment of outcomes from different health, social care and offender 
management sectors is likely to become a far more common theme over the 
coming years. This theme is explored in section 7 below. 
7.	 The likely configuration and nature of services in 2011 
7.1	 Recent and current legislative and strategic developments will influence the 
configuration and priorities of drug treatment services in 2011. The most 
significant of these are: Equality, Children & Families; Restructuring; and 
Integration 
7.2	 Equality 
With the change in equality and human rights legislation there is now a legal 
as well as moral imperative for government agencies, the National Health 
Service and all treatment providers to ensure equality of access and service. 
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7.3	 Both the Department of Health and Ministry of Justice now have a Single Equality 
Scheme (SES)
7 
The SES sets out the Departments’ public commitment and plan 
for action across the six equality strands of ethnicity, gender, disability, age, 
sexual orientation and religion or belief. The SES also incorporates the Human 
Rights programme. This scheme will cover the period 2009 – 2012. 
7.4	 Outcome metrics will need to measure and promote equality, and form an 
increasingly important part of any future quality assurance process. 
7.5	 Children and families 
As referenced earlier in this paper (sections 2.1 and 6.2), the well-being of 
children and families is a key element of the 2008-18 Government Drug Strategy 
Protecting families and communities. The 2007 UK Clinical Guidelines also 
underlined this ethos: 
“Greater emphasis has been put on child protection issues and clinicians’ 
responsibilities to maximise opportunities to identify and prevent harm to both 
children of drug misusing parents and young drug users themselves” 
DH & Devolved Administrations (2007) 
7.6	 Restructuring 
Earlier this year the NOMS agency was restructured within the Ministry of 
Justice, bringing together the headquarters of to enable more effective delivery 
of services. The two constitute bodies, the Probation Service and HM Prison 
Service,
8 
remain distinct but have a strong unity of purpose – to protect the 
public and reduce re-offending. NOMS is responsible for commissioning and 
delivering of adult offender management services, in custody and in the 
community, in England and Wales. 
7.7	 Responsibility for delivering a reduction in re-offending and the management of 
offenders is devolved to 10 regional offices in England and one office in Wales. 
Each is responsible for commissioning services, developing a reducing re-
offending delivery plan and coordinating partnerships in their area. This move to 
a more regional emphasis will create new relationships across England between 
Government Offices, Strategic Health Authorities and Directors of Offender 
Management. 
7.8	 The NHS itself is undergoing a significant change in the way it plans and delivers 
health services. The High Quality for All programme, initiated in 2008, placed 
primary care trusts, (the national network of local NHS organisations), at the 
centre of planning and commissioning of services. In spring 2009, each PCT 
published its strategic plan setting out a five-year plan for improving the health of 
people locally. 
7 
http://www.justice.gov.uk/noms-single-equality-scheme.htm 
8 
http://www.justice.gov.uk/news/newsrelease270409b.htm 
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‘Every primary care trust will commission comprehensive wellbeing and prevention 
services, in partnership with local authorities, with the services offered personalised 
to meet the specific needs of their local populations. Our efforts must be focused on 
six key goals: tackling obesity, reducing alcohol harm, treating drug addiction, 
reducing smoking rates, improving sexual health and improving mental health’. 
High Quality for All (NHS/DH, 2008) 
7.9 Outcomes will be a fundamental area of scrutiny within the NHS by 2011: 
‘All registered healthcare providers working for, or on behalf of, the NHS will be 
required by law to publish ‘Quality Accounts’ just as they publish financial 
accounts’. NHS Next Stage Review, Final Report, July 2008 
7.10	 As part of this change, a Quality and Outcomes Framework will be established, 
to include an independent and transparent process for both developing and 
reviewing indicators. It will be necessary that the outcomes decided upon by the 
Prison Drug Treatment Strategy Review Group harmonise with and become 
accepted within this Quality and Outcomes Framework. 
7.11	 The Government’s 2009 Green Paper on the future of care services 
9 
states: 
‘We want to build the first National Care Service in England’. 
7.12	 Among the changes being considered is the pooling of various strands of social 
care funding. Such pooling would create the potential for the commissioning of 
large integrated social care services, which may provide important opportunities 
for the commissioning of wraparound and aftercare services for drug users 
leaving prison drug treatment services. 
7.13	 Greater Integration 
This move towards a more integrated health and social care provision is currently 
being piloted by the new integrated care organisations (ICOs). ICOs bring 
together health and social care professionals from a range of organisations, 
including community services, hospitals, local authorities and others, depending 
on local needs. The Wakefield ICO pilot concentrates on services for substance 
misusers, and includes NOMS prisons and probation agencies, and the police. The 
aim of ICOs will be to achieve more personal, responsive care and better health 
outcomes for a local population 
7.14	 One of the aims of the Drug Strategy, Drugs: protecting families and 
communities (2008) is to deliver new approaches to drug treatment and 
social re-integration. As part of this aim, System Change pilots are testing new 
approaches that can provide better end-to-end management through the system, 
including a more effective use of pooled funding and individual budgets, and with 
HM Govt (2009) Green Paper: Shaping the Future of Care Together 
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a sharper focus on outcomes. This programme covers drug treatment both in the 
community and in prisons, and the continuity of care for drug-using offenders 
leaving prison. Four partnerships in particular are working in new ways that have 
the potential to influence: 
•	 Partnerships in Essex are already taking steps to move the responsibility for 
IDTS and CARATs funding and commissioning to Essex Drug and Alcohol 
Partnership (EDAP). They are also exploring aligning of related 
commissioning of DIP service. 
•	 In Hampshire self-directed support (SDS), tools for the assessment of SDS for 
substance misusers have been drafted and are ready to be piloted 
•	 Hertfordshire is aiming to develop new contracts to support the pilot, 
especially around wraparound and re-integration services. 
•	 Lambeth is currently considering a comprehensive re-tendering of prison and 
community drug services across the borough 
8.	 Commissioning for a full range of outcomes 
8.1	 In addition to the opportunities arising from the new developments described in 
section 7, the PDTSRG may want to explore the potential of outcome-based 
commissioning. 
8.2	 Although there are often discernable differences in the effectiveness of one 
treatment modality over another (ref PDTSRG Evidence Base Paper), other 
factors can have an equal or more profound influence on treatment outcomes. 
These include: 
Operational Governance – Poor financial and administrative governance can 
mean that resources are wasted and fewer people can access and enter 
treatment; 
Inequality – Treatment systems may provide a good service to some clients (e.g. 
white males), but fail to reach a significant proportion of the wider population (eg 
women, black and Asian drug users, people with learning disabilities or serious 
mental health problems) 
Staff quality, competence and motivation – Some services are not good at 
retaining clients in treatment. Rigid and outmoded approaches can cause clients 
to leave prematurely, whilst innovation in services, however, can engender 
positive outcomes
10 
8.3	 It is important to set and measure outcomes that cover all of the above. 
Outcomes that concentrate on client response to treatment will, for example, fail 
to detect a service’s failure to bring some people into treatment in the first 
instance (such as drug users with learning disabilities). 
10 
Simpson D, Joe G and Rowan-Szal G (2007). Linking the elements of change: Program and client responses to 
innovation, Journal of Substance Abuse Treatment 33, 2, 111-120 
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8.4	 The World Class Commissioning System recognises this need for a broad 
outcomes perspective. It therefore incorporates health outcomes, competencies 
and governance. World class commissioning may also provide the basis for 
outcome-based accountability, an approach to social provision used by 
Portsmouth and the City of Hull (see Appendix E). 
9.	 Conclusion 
With the recent restructuring of NOMS and the NHS and the imminent 
reconfiguration of social care provision in England, the introduction of Local Area 
Agreements and with the launch of pilot programmes like the Systems Change 
and the Integrated Care Organisation, we are now entering an era of 
partnerships. Integrated working is becoming the standard approach to service 
planning, commissioning and delivery. Much of this work is now undertaken at a 
local level, via Joint Strategic Needs Assessments, joint commissioning and Local 
Strategic Partnerships. 
We are also at a point of increased concentration on outcomes: the new NHS 
Quality and Outcomes Framework is one such example. 
These factors mean that outcome setting is a matter for regional and local 
organisations and agencies, within the greater context of national public service 
agreements. Any outcomes framework for prison drug treatment should be 
matched to these established and evolving systems. In view of the complexity of 
this picture, coupled with the technical challenges of adjusting and drawing 
together information management systems, the PDTSR Group may wish to 
consider the establishment of an Outcomes working group, which will take 
forward the embedding of key outcomes determined by the PDTSRG. 
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PSA targets 2007-2010 relating to prison and drug treatment

PSA Relevant Indicators for National Indicators Number 
mental health, offenders and Local 
health inequalities Areas 
with LAA 
PSA Delivery Indicator 1: Percentage NI 20 Assault with injury 
Agreement 25: change in the number of drug crime rate 
Reduce the harm 
caused by alcohol 
users recorded as being in 
effective treatment. It also 
NI 38 Drug-related (Class 
A) offending rate 
and drugs includes clinical drug NI 39 Rate of Hospital 
treatment in prisons. Admissions per 74/150 
Indicator 2: The rate of drug 100,000 for Alcohol 
related offending, defined as Related Harm 
those in contact with the CJS NI 40 Number of drug 
who are identified as misusing users recorded 
Class A drugs (currently heroin as being in effective 
and cocaine/crack). treatment 
NI 41 Perceptions of 
drunk or rowdy 
behaviour as a problem 
NI 42 Perceptions of drug 
use or drug dealing as a 
problem 
PSA Delivery 
Agreement 16: 
The most socially excluded 
adults are in settled 
NI 143 Offenders under 
probation supervision 
2/150 
Increase the 
proportion of 
socially excluded 
adults in settled 
accommodation 
accommodation 
Indicator 1: Proportion of 
former care leavers aged 19, 
who had left care aged 16 or 
over, who are in suitable 
living in settled and 
suitable accommodation 
at the end of their order 
or licence 
NI 144 Offenders under 
10/150 
and employment, 
education or 
accommodation. 
Indicator 2: Proportion of 
probation supervision in 
employment at the end 
10/150 
training offenders under probation 
supervision living in settled 
of their order or licence 
NI 145 Adults with 
29/150 
accommodation at the end of learning disabilities 
their order or license. in settled 
The most socially excluded 
adults are in employment, 
education or training 
accommodation 
NI 146 Adults with 
learning disabilities 9/150 
Indicator 5: Proportion of 
former care leavers aged 19, 
who had left care aged 16 or 
in employment 
NI 147 Care leavers in 
suitable accommodation 30/150 
over, who are in employment, NI 148 Care leavers in 
education or training. education, employment 
Indicator 6: Proportion of 
offenders under probation 
or training 
NI 149 Adults in contact 
supervision in employment at with secondary mental 
the end of their order or health services in settled 
license. accommodation 
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NI 150 Adults in contact 
with secondary mental 
health services in 
employment 
PSA Delivery 
Agreement 23: 
Making 
Communities Safer 
Indicator 2: Continue to make 
progress on serious acquisitive 
crime through a focus on the 
issues of greatest priority in 
each locality and the most 
harmful offenders – 
NI 15 Serious violent 
crime 
NI 16 Serious acquisitive 
crime 
NI 17 Perceptions of anti-
social behaviour 
particularly drug misusing 
offenders (ties into PSA 25 – 
by targeting drug use also 
target related crime). 
Indicators 5 and 6: Reduction 
in re-offending rates (ties into 
PSA 25 – targeting drug 
related crime). 
NI 18 Adult re-offending 
rates for those under 
probation supervision 
NI 19 Rate of proven re-
offending by young 
offenders 
NI 21 Dealing with local 
concerns about anti-
social behaviour and 
crime issues by the local 
council and police 
NI 26 Specialist support 
to victims of a serious 
sexual offence 
NI 28 Serious knife crime 
rate 
NI 29 Gun crime rate 
NI 32 Repeat incidents of 
domestic violence 
NI 34 Domestic violence 
– murder 
PSA Delivery 
Agreement 18: 
Indicator 1: All-age-all-cause 
mortality (AAACM) rate. By 
NI 120 All-age all cause 
mortality rate 
86/150 
Promote better 
health and 
wellbeing for all 
2010 increase the average life 
expectancy at birth in England 
to 78.6 years for men and to 
NI 123 Stopping smoking 
NI 136 People supported 
to live independently 
82.5 years for women. through social services 
Indicator 2: Gap in AAACM (all adults) 
rate between Spearhead 
Group and national average. 
Reduce health inequalities by 
10per cent as measured by 
life expectancy at birth. 
Indicator 3: Smoking 
prevalence – to reduce 
smoking rates to 21per cent 
or less by 2010 
Indicator 5: proportion of 
people with depression 
and/or anxiety disorders who 
are offered psychological 
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therapies. 
PSA Delivery The Prison PCT partnership NI 126 Early access for 
Agreement 19: should ensure that all of the women to maternity 
Ensure better care indicators in this PSA are services 
for all adhered to for the prison NI 127 Self-reported 
population. experience of social care 
users 
PSA Delivery NI 151 Overall 
Agreement 8: Employment rate 
Maximise (working-age) 
employment NI 152 Working age 
opportunity for all people on out of work 
benefits 
DH DSO Ensure better health and well- NI 119 Self-reported 10/150 
being for all measure of people’s 
overall health and 
wellbeing 
NI 121 Mortality rate 
from all circulatory 
diseases at ages under 75 
NI 122 Mortality rate 
from all cancers at ages 
under 75 
NI 125 Achieving 
independence for older 
people through 
rehabilitation / 
intermediate care 
DH DSO Ensure better care for all NI 124 People with a 
long-term 
condition supported to 
be 
independent and in 
control of their condition 
NI 128 User reported 
measure of respect and 
dignity in their treatment 
NI 129 End of life care – 
access to appropriate 
care enabling people to 
be able to choose to die 
10/150 
at home 
NI 131 Delayed transfers 
of care 
NI 132 Timeliness of 
social care assessment 
(all adults) 
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NI 133 Timeliness of 
social care packages 
following assessment 
NI 135 Carers receiving 
needs assessment or 
review and a specific 
carer’s service, or advice 
and information 
DH DSO Better value for all NI 134 The number of 
emergency bed days per 
head of weighted 
population 
PSA Delivery 
Agreement 25: 
Reduce the harm 
caused by alcohol 
Indicator 1: Percentage 
change in the number of drug 
users recorded as being in 
effective treatment. It also 
NI 20 Assault with injury 
crime rate 
NI 38 Drug-related (Class 
A) offending rate 
and drugs includes clinical drug NI 39 Rate of Hospital 
treatment in prisons. 
Indicator 2: The rate of drug 
Admissions per 
100,000 for Alcohol 
74/150 
related offending, defined as 
those in contact with the CJS 
Related Harm 
NI 40 Number of drug 
who are identified as misusing users recorded as being 
Class A drugs (currently heroin in effective treatment 
and cocaine/crack). NI 41 Perceptions of 
drunk or rowdy 
behaviour as a problem 
NI 42 Perceptions of drug 
use or drug dealing as a 
problem 
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Annex 3 
Treatment Outcomes Profile 
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Appendix D 
Prison Drug Treatment Strategy Review Group

Outcome Model 2010
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Prison Drug Treatment Strategy Review Group 2010 
Outcomes Framework 
This paper concentrates on outcomes. It may be suitable for adaptation into a Payment 
by Results (PbR) framework. A separate piece of work will be required to summarise and 
extend standards, and give formal guidance to commissioning groups on the creation by 
of weighted scorecards. 
Payment by results will also require an understanding of the challenges to frontline staff 
associated with the culture shift. These practitioners will need to be cognizant of those 
areas in the care pathway that their interventions affect, and focussed on the use of 
feedback in their performance reports to make changes that take service users forward 
on their journeys of recovery. 
The ambition of shifting toward effective measurement of a balanced treatment system 
focussing on recovery will require the ability to mine individual and aggregated data 
across data sets, and to manage information sharing effectively. 
Current sources of outcome information 
There are many sources of information that may be used to build outcome measures. 
They include: 
o	 National Drug Treatment Monitoring System (NDTMS) 
o	 Drug Interventions Programme data (DIRWeb and DIMIS) 
o	 Mental Health Minimum data set (MHMDS) 
o	 Supporting People data 
o	 DWP data 
o	 Offender assessment and sentence management (OASys) 
o	 Police National Computer 
o	 Medicines Management Prescribing Reports (PACT data) 
o	 Contract reviews (outcomes agreed locally and contained within contacts 
or service level agreements) 
o	 Accredited treatment programme placements and completions 
o	 NOMIS data 
o	 Department of Work & Pensions Labour Market System (LMS) 
o	 HMRC Job Entry data 
o	 Staff satisfaction surveys 
o	 Service User Satisfaction surveys 
o	 Clinical Governance (CQUINS , CQC data) 
o	 Service Audit 
o	 Quality Outcome Framework 
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There are four primary outcomes to this framework:

A 
B 
C 
D 
Primary Outcome 
Reduced drug use 
Reduced re-offending 
Improved health, social functioning and 
relationships 
Increased employment and enhanced 
workforce skills 
Each of these outcomes may be measured via a range of sub-outcomes and outputs, set 
out in the framework on pages 3 and 4 (below). These sub-outcomes and outputs have 
been specifically identified in view of the evidence for their effectiveness and by the 
findings of the national PDTSRG service-user consultation. 
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Sub-outcome and outputs 
Outcome monitoring would be via national and local data sources, and where possible both will be encouraged. 
Service 
Sub-Outcome 
/Output 
Suggested Measurement Evidence Base 
User 
(table 2, 
page 6) 
A Reduced Drug Use 
1 Reduced drug 
National 
per cent of service users receiving care planned intervention Table 1: 
use (DIRWeb & OASys) S, T & U 
TOP tracker reports (page 5) 
10, 11, 
Local 
12 
per cent reduction in +ve screens for class A drugs 
(Clinical & compact-based drug testing) 
per cent reduction in self-injecting 
per cent reduction in shared injecting 
2 Reduced drug 
supply 
National 
Randomised Mandatory Drug Test data Cosden (2010) 
16, 28, 
29 
Local 
Clinical Audit (medicines management) 
Security Information Reports 
Police Community perceptions reports 
3 Equality of 
National 
DIRWeb; NDTMS; Legal 
service NOMS PMS Diversity Report Requirement 17, 18, 
19 Local 
Service Audit 
Local ethnicity reporting 
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Service 
Sub-Outcome 
/Output 
Suggested Measurement Evidence Base 
User 
(table 2, 
page 6) 
Equality Outcome Objectives ( local/partnership report) 
B Reduced Re-offending 
4 Effective 
reintegration 
following 
release 
National 
DWP data / P2W data; 
Supporting People data; 
PNC: Reduction in the number/frequency of reconvictions from the 
predicted rate 
Reduction in the seriousness of reconviction 
Increased time to reconviction after release 
Table 1 
D G Ba & Ca 
25, 26 
30, 31 
Mental Health Minimum Dataset 
Local 
NOMS prison performance data 
Sentence Plan audit 
HMIP Audit 
5. 
Continuity of 
Community 
Treatment 
National 
DIRWeb; NDTMS Table 1 D & G 
27, 33, 
34, 35, 
36 
38, 39 
6 
Enhanced skills 
for 
independent 
Local 
per cent of care plans incorporating Life Skills*; 
per cent of service users receiving Life Skills assistance 
Table 1 Ba 
32, 37 
living (Life 
Skills) 
Service users’ rating of self-efficacy** 
per cent of Service users with budget plan 
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Service 
Sub-Outcome 
/Output 
Suggested Measurement Evidence Base 
User 
(table 2, 
page 6) 
C Improved Health, Social Functioning and Relationships 
7 High quality 
drug treatment 
National 
DIRWeb performance data; 
NDTMS data 
Treatment Planning review; 
TOP tracker reports 
Value-scoring 
Table 1 
Modalities 
(page 5) 
Gossop (2006) 1, 2, 3, 4, 
5, 14, 15, 
Local 
CQUIN framework 
CQC reporting Simpson (2006) 20 
Service User Survey; Service Audit 
Real time client feedback LSH & TM 
Skills Consortium data (2003) 
HR Records 
Staff satisfaction survey 
8 Reduction in 
drug-related 
deaths 
following 
release 
Local 
Clinical audit of prescribing against NICE (CQC administered) 
Medicines management audit (CQC) 
Local audit of drug-related death (General Mortality Registers) 
Death in custody review action plans 
Table 1, J & K 
Davoli (2007) 6, 7, 8, 9, 
9 Peer support 
per cent increase in service users accessing peer support groups 
per cent increase in service users involved in formal peer support NICE (2007) 
21, 22, 
23 24 
per cent increase in service users involved in informal peer support Table 1 B 
10 Facilitated 
support from 
Local 
per cent increase in service users reporting positive relationships Table 1 
40, 41 
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Service 
Sub-Outcome 
/Output 
Suggested Measurement Evidence Base 
User 
(table 2, 
page 6) 
family (where with family and carers V W X 
drug free) 
11 Family 
knowledge of 
Local 
Service user’s family audit Table 1 
(a) support; Referrals to local family services(where commissioned) V W X 42 
and (b) 
dependence 
12 Increased 
Local 
per cent increase in reported access to support for families and Table 1 
support for 
families and 
carers of service user 
per cent of service users with parental / guardian responsibility 
Y 43, 44, 
45 
carers accessing family support services 
per cent Service Users subject to Common Assessment Framework 
D Increased employment and enhanced workforce skills 
13 Entry to 
Progress to 
Work 
National 
DWP data / P2W data; 
Local 
Evidence of volunteering in workplace setting 
Table 1 Ba 
31, 32 & 
33 
programme Completion of literacy course 
Completion of vocational training course 
* Client evaluation support tools (CEST Forms) 
** Social satisfaction questionnaires and Holmes Rahe scores 
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Table 1: Scoring matrix for evidence of effectiveness (PDTSRG 2009)

Intervention 
Code 
Treatment Type Reduced 
Drug Use 
Reduced Use 
Prison 
Reduced Re-
offending 
Total Value 
A 12-step Programme 2 2 
B Peer support meetings 3 3 
C Therapeutic Communities 2 2 4 
D Case Management 1 1 
E Brief Interventions 3 3 
F Drug-focused counselling 1 1 
G Intensive support on 
release 
3 3 6 
H Psychodynamic 1 1 
I Harm reduction (Group) 0 
J Opioid substitution 3 2 3 8 
K Naltrexone 2 2 
Opioid detox without 
psychosocial support 
0 
Cognitive Behavioural Therapy 
L For stimulant use 1 1 
M For cannabis dependence 0 
N For methadone 
maintenance clients 
0 0* 
0 For generalised drug 
dependence 
1 1 
P For women drug users 1 0 1 
Contingency Management: 
S For stimulant use 3 3 
T For methadone 3 3 
200 
Intervention 
Code 
Treatment Type Reduced 
Drug Use 
Reduced Use 
Prison 
Reduced Re-
offending 
Total Value 
maintenance clients 
U For opioid detoxification 3 3 
Couples / Family interventions: 
V For opiate detoxification 3 3 
W For methadone 
maintenance clients 
3 2 5 
X Social Network Therapy 
for opioid detoxification 
2 2 
Y Self-help support for 
carers / families 
0** 
Other Categorisations: 
Z Vipassana meditation 2 2 
Aa Higher-intensity (All 
Treatment Types)*** 
2 2 4 
Beneficial non-treatment factors: 
Ba Enhanced life skills 3 2 5 
Ca Sober living communities 2 2 4 
* Evidence for effectiveness in the treatment of dual diagnosis 
** Evidence for improved psychological well-being among carers and families 
*** Includes clinical and psychosocial programmes, and combinations of both 
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Table 2: Themes from service user consultation (PDTSRG 2009)

Effective interventions in criminal justice, health and well being 
(range and quality of holistic drug treatment/workforce) 
1 People can also find the group work particularly therapeutic 
2 A transfer to another prison for a programme would mean clients could miss out on family contact 
3 Better information about the full range of treatment 
4 Some do not know what addiction means nor there is such a thing as treatment 
5 Prison should be of the same quality as the community 
6 Requests to switch between maintenance and detox can be ignored 
7 Healthcare staff should not make assumptions about people’s treatment needs 
8 Prescribing should be on the basis of individual needs 
9 Naloxone available on release 
10 For many prisons there are not enough CARAT workers 
11 More one-to-ones, keyworking and counselling 
12 A lack of counselling sessions and one to one work and a waiting list 
13 Mental health teams would not treat them because they were receiving drug treatment 
14 Some uneasiness about CARAT workers who are also prison officers 
15 Workers who were quite obviously fresh out of university and reading out of a text book 
User experience (including peer support) 
16 Prescribed medication given in cells which may help avoid bullying and targeting 
17 Hard for non-English-speaking people to find out what courses are on and access help 
18 12-step can be a particular struggle for people with mental health problems 
19 Drug treatment at the same time as religious needs such as attending chapel, is unacceptable 
20 Concern also about disinfectant measures not being available 
21 Unfortunately 12-step is not available in every prison 
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22 Meetings on the wing, led by more confident or experienced service users in the prison 
23 Education programmes led by peer mentors were also seen as quite positive 
24 The support that a cellmate can provide though is undervalued. 
Resettlement / Reintegration 
25 A specialist resettlement drugs worker in the DAAT can be a huge asset 
26	 Coming out of prison, you’ve got nowhere to go…the crack house is somewhere to go 
27	 Reasonable attempts made to ensure continuation of a community prescription on entry to prison and when 
transferred between prisons 
28	 Cat Ds a problem because of the amount of illicit drugs available 
29	 Difficulties in focusing on recovery because of the amount of illegal drugs in prison 
30 
DIP teams that provide support or activities 
31	 More all-round strategy around release with considerations of family life, accommodation...employment and 
finances 
32 
Programmes that “help you to help yourself” 
33	 Increased access to work, education and other programmes (during clinical management) 
34	 A wide range of programmes to reduce offending on release would be helpful 
35	 More focus given to resettlement while in prison with housing help and advice 
36	 Residential rehab….ensuring they continued with the progress that they had started in prison. 
37	 More information about entitlements such as community care grants 
38	 DIP and other programmes have meet people at the gate solutions 
39	 Someone to meet you at the gate and take you to some accommodation or a safe place 
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Families and Communities 
40 Better information sharing and dialogue with families to facilitate a smoother release from prison 
41 The support of my family, that's what would prevent me from coming back to prison 
42 Families can suffer though from a lack of information. 
43 Families….are also deserving of support for their own needs 
44 Care should be taken that they are not seen merely as a resource 
45 More information on administrative concerns [the operation of the prison system] for service users, their family 
and carers 
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1.	 INTRODUCTION 
1.1	 Commissioning describes the process of assessing need in a local area, 
identifying the resources available, planning how to make the best use of the 
resources, arranging service delivery, reviewing services and then reassessing 
need. This process should be ongoing and repeated continually to ensure 
that the services provided are effective, efficient and economical i.e. that the 
services offered are the ‘best value’ available and deliver the best possible 
outcomes. 
1.2	 The current commissioning arrangements for drug users in prison, however, 
are complex, with multiple agencies involved at a national, regional and local 
level resulting in fragmented funding streams, commissioning routes, and a 
lack of consistency of approach within prisons. 
1.3	 The Price Waterhouse Coopers report
11 
highlighted the key gaps and barriers 
in the current commissioning arrangements that need to be addressed, 
including: 
•	 An absence of an overall cross-departmental strategy for dealing with 
people in prison with drug problems, which balances the objectives and 
priorities, and sets out a framework for commissioning; 
•	 A lack of formal authority to make decisions on commissioning priorities 
across the whole drug treatment pathway and to join up treatment and 
care interventions for individuals moving from prison to prison – i.e. joint 
commissioning with authority and responsibility; and, 
•	 A lack of focus on attempting to join up commissioning to address the 
services gaps and duplication associated with community based teams 
and prison based teams. 
1.4	 In light of the above, Lord Patel established an expert Commissioning Sub-
Group to consider a range of options to develop a streamlined drug 
treatment and interventions commissioning system for people in prison, 
moving between prisons and on release from prison. 
1.5	 This paper summarises the discussions, conclusions and recommendations of 
the Commissioning Sub-Group. 
11 Report to the Department of Health and Ministry of Justice: Review of Prison-Based Drug Treatment Funding (Price 
Waterhouse Coopers, December 2007) 
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2.	 AIM AND PRINCIPLES UNDERPINNING COMMISSIONING FOR 
PEOPLE IN PRISON AND ON RELEASE 
2.1	 In order to develop a streamlined commissioning system, the Commissioning 
Sub-Group began by agreeing on the overall aim and the key principles that a 
commissioning system should be based on. 
2.2	 The Commissioning Sub-Group agreed that their overall aim was to agree on 
a commissioning system to: 
Commission a fully integrated drug treatment system in prisons that 
delivers evidence-based treatment with robust quality measures that meets 
the needs of the prison population. 
2.3	 The Commissioning Sub-Group also agreed that any commissioning system 
must be based on the following principles: 
•	 PRINCIPLE 1: A fully integrated drug treatment and interventions 
commissioning system in prisons must meet the needs, and address the 
priorities of all the relevant health, social care and criminal justice 
Government Departments and agencies – there must be a coherent 
commissioning/partnership structure that all relevant parties can engage 
with. 
•	 PRINCIPLE 2: The way in which drug treatment and intervention services 
are commissioned in prison must take into account the churn and 
movement of the prison population – there must be a balance between 
the needs of the prison population as a whole and an individual’s needs 
and perspectives. 
•	 PRINCIPLE 3: The current health and criminal justice commissioning and 
funding frameworks for drug treatment and interventions in prisons 
needs to be brought together into a coherent, multi-disciplinary, 
streamlined commissioning system and all partners, whether at a 
national, regional or local level must share a collective responsibility to 
ensure effective joint commissioning. 
•	 PRINCIPLE 4: The options for developing a coherent, multi-disciplinary, 
streamlined drug treatment and interventions commissioning system in 
prisons should be considered and a SWOT analysis carried out by the 
Commissioning Sub-Group of the Prison Drug Treatment Strategy Review 
Group on the possible options. 
•	 PRINCIPLE 5: There needs to be a range of drug treatment and 
intervention services available in prisons that is needs based and 
recognises local complexity, diversity, equality and choice. 
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•	 PRINCIPLE 6: In terms of commissioning, drug treatment and 
interventions provision in prisons should be viewed as far as possible as 
an integrated system and needs to take into account the community 
context if continuity of care is to be effectively commissioned. 
•	 PRINCIPLE 7: To work toward the commissioning of an integrated end-to-
end management system. 
•	 PRINCIPLE 8: The performance management of commissioning systems 
must focus on outcomes, not only activity and process. 
3.	 SUMMARY OF KEY ISSUES FOR CONSIDERATION 
3.1	 In developing a commissioning system, the Commissioning Sub-Group began 
by reviewing the current system, impact on partnership/joint working 
approaches, and commissioning for quality and outcomes. 
3.2	 As far as possible, the Commissioning Sub-Group have attempted to ensure 
that potential new developments are taken into account in the development 
of a commissioning system, such as the drive toward less central control and 
greater local decision-making. 
3.3	 The key issues emerging from this review and discussions is briefly 
summarised below. 
The Current Commissioning System 
3.4	 A variety of Government Departments and agencies fund and commission 
drug treatment and intervention services in prison and on release in the 
community. 
Commissioning in prisons 
3.5	 Commissioning for drug treatment and intervention services in prisons takes 
place at both a national and a local level. Responsibility for prisoners’ 
healthcare, including the clinical aspects of drug treatment, transferred from 
the Prison Service to the Department of Health from April 2003. This led to a 
split between the commissioning and funding of drug treatment and 
intervention services between the Department of Health and the National 
Offender Management Service. 
3.6	 The Department of Health funds primary care trusts (PCTs) to commission 
prison clinical drug treatment and health care at a local level. Funding is 
agreed annually – in 2009/10, the Department of Health allocated £39.5 
million for PCTs to commission clinical drug treatment services on behalf of 
prison/PCTs partnerships as part of the Integrated Drug Treatment System. 
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3.7	 The Healthcare Commission and the Prison’s Inspectorate published a 
12 
report looking specifically at the way prison health generally is 
commissioned and concluded that there was scope for improvement. They 
found that: 
•	 The quality of the provision of healthcare in prisons was variable. 
•	 The assessment of needs for healthcare is paramount and comprehensive 
assessments for this group have not always driven development and 
provision of healthcare services. 
•	 Although PCTs have emphasised the importance of an assessment of 
health needs to inform their priorities and strategies for commissioning 
services, the majority of PCTs did not have such an assessment, or had 
not completed it. 
•	 Overall, there has been some improvement in the commissioning of 
healthcare in prisons, but further work was needed to ensure that specific 
areas, such as access to health services and the assessment of health 
needs, were addressed. 
•	 Collecting information about healthcare in prisons was restricted by a lack 
of IT - the implementation of electronic records was at an early stage and 
some prisons used a system that was paper-based. 
•	 PCTs needed to adopt a more structured approach to resources, to clarify 
where budgets for healthcare in prisons sat within PCTs, so that it was 
seen to be a priority. 
3.8	 CARAT (Counselling, Assessment, Referral, Advice, Throughcare) services 
have been commissioned at a national level directly by the National Offender 
Management Service within a three-year commissioning cycle - in 2009/10, 
£33 million was available for the mainstream CARATs programme and £6 
million was available for the Integrated Drug Treatment System. 
3.9	 CARATs provide psychosocial support and advice to drug users by assessing 
the nature and extent of their problematic drug use before providing, or 
referring to, a range of psychosocial interventions. The service is designed to 
address the needs of low, moderate and severe drug users and to act as a 
gateway or link to other services within prisons and the community. 
Commissioning on release from prison 
12 Commissioning healthcare in prisons The results of joint work between the Healthcare Commission and Her Majesty’s 
Inspectorate of Prisons in 2007/08 (February 2009) 
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3.10	 The initial period following release from prison is particularly crucial for 
receiving treatment for drug use and joining up with services in the 
community. In the week following release, prisoners are 37 times more likely 
to die of drug overdose than other members of the public, due to diminished 
13 
opioid tolerance . Women are 69 times more likely to do so. 
3.11	 During the first 12 months after release, there is a 3-10 fold greater risk of 
suicide than the general population. Risk is particularly high during the first 
28 days, during which about a fifth of all suicides following release from 
prison occur. Therefore, effective strategic planning and commissioning 
needs to span prison and community, and remove barriers to coordination on 
release from prison. 
3.12	 It is important to note that there is no separate provision and commissioning 
system in the community for drug users released from prison. The 
commissioning of community services for adults is undertaken via joint 
commissioning groups drawn from local drug partnerships and are largely 
funded by three Government Departments: 
•	 Department of Health – the largest single contributor: around £400 
million for the Drug Pooled Treatment Budget and an estimated £200 
million spent annually from local mainstream monies (e.g. NHS and local 
authority funds), bringing the overall annual estimated spend on drug 
treatment to around £600 million. 
•	 Ministry of Justice – contributing £42 million overall to the Drug Pooled 
Treatment Budget to support Drug Rehabilitation Requirements orders. 
•	 Home Office – provides around £108 million to fund the Drug 
Interventions Programme. 
Impact on Partnership/Joint Working Approaches 
3.13	 The various funding and commissioning arrangements can create barriers to 
local and regional partnership working, potentially stifling innovations across 
both geographical and organisational boundaries. 
3.14	 It is vital that these issues are addressed – for example, on average, people 
are held 31 miles from their home location rising to 58 miles for women 
prisoners and 65 miles for those serving sentences of 4 years or over. 
Individuals serving lengthy prison sentences (of two years or more) are likely 
to be more stable geographically, located in one prison for much (or all) of 
their sentence. Individuals remanded in custody or serving short prison 
13 Farrell, M. and Marsden, J. Drug-related mortality among newly released offenders 1998 to 2000, Home Office Online 
Report 40/05 
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sentences are much more challenging to engage. They are likely to move 
between prison, hospital and community, as well as moving between 
different prisons and therefore will be the responsibility of three to four local 
commissioning partnerships with each change of location. 
3.15	 Partnership approaches that include case management and information 
exchange should help people to pass seamlessly from treatment provided or 
funded by any one of the above-mentioned agencies to another, whilst 
ensuring that robust continuity of care arrangements are achieved. However, 
this is not always the case and the difficulties arise, for example, because 
teams use different assessment tools or there is no electronic information 
14 
system to assist information sharing. The 2008 Drug Strategy highlighted 
the need to: 
‘…manage offenders better at crucial times, such as on discharge into the 
community from prison, when the risks of relapse and re-offending are high 
by improving the continuity of case management of drug-misusing offenders 
and reviewing and strengthening links between prisons, local Criminal Justice 
Intervention Teams and probation services.’ 
3.16	 Therefore, there is a need to establish a more integrated approach, which 
involves all key agencies working with people on release, both health and 
criminal justice, if they are to make better use of existing resources and to 
meet needs. 
3.17	 This might include the pooling of budgets and the aligning of priorities to 
ensure that the different partnership agencies are focusing on the same 
group of people, and successfully rehabilitating and resettling individuals into 
the community. Integrated approaches should also deepen and extend joint 
identification and assessment, improve offender management and 
information sharing frameworks for those people in the community who 
present the highest risk of re-offending, especially for those short sentenced 
offenders released from prison under no statutory supervision. 
3.18	 Therefore, there can be no doubt that developing effective local partnerships 
is vital to developing an integrated approach, and improving current 
commissioning practices is critical for delivering an overall strategic 
approach, which can address all the needs of offenders both in prison and on 
release into the community (housing, skills, finance). 
14 Drugs: protecting families and communities – The 2008 Drug Strategy (HM Government, 2008) 
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Commissioning for value for money, quality and outcomes 
3.19	 Commissioning for value for money, quality and outcomes requires 
partnerships to demonstrate the best use of available resources to ensure 
their drug treatment and reintegration systems deliver the best possible 
outcomes for the target group and local population. 
3.20	 Outcome based commissioning allows commissioners to move from a focus 
on inputs, process and outputs to a focus on outcomes or results for people 
who receive services. By working with partners to specify clearly required 
quality and outcomes, and influencing provision accordingly, commissioners 
can facilitate continuous improvement in service design to better meet the 
needs of the local population. This is supported by transparent and fair 
commissioning and decommissioning processes. 
3.21	 The opportunities afforded by outcome based commissioning include the 
potential to: 
•	 Develop a new way to distribute money and manage for results 
•	 Develop new thinking and behaviours to energise delivery 
•	 Be results focused to achieve success 
•	 Encourage performance, innovation and learning. 
The key benefits of any outcomes-based system can be: 
•	 Improved accountability to local community for results 
•	 A market managed on the basis of outcomes and customer value 
•	 Alignment and consolidation of performance targets and indicators 
•	 Acceleration of knowledge based practice and innovation 
3.22	 In the drug treatment and interventions sector, outcome based 
commissioning will first require clarity about which types of drug treatment 
and interventions yield what outcomes, and what is therefore required in 
treatment and reintegration systems to maximise client outcomes. The latter 
is being considered by the Prison Drug Treatment Strategy Review Group, 
Outcomes Sub-Group, which is developing a new outcomes framework. 
4.	 DEVELOPING A STREAMLINED COMMISSIONING SYSTEM 
4.1	 The Commissioning Sub-Group carried out a SWOT analysis and considered 
the pros and cons of a range of options against the established principles 
(outlined in section 2) and against the following criteria: 
•	 The commissioning system must not jeopardise current funding for drug 
treatment and interventions or risk disinvestment of any health, local 
authority or criminal justice mainstream funding. 
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•	 The commissioning system must have the capacity and flexibility to 
enable the commissioning of drug treatment and intervention services at 
whichever level (national, regional or local) is appropriate for the 
intervention - some commissioning at a national level may be required to 
ensure the needs of underrepresented groups are being met e.g. female 
drug users in prison and people under 21-years of age. 
•	 The commissioning system must link with community commissioning 
systems to ensure the continuity of care for people released from prison 
into community treatment services and for those entering prison from 
the community. 
•	 The commissioning system must be in line with the development of other 
commissioning systems within the NHS, local authorities and the criminal 
justice system and not work against them. 
•	 The commissioning system must support a commissioning for outcomes 
based approach, including health and criminal justice outcomes, and take 
into account the work carried out by the Outcomes Sub-Group. 
4.2	 The Commissioning Sub-Group also considered the potential risks that would 
need to be addressed, including: 
•	 A lack of ‘buy-in’ by commissioners, and external organisations and 
partners so the ‘status quo’ is maintained. 
•	 The requirement for agencies to change their commissioning and working 
practices, and to work beyond traditional boundaries will present a major 
challenge. 
•	 The time and effort needed to develop a common understanding of 
concepts and terminology cannot be underestimated. 
•	 Difficulties in developing appropriate protocols and effective 
communication between all agencies at both a regional and local level. 
•	 The needs of drug-using prison population and their families may not 
met. 
•	 Probation Service has statutory duties to discharge that must be taken 
into account. 
4.3	 One of the option considered was around the possibility of establishing fewer 
or possibly a single funding stream (held by either health or criminal justice) 
which could be used more flexibly to support the whole of the prison drug 
treatment and interventions pathway, including related support needs both 
inside and outside prisons. 
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4.4	 The Commissioning Sub-Group came to a consensus that all commissioning 
tasks (e.g. needs assessments, strategic planning, purchasing) should not to 
be undertaken by one body (either health or criminal justice) or just at one 
level (either national regional or local). It is more important to have a 
coherent structure to link these tasks across the health, social care and 
criminal justice sectors. It is essential that commissioners at all levels use 
local information and needs assessments to develop appropriate links and 
agree shared commissioning arrangements with other partners in order to 
create integrated packages of provision for drug users in prison and on 
release that avoids duplication. 
4.5	 The Commissioning Sub-Group concluded decision-making around 
commissioning should be focused primarily at a local level, and more 
responsibility given to local partnerships, commissioners, prison governors 
and users and carers. 
4.6	 Maximising local ownership would sustain and improve outcomes in terms of 
both re-offending and reduction of harm to the individual, their families and 
their communities. Local areas also require greater autonomy and flexibility 
to deliver better services by focusing on increasing the access and quality of 
drug interventions, matched to individual needs, and reducing bureaucracy. 
Therefore, options around single funding streams were rejected. 
5.	 A STREAMLINED COMMISSIONING SYSTEM 
5.1	 The Commissioning Sub-Group reached consensus on a commissioning 
system that best promotes collective responsibility, effective joint 
commissioning and aligned/pooled budgets in order to obtain the best 
outcomes, efficiencies and value for money, which would also create a more 
autonomous and accountable system. 
5.2	 It is recommended, therefore, that for the first time in England, the majority 
of drug funds be jointly commissioned at a local level - this includes the 
National Offender Management Service’s CARATs funding. 
5.3	 This would meant that local health commissioners, potentially within the new 
consortia of GP practices, and local drug partnerships including local 
authorities, prison governors, etc...., will share the responsibility for 
commissioning drug treatment and interventions both in prisons and on 
release and will have a collective responsibility to ensure effective joint 
commissioning. 
5.4	 Some commissioning at a national level may still be needed, for example, to 
ensure the needs of the women’s estate and under 21-year-old offenders are 
addressed and under this system, services can be commissioned based on 
needs, at whichever level (national, regional or local) is appropriate for the 
intervention. 
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5.5	 As this work programme and recommendations were being completed, major 
changes to commissioning systems within the NHS were announced. PCTs 
are to be abolished by April 2013: the main commissioning functions would 
pass to GP consortia and the public health function would pass to local 
authority commissioners. Healthcare commissioning will be the 
responsibility of GP consortiums working with local communities to 
commission the majority of local health services from the NHS, voluntary 
sector and private providers. 
5.6	 There is no detail yet about what will happen to local drugs partnerships and 
where the commissioning of drug treatment will fit - it may be that it would 
be the remit of GP consortia or be part of the public health remit of the local 
authority, or it may even be split between the two. 
5.7	 This recommended commissioning system, however, is aligned with the 
Coalition’s programme approach for a more autonomous and accountable 
system and with the NHS White Paper, Equity and excellence: Liberating the 
NHS. 
5.8	 Moreover, it is vital that a shift is made away from the current fragmented 
system to a streamlined effective and efficient commissioning system that is 
reflective of consensus on evidence and good practice, and clearly aligned 
with outcomes. 
5.9	 Therefore, it is recommended that the Government consider putting in place 
this revised commissioning system by 2011/12. 
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